



4 August 2016
 EMA/873138/2011 Rev 2* Draft for public consultation

³ Guideline on good pharmacovigilance practices (GVP)

4 Module VI – Management and reporting of adverse reactions to medicinal

5 products (Rev 2)

Date for coming into effect of Revision 1	16 September 2014
Draft Revision 2* finalised by the Agency in collaboration with Member States	15 July 2016
Draft Revision 2 agreed by the European Risk Management Facilitation Group (ERMS FG)	26 July 2016
Draft Revision 2 adopted by Executive Director	4 August 2016
Release for public consultation	8 August 2016
End of consultation (deadline for comments)	14 October 2016
Anticipated date for coming into effect after finalisation	Within 6 months of the announcement by the Agency, once the functionalities of the EudraVigilance database specified in Art. 24(2) of Reg. (EC) No 726/2004 are established

- 6 * <u>Note</u>: Revision 2 contains the following:
- 7 Update on the electronic reporting modalities of ICSRs under the new ICH-E2B(R3) format;
- Update on ICSRs reporting, following-up, duplicate detection, data quality management, in line
 with the provisions in Art. 24 of Reg. (EC) No 726/2004, Art 107 and 107a of Dir. 2001/83/EC;
- 10 Update on the validation of ICSRs based on patients and reporters identifiability;
- 11 Update on the management of ICSRs described in the scientific literature;
- 12 Update on the collection of information on patient's age;
- Guidance on the management of suspected adverse reactions reported through medical enquiry
 and product information services;
- 15 Guidance on the management of reports from post-authorisation efficacy studies;
- 16 Transfer of the guidance on Emerging Safety Issue to GVP Module IX;
- 17 Editorial amendments to align the format with other GVP Modules.
- 18

Comments should be provided using this <u>template</u>. The completed comments form should be sent to <u>gvp@ema.europa.eu</u>

- 19 <u>Note for public consultation</u>:
- 20 The public consultation is restricted to the revised texts or deleted texts highlighted in "track changes"
- 21 mode. However, if revisions or deletions impact or contradict other existing texts, comments on such
- 22 non-highlighted texts will be processed and taken into account.
- 23 See websites for contact details

European Medicines Agency www.ema.europa.eu Heads of Medicines Agencies www.hma.eu The European Medicines Agency is an agency of the European Union



© European Medicines Agency and Heads of Medicines Agencies, 2016. Reproduction is authorised provided the source is acknowledged.

24 TABLE OF CONTENTS

25	VI.A. Introduction	6
26	VI.A.1. Scope	6
27	VI.A.2. Definitions and terminology	6
28	VI.A.2.1. Adverse reaction	6
29 30	VI.A.2.1.2. Overdose, off-label use, misuse, abuse, occupational exposure, medication e falsified medicinal product	
31	VI.A.2.2. Medicinal product, active substance, excipient	
32	VI.A.2.3. Primary source	
33	VI.A.2.4. Seriousness	
34	VI.A.2.5. Individual case safety report (ICSR)	10
35	VI.A.2.6 Nullflavors	10
36	VI.B. Structures and processes	10
37	VI.B.1. Collection of reports	
38	VI.B.1.1. Unsolicited reports	
39	VI.B.1.1.1. Spontaneous reports	
40	VI.B.1.1.2. Literature reports	
41	VI.B.1.1.3. Reports from other sources (e.g. general news or other media)	
42	VI.B.1.1.4. Information on suspected adverse reactions from the internet or digital med	
43	VI.B.1.2. Solicited reports	13
44	VI.B.2. Validation of reports	14
45	VI.B.3. Follow-up of reports	16
46	VI.B.4. Data management	17
47	VI.B.5. Quality management	17
48	VI.B.6. Special situations	18
49	VI.B.6.1. Use of a medicinal product during pregnancy or breastfeeding	18
50	VI.B.6.2. Use of a medicinal product in a paediatric or elderly population	19
51 52	VI.B.6.3. Reports of overdose, abuse, off-label use, misuse, medication error or occupate exposure	
53	VI.B.6.4. Lack of therapeutic efficacy	20
54	VI.B.7. Reporting of individual case safety reports (ICSRs)	21
55	VI.B.7.1. Reporting time frames	21
56	VI. B.7.2 Report nullification	22
57	VI.B.7.3. Amendment report	22
58	VI.B.8. Reporting modalities	22
59	VI.C. Operation of the EU network	24
60	VI.C.1. Reporting rules for clinical trials and post-authorisation studies in the EU	24
61	VI.C.1.1. Reporting rules for clinical trials	25
62 63	VI.C.1.2. Reporting rules for non-interventional post-authorisation studies, compassionause and named patient use	
64	VI.C.1.2.1. Non-interventional post-authorisation studies	
65	VI.C.1.2.2. Compassionate use and named patient use	28
66	VI.C.2. Collection of reports	29
67	VI.C.2.1. Responsibilities of Member States	29
68	VI.C.2.2. Responsibilities of the marketing authorisation holder in the EU	31

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

69	VI.C.2.2.1. Spontaneous reports
70	VI.C.2.2.2. Solicited reports
71	VI.C.2.2.3. Case reports published in the scientific literature
72	VI.C.2.2.3.1 Monitoring of medical literature by the European Medicines Agency
73 74	VI.C.2.2.3.2 Exclusion criteria for the reporting of ICSRs published in the scientific literature 33
75	VI.C.2.2.4. Suspected adverse reactions related to quality defect or falsified medicinal
76	products
77	VI.C.2.2.5. Suspected transmission via a medicinal product of an infectious agent
78	VI.C.2.2.6. Emerging safety issues
79	VI.C.2.2.7. Period between the submission of the marketing authorisation application and
80	the granting of the marketing authorisation
81	VI.C.2.2.8. Period after suspension, revocation or withdrawal of marketing authorisation 36
82	VI.C.2.2.9. Period during a public health emergency
83	VI.C.2.2.10. Reports from class action lawsuits
84	VI.C.2.2.11. Reports from patient support programmes and market research programmes 37
85	VI.C.3. Reporting time frames
86	VI.C.4. Reporting modalities of ICSRs in EU
87	VI.C.5. Collaboration with bodies outside the EU regulatory network
88 89	VI.C.5.1. Collaboration with the World Health Organization and the European Monitoring Centre for Drugs and Drug Addiction
90	VI.C.6. Electronic exchange of safety information in the EU40
91	VI.C.6.1. Applicable guidelines, definitions, international formats, standards and
92	terminologies
93	VI.C.6.2. Electronic reporting of individual case safety reports
94	VI.C.6.2.1. EudraVigilance Database Modules
95 96	VI.C.6.2.1.1. Adverse reaction data collected in the EudraVigilance Post-Authorisation Module
97	VI.C.6.2.1.2. Adverse reaction data collected in the EudraVigilance Clinical Trial Module 44
98	VI.C.6.2.2. Preparation of individual case safety reports
99	VI.C.6.2.2.1. General principles
100	VI.C.6.2.2.2. Information on suspect, interacting and concomitant medicinal products 46
101	VI.C.6.2.2.3. Suspected adverse reactions
102	VI.C.6.2.2.4. Case narrative, causality assessment and comments
103	VI.C.6.2.2.5. Test results
104	VI.C.6.2.2.6. Supplementary records/information
105	VI.C.6.2.2.7. Follow-up information
106	VI.C.6.2.2.8. Amendment Report
107	VI.C.6.2.2.9. Nullification of cases
108	VI.C.6.2.2.10. What to take into account for data protection laws
109	VI.C.6.2.2.11. Handling of languages
110	VI.C.6.2.3. Special situations
111	VI.C.6.2.3.1. Use of a medicinal product during pregnancy or breastfeeding
112	VI.C.6.2.3.2. Suspected adverse reaction reports published in the scientific literature 64
113	VI.C.6.2.3.3. Suspected adverse reactions related to overdose, abuse, off-label use, misuse,
114 115	medication error or occupational exposure
115	VI.C.6.2.3.4. Lack of therapeutic efficacy

116 117	VI.C.6.2.3.5. Suspected adverse reactions related to quality defect or falsified medicinal products
118	VI.C.6.2.3.6. Suspected transmission via a medicinal product of an infectious agent71
119	VI.C.6.2.3.7. Reports of suspected adverse reactions originating from organised data collection systems and other systems
120	VI.C.6.2.3.8. Receipt of missing minimum information
121	VI.C.6.2.4. Data quality of individual case safety reports transmitted electronically and
122 123	duplicate management
124	VI.C.6.2.5. Electronic re-transmission of ICSRs between multiple senders and receivers 76
125	VI.C.6.2.6. Electronic reporting through company's headquarters
126	VI.C.6.3. Electronic submission of information on medicinal products
127	VI. Appendix 1 Follow-up process of ICSRs79
128	VI.App.1.1 Follow-up of ICSRs by marketing authorisation holders
129 130	VI.App.1.2 Follow-up of ICSRs by competent authorities in Member States involving consumers or healthcare professionals
131	VI.App.1.3 Follow-up of ICSRs by competent authorities in Member States with involvement
132	of marketing authorisation holders87
133	VI.App.1.4 Follow-up of ICSRs for identification of biological medicinal products
134	VI. Appendix 2 Detailed guidance on the monitoring of scientific literature
135	
136	VI.App.2.1 When to start and stop searching in the scientific literature
137	VI.App.2.2 Where to look
138	VI.App.2.3 Database Searches95
139	VI.App.2.3.1 Precision and recall95
140	VI.App.2.3.2 Search construction
141	VI.App.2.3.3 Selection of product terms
142	VI.App.2.3.4 Selection of search terms
143	VI.App.2.3.5 Limits to a search96
144	VI.App.2.4 Record keeping97
145	VI.App.2.5 Outputs
146	VI.App.2.6 Review and selection of articles
147	VI.App.2.7 Day zero
148	VI.App.2.8 Duplicates
149	VI.App.2.9 Contracting out literature search services
150 151	VI.App.2.10 Electronic submission of copies of articles on suspected adverse reactions published in the scientific literature
152 153	VI.App.2.11 Examples for the reporting of suspected adverse reactions described in the scientific and medical literature and referring to more than one patient
154	VI. Appendix 3 Reporting modalities of ICSRs in EU
155	VI.App.3.1. Requirements applicable to marketing authorisation holders
156	VI.App.3.2. Requirements applicable to competent authorities in Member States
157 158	VI.App.3.3 Transmission and rerouting of ICSRs to competent authorities in Member States

159 160	VI. Appendix 4 Transmission of ICSRs to the World Health Organization (WHO)
161	VI. Appendix 5 Nullification of cases128
162 163	VI. Appendix 6 Data quality monitoring of ICSRs transmitted electronically133
164	VI. Appendix 7 Duplicate detection and management of ICSRs
165 166	VI.App.7.1 Duplicate Detection in EudraVigilance – Collaboration between the Agency, Member States and MAHs where duplicates originate from the same sender
167 168	VI.App.7.2 Duplicate Detection in EudraVigilance – Collaboration between the Agency, Member States and MAHs where duplicates originate from different Senders
169 170	VI.App.7.3 Duplicates from same Sender Organisation – duplicates detected by the sender organisation prior to detection by the Agency in EudraVigilance
171 172	VI.App.7.4 Duplicates from different Sender Organisations - Duplicates detected by an Organisation prior detection by Agency in EudraVigilance
173 174 175	VI.App.7.5 Duplicate Detection in EudraVigilance – Collaboration between the Agency, Member States and MAHs where duplicates are first detected in a database other than EudraVigilance
176 177	VI.App.7.6 Duplicates identified as part of signal management as outlined in GVP Module IX - Collaboration between the Agency, Member States and MAHs
178 179	VI. Appendix 8 Examples of assesment of case validity162

180

181 VI.A. Introduction

182 VI.A.1. Scope

183 This Module of GVP addresses the legal requirements detailed in **Title**TITLE IX of Directive 2001/83/EC 184 [DIR] and chapterChapter 3 of TITLE II of Regulation (EC) No 726/2004 [REG], which are applicable to 185 competent authorities in Member States, marketing authorisation holders and the Agency as regards 186 the collection, data management and reporting of suspected adverse reactions (serious and non-187 serious) associated with medicinal products for human use authorised in the European Union (EU). 188 Recommendations regarding the reporting of emerging safety issues or of suspected adverse reactions 189 occurring in special situations are also presented in this Module. The requirements provided in 190 chapters Chapters IV, V and IX of the Commission Implementing Regulation (EU) No 520/2012 [IR] 191 shall be applied in this Module.

The guidance provided in this Module does not address the collection, management and reporting of events or patterns of use, which do not result in suspected adverse reactions (e.g. asymptomatic overdose, abuse, off-label use, misuse or medication error) or which doare not requirerequired to be reportedsubmitted as individual case safety reportor as emerging safety issues. This information may however need to be collected and presented in periodic safety update reports for the interpretation of safety data or for the benefit risk evaluation of medicinal products. In this aspect, the guidance provided in GVP Module VII applies.

Section B of this Module highlights the general principles in relation to the collection, recording and
 reporting of reports of suspected adverse reactions associated with medicinal products for human use,
 which are applicable to competent authorities and marketing authorisation holders. The definitions and
 recommendations provided in <u>VI.A</u>, should be followed. EU requirements are presented in <u>VI.C</u>.

All applicable legal requirements detailed in this Module are referenced in the way explained in the GVP Introductory Cover Note and are usually identifiable by the modal verb "shall". Guidance for the implementation of legal requirements is provided using the modal verb "should".

206 VI.A.2. Definitions and terminology

The definitions provided in Article 1 of Directive 2001/83/EC shall be applied for the purpose of this Module; of particular relevance are those provided in this Section. Some general principles presented in the ICH-E2A and ICH-E2D guidelines (see GVP Annex IV) should also be adhered to; they are included as well in this Section (see GVP Annex I for all definitions applicable to GVP).

211 VI.A.2.1. Adverse reaction

An adverse reaction is a response to a medicinal product which is noxious and unintended [DIR Art 1].
This includes adverse reactions which arise from: (11)]. Adverse reactions may arise from use of the
product within or outside the terms of the marketing authorisation or from occupational exposure [DIR
Art 101(1)]. Use outside the marketing authorisation includes off-label use, overdose, misuse, abuse
and medication errors.

217 • the use of a medicinal product within the terms of the marketing authorisation;

- the use outside the terms of the marketing authorisation, including overdose, off-label use,
 misuse, abuse and medication errors;
- 220 occupational exposure.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

221 VI.A.2.1.1. Causality

222 In accordance with ICH-E2A (see GVP Annex IV), the definition of an adverse reaction implies at least a reasonable possibility of a causal relationship between a suspected medicinal product and an adverse 223 224 event- (see GVP Annex I). An adverse reaction, in contrast to an adverse event, is characterised by the fact that a causal relationship between a medicinal product and an occurrence is suspected. For 225 226 regulatory reporting purposes, as detailed in ICH-E2D (see GVP Annex IV), if an event is spontaneously reported, even if the relationship is unknown or unstated, it meets the definition of an 227 228 adverse reaction. Therefore all spontaneous reports notified by healthcare professionals¹ or 229 consumers² are considered suspected adverse reactions, since they convey the suspicions of the 230 primary sources, unless the reporters specifically state that they believe the events to be unrelated or 231 that a causal relationship can be excluded. 232 VI.A.2.1.2. Overdose, off-label use, misuse, abuse, occupational exposure, medication error, 233 falsified medicinal product 234 a. Overdose 235 : This refers to the administration of a quantity of a medicinal product given per administration or 236 cumulatively, which is above the maximum recommended dose according to the authorised product 237 information. Clinical judgement should always be applied. 238 b. Off-label use 239 : This relates to situations where the medicinal product is intentionally used for a medical purpose not 240 in accordance with the authorised product information terms of the marketing authorisation. 241 e-Misuse 242 : This refers to situations where the medicinal product is intentionally and inappropriately used not in accordance with the authorised product information terms of the marketing authorisation. 243 244 d-Abuse 245 : This corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, which 246 is accompanied by harmful physical or psychological effects [DIR Art 1+(16)]. 247 e. Occupational exposure 248 : This refers to the exposure to a medicinal product (as defined in [DIR Art $1\frac{1}{1}$, (2)]), as a result of 249 one's professional or non-professional occupation. It does not include the exposure to one of the 250 ingredients during the manufacturing process before the release as finished product. 251 Medication error: This is an unintended failure in the drug treatment process that leads to, or has the potential to lead to harm to the patient². 252 253 Falsified medicinal product: This relates to any medicinal product with a false representation of: 254 • its identity, including its packaging and labelling, its name or its composition as regards any of 255 the ingredients including excipients and the strength of those ingredients; 256 • its source, including its manufacturer, its country of manufacturing, its country of origin or its 257 marketing authorisation holder; or

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

¹ See <u>VI.A.2.3.</u> for definition of primary source

² See Good Practice Guide on Recording, Coding, Reporting and Assessment of Medication Errors, EMA/762563/2014

- its history, including the records and documents relating to the distribution channels used.
- 259 This definition does not include unintentional quality defects and is without prejudice to infringements260 of intellectual property rights [DIR Art 1(33)].

261 VI.A.2.2. Medicinal product, Aactive substance, excipient

- 262 *Medicinal product:* A medicinal product is characterised by any substance or combination of
 263 substances,
- presented as having properties for treating or preventing disease in human beings; or
- which may be used in or administered to human beings either with a view to restoring, correcting or modifying physiological functions by exerting a pharmacological, immunological or metabolic action, or to making a medical diagnosis [DIR Art 1]-(2)].
- Active substance: An active substance corresponds to any substance or mixture of substances
 intended to be used in the manufacture of a medicinal product and that, when used in its production,
 becomes an active ingredient of that product intended to exert a pharmacological, immunological or
 metabolic action with a view to restoring, correcting or modifying physiological functions or to make a
 medical diagnosis [DIR Art 1(3a)].
- 273 *Excipient:* An excipient corresponds to any constituent of a medicinal product other than the active
 274 substance and the packaging material [DIR Art 1(3b)].
- In accordance with Article 107 of Directive 2001/83/EC, the scope of this module Module is not only 275 276 applicable to medicinal products authorised in the EU but also to any such medicinal products 277 commercialised outside the EU by the same marketing authorisation holder (see VI.C.2.2.). Given that 278 a medicinal product is authorised with a defined composition, all the adverse reactions suspected to be 279 related to any of the active substances being part of a medicinal product authorised in the EU should 280 be managed in accordance with the requirements presented in this module. This is valid 281 independently of the strengths, pharmaceutical forms, routes of administration, presentations, 282 authorised indications, or trade names of the medicinal product. For the definition of the name and 283 strength of a medicinal product, refer to Article 1(20) and Article 1(22) of Directive 2001/83/EC.
- The guidance provided in this Module also applies, subject to amendments where appropriate, to medicinal products supplied in the context of compassionate use (see VI.C.1.2.2.) as defined in Article 83(2) of Regulation (EC) No 726/2004, subject to and without prejudice to applicable national law of the EU Member States. As the case may be, this guidance may also apply to named patient use as defined under Article 5(1) of Directive 2001/83/EC.

289 For devices containing active substances, whether they are authorised in the EU as medicinal products 290 or CE marked as medical devices determines which procedure should be followed for the safety 291 reporting of suspected adverse reactions and/or incidents. In this aspect, medicinal products follow the 292 requirements for pharmacovigilance provided in Directive 2001/83/EC and Regulation (EC) No 293 726/2004, whereas medical devices follow the requirements for medical device vigilance in accordance with Directive 90/385/EEC and Directive 93/42/EEC. As detailed in the Guidelines on a Medical Devices 294 295 Vigilance System³, a medical device incorporating a medicinal product or substance, where the action of the medicinal product or substance is ancillary to that of the device, follows the legal requirements 296 297 of Directive 90/385/EEC and Directive 93/42/EEC.

³ Ref.: <u>MEDDEV 2.12-1 rev 8</u>

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

298 VI.A.2.3. Primary source

The-In accordance with ICH-E2B, the primary source of the information on a suspected adverse
 reaction(s) is the person who reports the facts- about an individual case safety report. Several primary
 sources, such as healthcare professionals and/or a consumer consumers, may provide information on
 the same case. In this situation, all the primary sources' details, including the qualifications, should be
 provided in the case report, with and the "Primary source(s)" section should be repeated as necessary
 in line with ICH-E2B(R2) (see GVP Annex IV)⁴, VI.B.2. for validation of reports).

- 305 In accordanceline with-the ICH-E2D (see GVP Annex IV),
- a healthcare professional is defined as a medically-qualified person such as a physician, dentist,
 pharmacist, nurse, coroner or as otherwise specified by local regulations;
- a consumer is defined as a person who is not a healthcare professional such as a patient, lawyer,
 friend, relative of a patient or carer.
- Medical documentations The "Primary Source for Regulatory Purposes" is defined in ICH-E2B(R3) and is
 not applicable for the electronic transmission under ICH-E2B(R2) format. This data element refers to
 the person who first reported the facts. In case of multiple sources, it identifies the source of the
 worldwide case unique identification number by defining the country where the case occurred.
- A consumer may provide medical documentation (e.g. laboratory or other test data) provided by a
 consumer that supports upports the occurrence of thea suspected adverse reaction, or which
 indicate indicates that an identifiable healthcare professional suspects a reasonable possibility of causal
 relationship between a medicinal product and the reported adverse event, are sufficient to consider the
 spontaneous report as confirmed by a healthcare professional.
- 319 If a consumer initially reports more than one reaction and at least one receives medical confirmation,
 320 the whole report should be documented as a spontaneous report confirmed by a healthcare
 321 professional and be reported accordingly. Similarly, if a report is may be submitted by a medically
- professional and be reported accordingly. Similarly, if a report ismay be submitted by a medically
 qualified patient, friend, relative or carer of the patient or carer. In these situations, the case should
 also be reported information is considered as a spontaneous report medically confirmed by a healthcare
 professional.
- In the same way, where one or more suspected adverse reactions initially reported by a consumer is
 subsequently confirmed by a healthcare professional or contains medical documentation that supports
 the occurrence of a suspected adverse reaction, the case should be considered medically confirmed. It
 should be updated at case level in line with ICH-E2B(R2), or at adverse reaction level in accordance
 with ICH-E2B(R3) for each subsequently medically confirmed suspected adverse reaction.

330 VI.A.2.4. Seriousness

- 331 As described in ICH-E2A (see GVP Annex IV), a serious adverse reaction corresponds to any untoward
- medical occurrence that at any dose results in death, is life-threatening, requires inpatient
- hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect.
- The characteristics/consequences should be considered at the time of the reaction to determine the seriousness-of a case. For example, life-threatening refers to a reaction in which the patient was at risk
 - ⁴-See <u>VI.C.6</u> as regards the electronic reporting of ICSRs in the EU.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

of death at the time of the reaction; it does not refer to a reaction that hypothetically might havecaused death if more severe.

339 Medical judgement should be exercised in deciding whether other situations should be considered as 340 serious reactions. Some medical events may jeopardise the patient or may require an intervention to 341 prevent one of the above characteristics/consequences. Such important medical events should be 342 considered as serious⁵. The EudraVigilance Expert Working Group has co-ordinated the development of 343 an important medical event (IME) terms list based on the Medical Dictionary for Regulatory Activities (MedDRA) (see GVP Annex IV). This IME list aims to facilitate the classification of suspected adverse 344 reactions, the analysis of aggregated data and the assessment of the individual case safety reports 345 346 (ICSRs) in the framework of the day-to-day pharmacovigilance activities. The IME list is intended for 347 quidance purposes only and is available on the EudraVigilance web site⁶ to stakeholders who wish to 348 use it for their pharmacovigilance activities. It is regularly updated in line with the latest version of MedDRA. 349

Where one or more serious suspected adverse reactions are reported in an ICSR, the information on
the seriousness should be documented at case level in line with ICH-E2B(R2) or for each reported
suspected adverse reaction in accordance with ICH-E2B(R3).

353 VI.A.2.5. Individual case safety report (ICSR)

This refers to the format and content for the reporting of one or several suspected adverse reactions in relation to a medicinal product that occur in a single patient at a specific point of time. [IR Art 27]. A valid ICSR should include at least one identifiable reporter, one single identifiable patient, at least one suspect adverse reaction and at least one suspect medicinal product.

358 VI.A.2.6 Nullflavors

359 Nullflavors are a collection of codes specifying why a valid value is not present in an ICSR. This refers 360 to instances, where for example a proper value is applicable, but not known (e.g. age of the patient), 361 or the value is masked i.e. information is available to a sender of an ICSR but cannot be provided due 362 to security, privacy or other reasons (e.g. date of birth of the patient). ICH ICSR uses Nullflavour code sets from the HL7 Messaging Standard primarily to classify the set of source data situations that may 363 give rise to a missing value. For examples how a Nullflavors can be used to code values in the ICSR, 364 365 refer to chapter 3.3.6. of the ICH Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs) E2B(R3) Data Elements and Message Specification, Version 5.01, 12 April 366 367 2013⁷. Additional EU guidance on the use of the Nullflavor in some specific situations is also provided in chapter I.C.3.7. of the EU Individual Case Safety Report (ICSR) Implementation Guide⁸. 368

369 VI.B. Structures and processes

Section B of this Module highlights the general principles in relation to the collection, recording and
 reporting of reports of suspected adverse reactions associated with medicinal products for human use,
 which are applicable to competent authorities and marketing authorisation holders. The definitions and
 recommendations provided in <u>VI.A.</u> should be followed. EU requirements are presented in VI.C.

⁵ Examples are provided in section II.B of ICH-E2A (see GVP Annex IV).

⁶ <u>http://eudravigilance.ema.europa.eu/human/textforIME.asp</u>.

⁷ Accessible at <u>http://estri.ich.org/e2br3/index.htm</u>

⁸ Ref. <u>EMA/51938/2013</u>, 4 December 2014.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

374 VI.B.1. Collection of reports

- 375 Competent authorities and marketing authorisation holders should take appropriate measures in order
- to collect and collate all reports of suspected adverse reactions associated with medicinal products forhuman use originating from unsolicited or solicited sources.
- For this purpose, a pharmacovigilance system should be developed to allow the acquisition of sufficient information for the scientific evaluation of those reports.
- The system should be designed so that it helps to ensure that the collected reports are authentic, legible, accurate, consistent, verifiable and as complete as possible for their clinical assessment.
- All notifications that contain pharmacovigilance data should be recorded and archived in compliance with the applicable data protection requirements (see <u>VI.C.6.2.2.8.</u> for EU requirements).
- The system should also be structured in a way that allows for reports of suspected adverse reactions to
- be validated (see <u>VI.B.2.</u>) in a timely manner and exchanged between competent authorities and
 marketing authorisation holders within the legal reporting time frame (see <u>VI.B.7.1.</u>).
- In accordance with the ICH-E2D (see GVP Annex IV), two types of safety reports are distinguished in
 the post-authorisation phase; reports originating from unsolicited sources and those reported as
 solicited.

390 VI.B.1.1. Unsolicited reports

391 VI.B.1.1.1. Spontaneous reports

- A spontaneous report is an unsolicited communication by a healthcare professional, or consumer to a competent authority, marketing authorisation holder or other organisation (e.g. Regional Pharmacovigilance Centre, Poison Control Centre) that describes one or more suspected adverse reactions in a patient who was given one or more medicinal products-and that. It does not derive from a study or any organised data collection systems where adverse events reporting is actively sought, as defined in VI.B.1.2. In this aspect, the following situations should also be considered as spontaneous reports:
- Stimulated reporting that occurs consequent to a direct healthcare professional communication (see Module XV), GVP Module XV), publication in the press, questioning of healthcare professionals by company representatives, communication from patients' organisations to their members, or class action lawsuits should be considered spontaneous reports.;
- Unsolicited consumer adverse reactions reports should be handled as spontaneous reports
 irrespective of any subsequent "medical confirmation"...;
- Reports of suspected adverse reactions, which are not related to any organised data collection
 systems and which are notified through medical enquiry/product information services or which are
 consequent of the distribution of information materials;
- Cases notified by different reporters, referring to the same patient and same suspected adverse
 reaction, and at least one notification is done in an unsolicited manner;
- Reports of suspected adverse reactions originating from non-interventional post-authorisation studies and for which the protocol does not require a systematic collection (see <u>VI.C.1.2.1.</u> and <u>VI.C.6.2.3.7.</u>, subsection 2);

413 Reports of suspected adverse reactions originating from compassionate use or named patient use
414 conducted in a country where the active collection of adverse events occurring in these programmes is

415 not required (see <u>VI.C.1.2.2</u>, and <u>VI.C.6.2.3.7</u>, subsection 2). The reporting modalities and applicable

time frames for spontaneous reports are described in VI.B.7. and VI.B.8.

417 VI.B.1.1.2. Literature reports

The scientific and medical literature is a significant source of information for the monitoring of the 418 419 safety profile and of the risk-benefit balance of medicinal products, particularly in relation to the 420 detection of new safety signals or emerging safety issues. Marketing authorisation holders are 421 therefore expected to maintain awareness of possible publications through a systematic literature 422 review of widely used reference databases (e.g. Medline, Excerpta Medica or Embase) no less 423 frequently than once a week. The marketing authorisation holder should ensure that the literature 424 review includes the use of reference databases that contain the largest reference of articles in relation 425 to the medicinal product properties⁹. In addition, marketing authorisation holders should have 426 procedures in place to monitor scientific and medical publications in local journals in countries where 427 medicinal products have a marketing authorisation, and to bring them to the attention of the company

428 safety department as appropriate.

429 Reports of suspected adverse reactions from the scientific and medical literature, including relevant

430 published abstracts from meetings and draft manuscripts, should be reviewed and assessed by

- marketing authorisation holders to identify and record ICSRs originating from spontaneous reports ornon-interventional post-authorisation studies.
- If multiple medicinal products are mentioned in the publication, only those which are identified by the
 publication's author(s) as having at least a possible causal relationship with the suspected adverse
 reaction should be considered by the concerned marketing authorisation holder(s).
- 436 Valid ICSRs should be reported submitted according to the modalities detailed in VI.B.7. and VI.B.8.

One case should be created for each single patient identifiable based on characteristics provided in
VI.B.2-, Relevant medical information should be provided and the first publication author(s) should be
considered as the primary source(s)- as well as the primary source for regulatory purposes in line with
ICH-E2B(R3) (see VI.A.2.3.). The co-authors should not be reflected as part of the primary source
information.

EU specific requirements, as regards medicinal products and scientific and medical publications, which
are not monitored by the Agency and for which valid ICSRs shall be reported submitted by marketing
authorisation holders, are provided in <u>VI.C.2.2.3</u>.

445 VI.B.1.1.3. Reports from other sources (e.g. general news or other media)

If a marketing authorisation holder becomes aware of a report of suspected adverse reactions
originating from a non-medical source, for example the lay press or other media, it should be handled
as a spontaneous report. Every attempt should be made to follow-up the case to obtain the minimum
information that constitutes a valid ICSR. The same reporting time frames should be applied as for

450 other spontaneous reports.

⁹ See <u>VI.-Appendix-App.2</u> for the detailed guidance on the monitoring of medical and scientific literature.

451 VI.B.1.1.4. Information on suspected adverse reactions from the internet or digital media

452 Marketing In line with ICH-E2D, marketing authorisation holders should regularly screen internet or digital media¹⁰ under their management or responsibility, for potential reports of suspected adverse 453 reactions. In this aspect, digital media is considered to be company sponsored if it is owned, paid for 454 and/or controlled by the marketing authorisation holder¹¹. The frequency of the screening should allow 455 456 for potential valid ICSRs to be reported submitted to the competent authorities within the appropriate 457 reporting timeframe based on the date the information was posted on the internet site/digital medium. 458 Marketing authorisation holders may also consider utilising their websites to facilitate the collection of 459 reports of suspected adverse reactions (see VI.C.2.2.1.).

- If a marketing authorisation holder becomes aware of a report of suspected adverse reaction described
 in any non-company sponsored digital medium, the report should be assessed to determine whether it
 qualifies for reporting.
- 463 Unsolicited cases of suspected adverse reactions from the internet or digital media should be handled
 464 as spontaneous reports. The same reporting time frames as for spontaneous reports should be applied
 465 (see VI.B.7.).

In relation to cases from the internet or digital media, the identifiability of the reporter refers to the
possibility of verification of the existence of a real person, that is, it is possible to verify the contact
details of the reporter (based on the information available e.g., an email address under a valid format
has been provided (see VI.B.2. for case validation). If the country of the primary source is missing, the
country where the information was received, or where the review took place, should be used as the
primary source country.

472 VI.B.1.2. Solicited reports

As defined in ICH-E2D (see GVP Annex IV), solicited reports of suspected adverse reactions are those
derived from organised data collection systems, which include clinical trials, non-interventional studies,
registries, post-approval named patient use programmes, other patient support and disease
management programmes, surveys of patients or healthcare providers, compassionate use or name
patient use, or information gathering on efficacy or patient compliance. Reports of suspected adverse
reactions obtained from any of these data collection systems should not be considered spontaneous.
This is with the exception of:

- suspected adverse reactions in relation to those adverse events for which the protocol of noninterventional post-authorisation studies provides differently and does not require their systematic collection (see <u>VI.C.1.2.1.</u>),
- suspected adverse reactions originating from compassionate use or named patient use conducted
 in Member States where the active collection of adverse events occurring in these programmes is
 not required (see VI.C.1.2.2.).
- For the purpose of safety reporting, solicited reports should be classified as study reports, and should
 have an appropriate causality assessment, to consider whether they refer to suspected adverse
 reactions and therefore meet the criteria for reporting. Valid cases of suspected adverse reactions
 should be sent according to the modalities detailed in <u>VI.B.7</u>, and <u>VI.B.8</u>.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

¹⁰ Although not exhaustive, the following list should be considered as digital media: web site, web page, blog, vlog, social network, internet forum, chat room, health portal.

¹¹ A donation (financial or otherwise) to an organisation/site by a marketing authorisation holder does not constitute ownership, provided that the marketing authorisation holder does not control the final content of the site.

490 General reporting rules for suspected adverse reactions occurring in organised data collection systems 491 conducted in the EU under the scope of Directive 2001/83/EC, Regulation (EC) No 726/2004 or 492 Directive 2001/20/EC, are presented in VI.C.1.. Guidance on the management of solicited reports in the EU by marketing authorisation holders is provided in VI.C.2.2.2. 493

VI.B.2. Validation of reports 494

495 Only valid ICSRs qualify for reporting. All reports of suspected adverse reactions should therefore be 496 validated before reporting them to the competent authorities to make sure that the minimum criteria 497 for reporting are included in the reports (see ICH-E2D (see GVP Annex IV)). These are:

- 498 one or more identifiable¹² reporter (primary source), see VI.A.2.3.), characterised by a 499 qualification (e.g. physician, pharmacist, other healthcare professional, lawyer, consumer or other 500 non-healthcare professional) name, initials or address¹³-and at least one of the following parameters¹⁴: name, address¹⁵ or phone number⁻ An ICSR should not be considered valid for 501 reporting unless this information is available for at least one reporter. Whenever possible, contact 502 503 details for the reporter should be recorded so that follow-up activities can be performed. However, 504 if the reporter does not wish to provide contact details, the ICSR should still be considered as valid, 505 providing the organisation who was informed of the case was able to confirm it directly with the reporter. All parties providing case information or approached for case information should be 506 507 identifiable, (not only the initial reporter-);
- one single identifiable¹² patient, characterised by at least one of the following gualifying 508 descriptors: initials, patient identification number, date of birth, age, age group or gender. The 509 information should be as complete as possible¹⁴.-possible¹⁴. An ICSR should not be considered 510 511 valid for reporting unless information is available for at least one of the patient gualifying descriptors Furthermore, as specified in ICH-E2D, a report referring to a definite number of 512 patients should not be regarded as valid until the patients can be characterised by one of the 513 aforementioned qualifying descriptors. For example, "Two patients experienced nausea with drug X 514 515 ..." should not be considered valid without further information;
- one or more suspected¹⁷ substance/medicinal product (see VI.A.2.2.). 516
- one or more suspected adverse reaction (see VI.A.2.1.). 517
- 518 Examples of case validity assessment based on the reporter and the patient identifiability are provided 519 in VI.App.8.

520 If the primary source has made an explicit statement that a causal relationship between the medicinal 521 product and the reported adverse event has been excluded and the receiver (notified competent authority or marketing authorisation holder) agrees with this assessment, the report does not qualify 522 as a valid ICSR since the minimum information for reporting is incomplete¹⁸. The report also does not 523 524 also gualify as a valid ICSR if it is reported that the patient experienced an unspecified adverse 525 reaction and there is no information provided on the type of adverse reaction experienced. Similarly,

- 526 the report is not valid if only an outcome (or consequence) is notified and (i) no further information 527
 - about the clinical circumstances is provided to consider it as a suspected adverse reaction, or (ii) the

- ³ Local data privacy laws regarding patient's and reporter's identifiability might apply.
- ¹⁴ Local data protection laws regarding reporter's and patient's identifiability might apply.
- ¹⁵ Such as reporter's organisation, department, street, city, state/province, postcode, country, or email.
- ¹⁶-See Footnote 9

¹⁸ There is no suspected adverse reaction.

¹² In line with ICH-E2D, the term 'identifiable' is considered in EU as referring to the possibility of verification of the existence of a reporter and of a patient based on the information available.

¹⁷ Interacting medications are also considered suspected.

528 primary source has not indicated a possible causal relationship with the suspected medicinal product. 529 For instance a marketing authorisation holder is made aware that a patient was hospitalised or died, 530 without any further information. In this particular situation, medical judgement should always be 531 applied in deciding whether the notified information is an adverse reaction or an event. For example, a 532 report of sudden death would usually need to be considered as a case of suspected adverse reaction 533 and reported the valid ICSR should be submitted to the competent authorities.

The lack of any of thesethe four elements means that the case is considered incomplete and does not
qualify for reporting. Competent authorities and marketing authorisation holders are expected to
exercise due diligence in following up the case to collect the missing data elements- and follow-up
activities should be documented. Reports, for which the minimum information is incomplete, should
nevertheless be recorded within the pharmacovigilance system for use in on-going safety evaluation
activities. Recommendations on the electronic reporting of valid ICSRs, when missing information has
been obtained, are provided in VI.C.6.2.3.8-

When collecting reports of suspected adverse reactions via the internet or digital media, the term
"identifiable" refers to the possibility of verification of the existence of a reporter and a patient (see
<u>VI.B.1.1.4.</u>). Further guidance is available in <u>VI.C.6.2.2.10.</u> for the electronic reporting of ICSRs
where primary source information cannot be transmitted for data protection considerations.

545 When one party (competent authority or a marketing authorisation holder) is made aware that the 546 primary source may also have reported the suspected adverse reaction to another concerned party, 547 the report should still be considered as a valid ICSR. All the relevant information necessary for the 548 detection of the duplicate case should be included in the ICSR¹⁹. Guidance on the electronic 549 transmission of information allowing the detection of duplicate ICSRs in line with ICH-E2B is provided 550 in VI.C.6.2.2.6.

A valid case of suspected adverse reaction initially submitted reported by a consumer cannot be downgraded to a report of non-related adverse event if the contacted healthcare professional (nominated by the consumer for follow-up information) subsequently disagrees with the consumer's suspicion (see VI.A.2.1.1.). In this situation, the opinions of both the consumer and the healthcare professional should be included in the ICSR. Guidance on the reporting of the medical confirmation of a case, provided in ICH-E2B(R2) Section A.1.14 ("Was the case medically confirmed, if not initially from a healthcare professional?") (see GVP Annex IV), VI.A.2.3. should be followed.

For solicited reports of suspected adverse reactions (see <u>VI.B.1.2.</u>), where the receivernotified
recipient (competent authority or marketing authorisation holder) disagrees with the reasonable
possibility of causal relationship between the suspected medicinal product and the adverse reaction
expressed by the primary source, the case should not be downgraded to a report of non-not causally

related adverse event. The opinions of both, the primary source and the receiver, should be recordedin the ICSR.

564 The same principle applies to the ICSR seriousness criterion, which should not be downgraded from

565 serious to non-serious if the receivernotified recipient disagrees with the seriousness reported by the

566 primary source.

¹⁹ For further guidance on reporting of other duplicate ICSRs, refer to section A.1.11 "Other case identifiers in previous transmission" of ICH-E2B(R2) (see CVP Annex IV).

567 VI.B.3. Follow-up of reports

When first received, the information in suspected adverse reactions reports may be incomplete. These
reports should be followed-up as necessary to obtain supplementary detailed information significant for
the scientific evaluation of the cases. This is particularly relevant for monitored events of special
interest, prospective reports of pregnancy, cases notifying the death of a patient, or cases reporting
new risks or changes in the known risks. This is in addition to any effort to collect missing minimum
information-criteria for reporting (see VI.B.2.).

The provision in ICSRs of patient's age information is important in order to be able to identify safety
issues occurring specifically in the paediatric or elderly population. All possible efforts should be made
to follow-up on an individual case to obtain age information of the patient, where it is initially not
reported by the primary source (see VI.B.6.2.).

578 Any attempt to obtain follow-up information should be documented.

579 Follow-up methods should be tailored towards optimising the collection of missing information. This 580 should be done in ways that encourage the primary source to submit new information relevant for the 581 scientific evaluation of a particular safety concern. The use of targeted specific forms in the local 582 language should avoid requesting the primary source to repeat information already provided in the 583 initial report and/or to complete extensive guestionnaires, which could discourage future spontaneous 584 reporting. Therefore, consideration should be given to pre-populating some data fields in those follow-585 up report forms to make their completion by the primary source easy. Further requirements applicable 586 to competent authorities in Member States and to marketing authorisation holders are provided respectively in VI.C.2.1. and VI.C.2.2. with business process maps and process descriptions included 587 588 in VI.App.1. Guidance on the electronic reporting of follow-up reports is available in VI.C.6.2.2.7.

When information is received directly from a consumer suggesting that an adverse reaction may have
occurred, if the information is incomplete, attempts should be made to obtain follow-up with the
consumer to collect further information and to obtain consent to contact a nominated healthcare
professional to obtain further follow-up information. When such athe case, initially reported by a
consumer, has been is subsequently confirmed (totally or partially) by a healthcare professional, this
information should be clearly highlighted captured in the ICSR²⁰, in line with ICH-E2B (see VI.A.2.3.).

For suspected adverse reactions relating to biological medicinal products, the definite identification of
the concerned product with regard to its manufacturing is of particular importance. Therefore, all
appropriate measures should be taken to clearly identify the name of the product and the batch
number. A business process map and a process description in relation to the mandatory follow-up of
information for the identification of suspected biological medicinal products isare presented in
<u>VI.Appendix 1.</u>..VI.App.1.4.

601 For cases related to vaccines, GVP P.I. should also be followed as appropriate.

For individual cases related to medication errors that result in harm, it may not always be possible to
perform follow-up activities taking into account that the primary source information may have been
anonymised in accordance with local legal requirements or due to provisions that allow for anonymous
reporting.

²⁰ For further guidance on reporting this information, refer to ICH-E2B(R2), section A.1.14 ("Was the case medically confirmed, if not initially from a healthcare professional?") (see <u>GVP Annex IV</u>).

606 VI.B.4. Data management

607 Electronic data and paper reports of suspected adverse reactions should be stored and treated in the 608 same way as other medical records with appropriate respect for confidentiality regarding patients' and 609 reporters' identifiability and in accordance with localapplicable data privacyprotection laws.

- 610 Confidentiality of patients' records including personal identifiers, if provided, should always be
- 611 maintained. Identifiable personal details of reporting healthcare professionals should be kept in
- 612 confidence- protected from unauthorised access. With regards to patient's and reporter's identifiability,
- 613 case report information should be transmitted between stakeholders (marketing authorisation holders
- 614 or competent authorities) in accordance with local data privacyprotection laws (see
- 615 <u>VI.C.6.2.2.8.VI.C.6.2.2.10.</u> for the processing of personal data in ICSRs-in the EU).
- 616 In order toTo ensure pharmacovigilance data security and confidentiality, strict access controls should
 617 be applied to documents and to databases to authorised personnel only. This security extends to the
 618 complete data path. In this aspect, procedures should be implemented to ensure security and non619 corruption of data during data transfer.
- 620 When transfer of pharmacovigilance data occurs within an organisation or between organisations

having concluded contractual agreements, the mechanism should be such that there is confidence that

all notifications are received; in that, a confirmation and/or reconciliation process should be

- 623 undertaken.
- 624 Correct data entry, including the appropriate use of terminologies, should be verified by quality
 625 assurance auditing, either systematically or by regular random evaluation. Data entry staff should be
 626 instructed in the use of the terminologies, and their proficiency confirmed.
- Data received from the primary source should be treated in an unbiased and unfiltered way and
 inferences as well as imputations should be avoided during data entry or electronic transmission. The
 reports should include the verbatim text as used by the primary source or and an accurate translation
- 630 of it- where applicable (see <u>VI.C.6.2.2.9</u> for EU requirements on languages handling). The original

631 verbatim text should be coded using the appropriate terminology as described in <u>VI.B.8</u>. In order to To

- ensure consistency in the coding practices, it is recommended to use, where applicable, the translation
- 633 of the terminology in the local language to code the verbatim text.
- Electronic data storage should allow traceability (audit trail) of all data entered or modified, includingdates and sources of received data, as well as dates and destinations of transmitted data.
- 636 A procedure should be in place to account for identification and management of duplicate cases at data 637 entry and during the generation of aggregated reports (see VI.C.6.2.4.).

638 VI.B.5. Quality management

- 639 Competent authorities and marketing authorisation holders should have a quality management system
 640 in place to ensure compliance with the necessary quality standards at every stage of case
 641 documentation, such as data collection, data transfer, data management, data coding, case validation,
- case evaluation, case follow-up, ICSR reporting and case archiving (see <u>VI.C.6.2.4.</u> and GVP <u>Module I</u>).
 Correct data entry, including the appropriate use of terminologies, should be monitored by quality
- 644 assurance auditing, either systematically or by regular random evaluation.
- 645 Conformity of stored data with initial and follow-up reports should be verified by quality control
 646 procedures, which permit for the validation against the original data or images thereof. In this aspect,
 647 the source data (e.g., letters, emails, records of telephone calls that include details of an event) or an
 648 image of the source data should be easily accessible.

649 Clear written standard operating procedures should guarantee that the roles and responsibilities and 650 the required tasks are clear to all parties involved and that there is provision for proper control and, 651 when needed, change of the system. This is equally applicable to activities that are contracted out to 652 third parties, whose procedures should be reviewed to verify that they are adequate and compliant 653 with applicable requirements.

Staff directly performing pharmacovigilance activities, should be appropriately trained in applicable
pharmacovigilance legislation and guidelines in addition to specific training in report processing
activities for which they are responsible and/or undertake. Data entry staff should be instructed in the
use of the terminologies, and their proficiency confirmed. Other personnel who may receive or process
safety reports (e.g. clinical development, sales, medical information, legal, quality control) should be
trained in adverse event collection and reporting in accordance with internal policies and procedures.

660 VI.B.6. Special situations

VI.B.6.1. Use of a medicinal product during pregnancy or breastfeeding

662 a. Pregnancy

663 Reports, where the embryo or foetus may have been exposed to medicinal products (either through 664 maternal exposure or transmission of a medicinal product via semen following paternal exposure), should be followed-up in order to collect information on the outcome of the pregnancy and 665 development of the child after birth. The recommendations provided in the Guideline on the Exposure 666 667 to Medicinal Products during Pregnancy: Need for Post-Authorisation Data (see GVP Annex III) and in 668 GVP P. III. should be considered as regard the monitoring, collection and reporting of information in 669 these specific situations in order to facilitate the scientific evaluation. When an active substance (or 670 one of its metabolites) has a long half-life, this should be taken into account when assessing the possibility of exposure of the embryo, if the medicinal product was taken before conception. 671

Not infrequently, pregnant women or healthcare professionals will contact either competent authoritiesor marketing authorisation holders to request information on the teratogenicity of a medicinal product

and/or experience of use during pregnancy. Reasonable attempts should be made to obtain

- 675 information on any possible medicinal product exposure to an embryo or foetus and to follow-up on the 676 outcome of the pregnancy.
- 677 Reports of exposure to medicinal products during pregnancy should contain as many detailed elements
 678 as possible in order to assess the causal relationships between any reported adverse events and the
 679 exposure to the suspected medicinal product. In this context the use of standard structured
 680 questionnaires is recommended.

681 Individual cases with an abnormal outcome associated with a medicinal product following exposure 682 during pregnancy are classified as serious reports and should be reported submitted, in accordance with 683 the requirements outlined in VI.B.7. ²¹- and with the electronic reporting recommendations provided in 684 VI.C.6.2.3.1.

- 685 This especially refers to:
- reports of congenital anomalies or developmental delay, in the foetus or the child;
- reports of foetal death and spontaneous abortion; and
- reports of suspected adverse reactions in the neonate that are classified as serious.

²¹ See <u>VI.C.6.2.3.1</u> for electronic reporting recommendations in the EU.

Other cases, such as reports of induced termination of pregnancy without information on congenital
 malformation, reports of pregnancy exposure without outcome data or reports which have a normal
 outcome, should not be reported submitted since there is no suspected adverse reaction. These reports
 should however be collected and discussed in the periodic safety update reports (see GVP Module VII).

693 However, in certain circumstances, reports of pregnancy exposure with no suspected reactions may

- 694 necessitate to be reported.submitted as ICSRs. This may be a condition of the marketing authorisation
- or stipulated in the risk management plan; for example pregnancy exposure to medicinal products
- 696 contraindicated in pregnancy or medicinal products with a special need for surveillance because of a
- high teratogenic potential (e.g. thalidomide, isotretinoin).
- A signal of a possible teratogen effect (e.g. through a cluster of similar abnormal outcomes) should be
 notified immediately to the competent authorities in accordance with the recommendations presented
 in VI.C.2.2.6.

701 *b. Breastfeeding*

The guidance provided in GVP P. III. on the conduct of pharmacovigilance for medicines exposed via
 breastfeeding should be followed. Suspected adverse reactions which occur in infants following
 exposure to a medicinal product from breast milk should be reported submitted in accordance with the
 criteria outlined in VI.B.7.²²- and in line with the recommendations on electronic reporting provided in
 VI.C.6.2.3.1.

VI.B.6.2. Use of a medicinal product in a paediatric or elderly population

The collection of safety information in the paediatric or elderly population is important. Reasonable attempts should therefore be made to obtain and submit the age or age group of the patient when a case is reported by a healthcare professional, or consumer in order to be able to identify potential safety signals specific to a particular population. General guidance in <u>VI.B.3.</u> on reports follow-up should be applied.

As regards the paediatric population, the guidance published by the Agency²³Guidance provided in GVP
P. IV. on the conduct of pharmacovigilance in this
GVP P. V. on the conduct of pharmacovigilance for medicines used in elderly population should be
followed.

VI.B.6.3. Reports of overdose, abuse, off-label use, misuse, medication error or occupational exposure

For the purpose of this Module, medication error refers to any unintentional error in the prescribing,
 dispensing, or administration of a medicinal product while in the control of the healthcare professional
 or consumer.

- Definitions of overdose, abuse, off-label use, misuse, medication error or occupational exposure are
 detailed in VI.A.2.1.2.
- Reports of overdose, abuse, off-label use, misuse, medication error or occupational exposure with no associated adverse reaction should not be reportedsubmitted as ICSRs. They should be considered in
- periodic safety update reports as applicable. When those reports constitute safety issues impacting on

²² See Footnote 16.

²³ Guideline on conduct of pharmacovigilance for medicines used by the paediatric population.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

- the risk-benefit balance of the medicinal product, they should be notified to the competent authorities
 in accordance with the recommendations provided in <u>VI.C.2.2.6</u>.
- Reports associated with suspected adverse reactions should be subject to reporting in accordance with the criteria outlined in VI.B.7, and with the electronic reporting requirements described in VI.C.6.2.3.3.
- the criteria outlined in <u>VI.B.7</u> and with the electronic reporting requirements described in <u>VI.C.6.2.3.3</u>.
 They should be routinely followed-up to ensure that the information is as complete as possible with
- regards to the symptoms, treatments uspected medicinal products name, outcomes, context of
- 733 occurrence (e.g., error in prescription, administration, dispensing, dosage, unauthorised indication or
- 734 population, etc.).

With regards to reports of medication errors, further guidance concerning their management and
 assessment, provided in the Good Practice Guide on Recording, Coding, Reporting and Assessment of
 Medication Errors²⁴, should be followed.

738 VI.B.6.4. Lack of therapeutic efficacy

739 Reports of lack of therapeutic efficacy should be recorded and followed-up if incomplete. They should 740 not normally be reported, but submitted as ICSRs if there is no associated suspected adverse reaction, 741 but they should be discussed in periodic safety update reports as applicable, (see GVP Module VII). However, in certain circumstances, these reports of lack of therapeutic efficacy may require to be 742 reported submitted within a 15-day time frame (see VI.C.6.2.3.4. as regards electronic reporting in the 743 744 EU). Medicinal products used in critical conditions or for the treatment of life-threatening diseases, 745 vaccines, contraceptives are examples of such cases. This applies unless the reporter has specifically 746 stated that the outcome was due to disease progression and was not related to the medicinal product.

The requirement to submit these reports of lack of efficacy does not apply when the notification
occurred in the frame of a non-interventional efficacy study. This is because they refer to the main end
point of the study. For those efficacy studies, the requirements provided in <u>VI.C.1.2.1</u> for noninterventional post-authorisation studies should be followed.

Clinical judgement should be used when considering if other cases of lack of therapeutic efficacy
qualify for reporting. For example, a report of lack of therapeutic efficacy with an antibiotic used in a
life-threatening situation where the use of the medicinal product was not in fact appropriate for the
infective agent should not be reported submitted. However, a report of lack of therapeutic efficacy for a
life-threatening infection, where the lack of therapeutic efficacy which appears to be due to the
development of a newly resistant strain of a bacterium previously regarded as susceptible, should be
reported submitted as ICSR within 15 days.

758 For vaccines, cases of lack of therapeuticprophylactic efficacy should be reported submitted as ICSRs, 759 in particular with the view to highlight potential signals of reduced immunogenicity in a sub-group of vaccinees, waning immunity, or strain replacement. With regard to the latter, it is considered that 760 761 spontaneously reported cases of lack of therapeutic prophylactic efficacy by a healthcare professional may constitute a signal of strain replacement. Such a signal may need prompt action and further 762 investigation through post-authorisation safety studies as appropriate. General guidance regarding the 763 monitoring of vaccines failure, provided in the Report of CIOMS/WHO Working Group on Vaccine 764 765 Pharmacovigilance²⁵, may be followed.

²⁴ Ref.: <u>EMA/762563/2014</u>

²⁵ Council for International Organizations of Medical Sciences (CIOMS). Definition and application of terms of vaccine pharmacovigilance (report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance). Genève: CIOMS; 2012. Accessible at: <u>http://www.cioms.ch/</u>

766 VI.B.7. Reporting of individual case safety reports (ICSRs)

Only valid ICSRs (see VI.B.2.) should be reportedsubmitted. The clock for the reporting of a valid ICSR starts as soon as the information containing the minimum reporting criteria has been brought to the attention of the national or regional pharmacovigilance centre of a competent authority or of any personnel of the marketing authorisation holder, including medical representatives and contractors. This date should be considered as day zero. It is the first day when a receiver gains knowledge of a valid ICSR, irrespective of whether the information is received during a weekend or public holiday. Reporting timelines are based on calendar days.

Where the marketing authorisation holder has set up contractual arrangements with a person or an
organisation, explicit procedures and detailed agreements should exist between the marketing
authorisation holder and the person/organisation to ensure that the marketing authorisation holder can
comply with the reporting obligations. These procedures should in particular specify the processes for
exchange of safety information, including timelines and regulatory reporting responsibilities and should
avoid duplicate reporting to the competent authorities.

For ICSRs described in the scientific and medical literature (see <u>VI.B.1.1.2.</u>), the clock starts (day zero) with awareness of a publication containing the minimum information for reporting. Where contractual arrangements are made with a person/organisation to perform literature searches and/or report valid ICSRs, detailed agreements should exist to ensure that the marketing authorisation holder can comply with the reporting obligations.

785 When additional significant information is received for a previously reported submitted case, the 786 reporting time clock starts again for the submission of a follow-up report starts again from the date of 787 receipt of the relevant follow-up information. For the purpose of reporting, significant follow-up 788 information corresponds to new medical or administrative information that could impact on the 789 assessment or management of a case, or could change its seriousness criteria; non-significant 790 information includes updated comments on the case assessment, or corrections of typographical errors 791 in the previous case version. See also VI.C.6.2.2.7. as regards the distinction between significant and 792 non-significant follow-up information.

793 VI.B.7.1. Reporting time frames

In general, the reporting of serious valid ICSRs is required as soon as possible, but in no case later
than 15 calendar days after initial receipt of the information by the national or regional
pharmacovigilance centre of a competent authority or by any personnel of the marketing authorisation
holder, including medical representatives and contractors. This applies to initial and follow-up
information. Where a case initially reportedsent as serious becomes non-serious, based on new followup information, this information should still be reportedsubmitted within 15 days; the reporting time
frame for non-serious reports should then be applied for the subsequent follow-up reports.

Information as regards the reporting time frame of non-serious valid ICSRs in the EU is provided in
 <u>VI.C.3.</u>

803 ICH-E2B provides a mechanism to the sender to indicate whether the case fulfils the local expedited
 804 requirements. Further guidance on this aspect is provided in <u>VI.C.3</u>.

805

VI. B.7.2 Report nullification

806 The nullification of a report should be used to indicate that a previously transmitted ICSR is considered
807 completely void (nullified), for example when the whole case was found to be erroneous. Guidance on
808 ICSRs nullification in line with ICH-E2B is provided in <u>VI.C.6.2.2.10</u>.

809 VI.B.7.3. Amendment report

810 There may be instances, where a report may need to be amended for example when, after an internal
811 review or according to an expert opinion some items have been corrected, such as adverse
812 event/reaction terms, seriousness, seriousness criteria or causality assessment but without receipt of
813 new information that would warrant submission of a follow-up report. The same would apply where
814 documentation mentioned in ICSRs, translations or literature articles are requested by the Agency or
815 other Member States and are further sent as attachments in line with ICH E2B(R3). Further guidance
816 on the amendment of ICSRs in line with ICH-E2B is provided in VI.C.6.2.2.8.

817 VI.B.8. Reporting modalities

Taking into accountGiven the international dimension of adverse reactions reporting and the need to
achieve harmonisation and high quality between all involved parties, ICSRs should be submitted
electronically as structured data with the use of controlled vocabularies for the relevant data elements
where applicable.

In this aspect, with regard to the content and format of electronic ICSRs, competent authorities and
 marketing authorisation holders should adhere to the following internationally agreed ICH²⁶ guidelines
 and standards (see GVP Annex IV) taking into count the transition from ICH-E2B(R2) to ICH-E2B(R3)
 formats:

- ICH M1 terminology Medical Dictionary for Regulatory Activities (MedDRA) (see GVP Annex IV),
 which should be used at the lowest level term for the transmission of ICSRs;
- MedDRA Term Selection: Points to Consider Document The latest version of the ICH-endorsed
 Guide for MedDRA Users (see GVP Annex IV);
- 830 ICH M2 EWG Electronic Transmission of Individual Case Safety Reports Message Specification
 831 (see GVP Annex IV);
- 832 ICH E2B(R2) Maintenance of the ICH Guideline on Clinical Safety Data Management: Data
 833 Elements for Transmission of Individual Case Safety Reports (see GVP Annex IV);
- ICH E2B Implementation Working Group Questions & Answers (R5) (March 3, 2005) (see GVP
 Annex IV).
- The guidelines applicable based on ICSRs ICH-E2B format:

Reference	Guidelines
ICH-E2B(R2)	ICH-M2 EWG - Electronic Transmission of Individual Case Safety Reports Message Specification (see GVP Annex IV);
	• ICH-E2B(R2) - Maintenance of the ICH Guideline on Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety

26 http://www.ich.org/

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

	Reference	Guidelines
		Reports (see GVP Annex IV);
		ICH-E2B Implementation Working Group - Questions & Answers (R5) (see GVP Annex IV);
	ICH-E2B(R3)	 ICH Implementation guide package including the ICH-E2B(R3) Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs) - Data Elements and Message Specification (see GVP Annex IV);
		 ICH-E2B(R3) Implementation Working Group - Electronic Transmission of Individual Case Safety Reports (ICSRs) - Questions & Answers (see GVP Annex IV);
main		rds evolve over time, the above referred documents may require revision and ision. In this context, the latest version of these documents should always be take
Infor	mation regardii	ng-EU specific reporting modalities isfor ICSRs and the applicable guidelines,

841 definitions, formats, standards and terminologies are provided respectively in VI.C.4. and VI.C.6.1.

843 VI.C. Operation of the EU network

844 Section C of this Module highlights the EU specific requirements, as defined in Directive 2001/83/EC 845 and Regulation (EC) No 726/2004, in relation to the collection, management and reporting of reports 846 of suspected adverse reactions (serious and non-serious) associated with medicinal products for 847 human use authorised in the EU, independently of their condition of use. They are applicable to 848 competent authorities in Member States and/or to marketing authorisation holders. Section C should 849 be read in conjunction with the definitions and general principles detailed in VI.A. and VI.B-of this 850 Module. and with the requirements provided in chapters IV, V and IX of the Commission Implementing 851 Regulation (EU) No 520/2012 [IR].

VI.C.1. Reporting rules for clinical trials and post-authorisation studies in the EU

The pharmacovigilance rules laid down in Directive 2001/83/EC and Regulation (EC) No 726/2004 do
 not apply to investigational medicinal products (IMPs) and non-investigational medicinal products²⁷
 (NIMPs) used in clinical trials conducted in accordance with Directive 2001/20/EC²⁸.

Post-authorisation safety or efficacy studies requested by competent authorities in Member States or the Agency in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004, or conducted voluntarily by marketing authorisation holders, can either be clinical trials or non-interventional postauthorisation studies as shown in Figure VI.1... The safety reporting falls therefore either


- under the scope of Directive 2001/20/EC for any clinical trials; or
- under the provisions set out in Directive 2001/83/EC and Regulation (EC) No 726/2004 for any
 non-interventional post-authorisation studies.
- Suspected adverse reactions should not be reported submitted under both regimes, that isare Directive
 2001/20/EC as well as Regulation (EC) No 726/2004 and Directive 2001/83/EC, as this creates
 duplicate reports.
- 867 Further guidance on post-authorisation safety studies is provided in GVP Module VIII.

The different types of studies and clinical trials which can be conducted in the EU are illustrated in 868 Figure VI.1-. The safety reporting for clinical trials corresponding to sections A, B, C and D of Figure 869 870 VI.1. follows the requirements of Directive 2001/20/EC. The safety reporting for non-interventional 871 post-authorisation studies corresponding to section E and F follows the requirements of Directive 872 2001/83/EC and Regulation (EC) No 726/2004. The reporting rulesrule of reports of suspected adverse reactions to the appropriate EudraVigilance database modules are dependent depends on the types of 873 organised collection systems where they the reactions occurred; recommendations provided in 874 875 VI.C.6.2.1 should be followed.

²⁷ For guidance on these terms, see The Rules Governing Medicinal Products in the European Union, Volume 10, Guidance Applying to Clinical Trials, Guidance on Investigational Medicinal Products and Non-Investigational Medicinal Products (NIMPs) (Ares(2011)300458 - 18/03/2011), and the Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use ('CT-3'), (2011/C 172/01).
²⁸ See DIR Art 3(3) and Art 107(1) third subparagraph.

Figure VI.1. Diagram illustrating different Different types of clinical trials and studies conducted in the
 EU





879		
880 881	Section A:	Clinical trials, which fall under the scope of Directive 2001/20/EC and which are conducted when no marketing authorisation exists in the EU.
882 883	Section B:	Clinical trials, which fall under the scope of Directive 2001/20/EC and which are conducted in the post- authorisation period, e.g. for new indication.
884 885 886	Section C:	Post-authorisation clinical trials conducted in accordance with the summaryterms of the marketing authorisation of the medicinal product-characteristics (SmPC) indication and condition of use, but which fall under the scope of Directive 2001/20/EC due to the nature of the intervention.
887 888 889	Section D:	Post-authorisation safety or efficacy clinical trials requested in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 or conducted voluntarily by marketing authorisation holders, but which fall under the scope of Directive 2001/20/EC due to the nature of the intervention.
890 891 892	Section E:	Non-interventional post-authorisation safety or efficacy studies requested in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004 or conducted voluntarily by the marketing authorisation holders and which follow the same legal requirements.
893 894 895	Section F:	Non-interventional post-authorisation studies conducted in accordance with SmPC indication and condition of use the terms of the marketing authorisation of the medicinal product and which fall under the scope of Directive 2001/83/EC or Regulation (EC) No 726/2004.

896 VI.C.1.1. Reporting rules for clinical trials

- A suspected adverse reaction to an investigational medicinal product occurring in a clinical trial which
 falls under the scope of Directive 2001/20/EC is only to be addressed by the sponsor based on the
- 899 requirements detailed in that Directive. It is therefore excluded from the scope of this Module even if
- 900 the clinical trial where the suspected adverse reaction occurred is a post-authorisation safety or
- 901 efficacy study, requested in accordance with Directive 2001/83/EC or Regulation (EC) No 726/2004, or
- 902 conducted voluntarily.
- 903 If a clinical trial, conducted under the scope of Directive 2001/20/EC, yields safety concerns which
- 904 impact on the risk-benefit balance of an authorised medicinal product, the competent authorities in the
- 905 Member States where the medicinal product is authorised and the Agency should be notified
- 906 immediately in accordance with the modalities detailed in VI.C.2.2.6-. This applies as well if a safety
- 907 concern arises from a clinical trial conducted exclusively outside the EU.
- The safety data from clinical trials to be presented in the relevant sections of the periodic safety
 update report of the authorised medicinal product are detailed in GVP Module VII.

- Where an untoward and unintended response originating from a clinical trial conducted in accordance
 with Directive 2001/20/EC, is suspected to be related only to a non-investigational medicinal product
 (or another medicinal product, which is not part of other than the clinical trial protocol) IMP or NIMP and
 does not result from a possible interaction with the investigational medicinal product IMP or NIMP , it
 does not follow the expedited reporting requirements of Directive 2001/20/EC, which apply only to the
- 915 **investigational medicinal product**. The investigator or the sponsor is encouraged to report the case to
- the competent authority in the Member State where the reaction occurred or to the marketing
 authorisation holder of the suspected medicinal product, but not to both to avoid duplicate reporting²⁹.
- 918 Where made aware of such case, the competent authority or the marketing authorisation holder should
- 919 apply the reporting requirements described in VI.C.3-., VI.C.4. and VI.C.6-. As regards electronic
- 920 reporting, the recommendations detailed in <u>VI.C.6.2.3.7.</u>, subsection 3 should be followed.

VI.C.1.2. Reporting rules for non-interventional post-authorisation studies, compassionate use and named patient use

- 923 This Section applies to non-interventional post-authorisation studies, compassionate use and named 924 patient use. For these organised data collection schemes, a system should be put in place to record 925 and document complete and comprehensive case information on solicited adverse events³⁰(see GVP Annex I) which need to be collected as specified in VI.C.1.2.1. and in VI.C.1.2.2. These In line with 926 927 ICH-E2D (see GVP Annex IV), these adverse events should be systematically assessed to determine 928 whether they are possibly related to the studied (or supplied) medicinal products (see ICH-E2D (see 929 GVP Annex IV)). A method of causality assessment should be applied for assessing the causal role of 930 the studied (or supplied) medicinal products in the solicited adverse events (for example, the WHO-931 UMC system for standardised case causality assessment). An adverse event should be classified as an 932 adverse reaction, if there is at least a reasonable possibility of causal relationship. Only valid ICSRs 933 (see VI.B.2.) of adverse reactions, which are suspected to be related to the studied (or supplied) 934 medicinal product by the primary source or the receiver of the case, should be reported submitted in 935 accordance with the requirements provided in VI.C.3., VI.C.4. and VI.C.6.2.3.7. Other reports of 936 adverse events should be summarised as part of any interim safety analysis and in the final study 937 report, where applicable. In situations where adverse reactions are suspected to be related to 938 medicinal products other than the studied (or supplied) medicine, these reports should be managed, 939 classified and reported submitted as spontaneous ICSRs. They should be notified by the primary source 940 to the competent authority in the Member State where the reactions occurred or to the marketing 941 authorisation holder of the suspected medicinal product, but not to both (to avoid duplicate reporting).
- Where made aware, in the frame of these organised data collection schemes, of events which affect the known risk-benefit balance of the studied (or supplied) medicinal product and/or impact on public health, the marketing authorisation holder should notify the concerned competent authorities and the
- 945 Agency in accordance with the modalities detailed in VI.C.2.2.6.
- Further guidance on post-authorisation studies conducted by marketing authorisation holders is
 provided in <u>VI.C.2.2.2</u>.
- 948 The requirements provided in this Module do not apply to non-interventional post-authorisation studies 949 conducted by organisations such as academia, medical research charities or research organisations in
- 950 the public sector. These organisations should follow local requirements as regards the reporting of
- 951 cases of suspected adverse reactions to the competent authority in the Member State where the

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

²⁹ See The Rules Governing Medicinal Products in the European Union, Volume 10, <u>Detailed guidance on the collection</u>, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use ('CT-3'), (2011/C 172/01).
³⁰See GVP <u>Annex 1</u> for definition of adverse event.

952 reaction occurred. However, where a study conducted by one of these organisations is directly 953 initiated, managed, financed, or where its design is controlled by a marketing authorisation holder 954 (voluntarily or pursuant to obligations imposed in accordance with Articles 21a or 22a of Directive 955 2001/83/EC and Articles 10 or 10(a) of Regulation 726/2004), the requirements provided in this Module are applicable³¹. In this context, contractual agreements should be in place to clearly define 956 the role and responsibilities for implementing these requirements (see GVP Module I). 957

958 VI.C.1.2.1. Non-interventional post-authorisation studies

959 Non-interventional post-authorisation studies³² (see <u>GVP Annex I</u>) should be distinguished between 960 those with primary data collection directly from healthcare professionals or consumers and study 961 designs which are based on the secondary use of data. Depending on the study design, the requirements provided hereafter apply³³. In case of doubt, the reporting requirements should be 962 963 clarified with the concerned competent authorities in Member States. National legislation should be 964 followed as applicable regarding the obligations towards local ethics committees.

965 a. Non-interventional post-authorisation studies with primary data collection

966 Information on all adverse events should be collected from healthcare professionals or consumers in 967 the course of the study unless the protocol provides differently with a due justification for not collecting 968 certain adverse events. For all collected adverse events, comprehensive and high quality information 969 should be sought in a manner which allow for valid ICSRs to be reported submitted within the 970 appropriate timeframes (see VI.C.3.).

- 971 For all collected adverse events, cases of adverse reactions, which are suspected to be related to the 972
- studied medicinal product by the primary source or the receiver of the case, should be
- 973 reported submitted in accordance with the requirements provided in VI.C.3. and VI.C.4. Valid ICSRs 974 should be classified as solicited reports (see <u>VI.C.2.2.2</u>. and <u>VI.C.6.2.3.7.</u>). See summary in Table 975 VI.1..
- 976 All fatal outcomes should be considered as adverse events which should be collected. In certain
- 977 circumstances, suspected adverse reactions with fatal outcome may not be subject to expedited
- 978 reporting as ICSRs, for example because they refer to study outcomes (efficacy end points), because
- 979 the patients included in the study have a disease with high mortality, or because the fatal outcomes
- 980 have no relation to the objective of the study. For these particular situations, the rational for not
- 981 reporting as ICSRs certain adverse reactions with fatal outcomes should be clearly described in the
- 982 protocol.

⁹⁸³ All collected adverse events should be summarised as part of any interim safety analysis and in the 984 final study report.

³¹ This does not concern donation of a medicinal product for research purpose if the marketing authorisation holder has no control on the study.

study

³³ For combined study designs withbased on primary and secondary data collection and secondary use of data, the same requirements as for studies with primary data collection should be followed.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

985 986 987 **Table VI.1.** Non-interventional post-authorisation studies with primary data collection: Requirements concerning adverse events collection and suspected adverse reactions reporting. for non-interventional post-authorisation studies with primary data collection

	Adverse events for which the protocol does not provide differently requires their systematic collection and those with fatal outcomes
Collection requirements	Collect comprehensive and high quality information.Perform causality assessment.
Reporting requirements for suspected adverse reactions	 Cases of adverse reactions, which are suspected to be related to the studied medicinal product by the primary source or the receiver of the case, should be reportedsubmitted in the form of valid ICSRs in line with the appropriate timeframes (See VI.C.3)see VI.C.3.). In certain circumstances, fatal outcome may not be subject to expedited reporting as ICSRs. A justification should always be provided in the protocol.
Reporting requirements for adverse events	 Summarise all collected adverse events as part of any interim safety analysis and in the final study report.

988 For adverse events for which the protocol provides differently and does not require their systematic 989 collection, healthcare professionals and consumers should be informed in the protocol (or other study 990 documents) of the possibility to report adverse reactions (for which they suspect a causal role of a 991 medicine) to the marketing authorisation holder of the suspected medicinal product (studied or not) or 992 to the concerned competent authorities authority via the national spontaneous reporting system. 993 Valid The resulting valid ICSRs should be managed, classified and reported submitted as spontaneous 994 (see VI.C.6.2.3.7. subsection 2) by the receiver of the reports.notified competent authority or 995 marketing authorisation holder. When made aware of them, these reports should also be summarised 996 by the marketing authorisation holder in the relevant study reports.

997 b. Non-interventional post-authorisation studies based on secondary use of data

998 The design of such studies is characterised by the secondary use of data previously collected from
999 consumers or healthcare professionals for other purposes. Examples include medical chart reviews
1000 (including following-up on data with healthcare professionals), analysis of electronic healthcare
1001 records, systematic reviews, meta-analyses.

For these studies, the reporting of suspected adverse reactions in the form of ICSRs is not required. Reports of adverse events/reactions should be summarised as part of any interim safety analysis and in the final study report unless the protocol provides for different reporting.

1005 VI.C.1.2.2. Compassionate use and named patient use

1006 The guidance provided in this Module applies, subject to amendments where appropriate, to medicinal 1007 products supplied in the context of compassionate use as defined in Article 83(2) of Regulation (EC) No 1008 726/2004,, subject to and without prejudice to applicable national law in the EU Member States. As the 1009 case may be, this guidance may also apply to named patient use as defined under Article 5(1) of 1010 Directive 2001/83/EC. Local requirements should be followed as applicable. 1011 Where an organisation³⁴ or a healthcare professional, supplying a medicinal product under
1012 compassionate use or named patient use, is notified or becomes aware of an adverse event, it should
1013 be managed as follows depending on the requirements in the concerned Member State:

- For compassionate use and named patient use conducted in Member States where the active collection of adverse events occurring in these programmes is required, reports of adverse reactions, which are suspected to be related to the supplied medicinal product by the primary source or the receiver of the case, should be reported submitted as ICSRs. They should be considered as solicited reports (see VI.C.2.2.2. and VI.C.6.2.3.7.). subsection 1).
- For compassionate use and named patient use conducted in Member States where the active collection of adverse events occurring in these programmes is not required, any notified noxious or unintended response to the supplied medicinal product should be reported.submitted as ICSR. It should be considered as a spontaneous report of suspected adverse reaction. (see VI.C.6.2.3.7.
 subsection 2).

1024 VI.C.2. Collection of reports

1025 VI.C.2.1. Responsibilities of Member States

Each Member State shall have in place a system for the collection and recording of unsolicited and 1026 solicited reports of suspected adverse reactions that occur in its territory and which are brought to its 1027 attention by healthcare professionals, consumers, or marketing authorisation holders³⁵ [DIR Art 101(1) 1028 1029 and 107a(1)]. In this context, competent authorities in Member States shall establish procedures for 1030 collecting and recording all reports of suspected adverse reactions that occur in their territory [IR Art 1031 15 (2)]. The general principles detailed in VI.B₇, together with the reporting modalities presented in 1032 VI.C.3., VI.C.4. and VI.C.6. should be applied to those reports. should be applied to those reports. 1033 Member States shall involve patients and healthcare professionals, as appropriate, in the follow-up of 1034 any reports they receive in order to comply with Article 102(c) and (e) [DIR Art 107a(1)]. 1035 Furthermore, for reports submitted by a marketing authorisation holder, Member States on whose 1036 territory the suspected adverse reaction occurred may involve the marketing authorisation holder in the follow-up of the reports [DIR Art 107a(2)]. In support of the operation of these follow-up 1037 1038 procedures, business process maps and process descriptions are provided in VI.App.1.2 and 1039 VI.App.1.3. The criteria upon which competent authorities in Member States may involve a marketing 1040 authorisation holder in the follow-up of individual cases refer to the need to seek clarifications on 1041 inconsistent data in ICSRs, but also to the need to obtain further information in the context of the 1042 validation of a signal, the evaluation of a safety issue, the assessment of a periodic safety update 1043 report or the confirmation of a safety concern in a risk management plan. Further guidance on the follow-up of ICSRs is provided in VI.B.3. 1044

Pharmacovigilance data and documents relating to individual authorised medicinal products shall be
retained as long as the product is authorised and for at least 10 years after the marketing
authorisation has expired. However, the documents shall be retained for a longer period where Union
law or national law so requires [IR Art 16(2)].

Each Member State shall take all appropriate measures to encourage healthcare professionals and
consumers in their territory to report suspected adverse reactions to their competent authority. In
addition, the competent authority in a Member State may impose specific obligations on healthcare

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

³⁴ E.g. sponsor, applicant, marketing authorisation holder, hospital or wholesaler.

³⁵ Marketing authorisation holders shall report ICSRs to the competent authorities in Member States in accordance with the transitional provisions set out in Article 2(4) and Article 2(5) of Directive 2010/84/EU and further detailed in <u>VI.C.4.1</u>.

professionals. To this end, competent authorities in Member States shall facilitate in their territory the
reporting of suspected adverse reactions by means of alternative straightforward reporting systems,
accessible to healthcare professionals and consumers, in addition to web-based formats [DIR Art 102].
Information on the different ways of reporting suspected adverse reactions related to medicinal
products, shall be made publicly available including by means of national medicines web-based portals
[DIR 106(e)]. To increase awareness of the reporting systems, organisations representing consumers
and healthcare professionals may be involved as appropriate [DIR Art 102].

StandardIn line with Article 25 of Regulation (EC) No 726/2004, standard web-based structured forms
for the reporting of suspected adverse reactions by healthcare professionals and consumers shall
behave been developed by the AgencyMember States in collaboration with Member States the Agency
in order to collect across the EU harmonised information relevant for the evaluation of suspected
adverse reactions, including errors associated with the use of medicinal products [REG Art 25]. In this
context, core data fields for reporting will be made available by the Agency to the competent
authorities in Member States for use in their national reporting systems as applicable.

The reports of suspected adverse reactions received from healthcare professionals and consumers
should be acknowledged where appropriate and further information should be provided to the reporters
as requested and when available.

1069 For reports submitted by a marketing authorisation holder, Member States on whose territory the
 1070 suspected adverse reaction occurred may involve the marketing authorisation holder in the follow-up
 1071 of the reports [DIR Art 107a(2)].

1072 Each Member State-shall ensure that the competent authority reports of suspected adverse reactions 1073 arising from an error associated with the use of a medicinal product that are brought to their attention 1074 are made available to the EudraVigilance database and to any authorities, bodies, organisations and/or 1075 institutions, responsible for patient safety within that Member State. They shall also ensure that the 1076 authorities responsible for medicinal products within that Member State issue informed of any 1077 suspected adverse reaction, reactions brought to the attention of any other authority, body, institution 1078 or organisation responsible for patient safety within that Member State, and that valid ICSRs are made available to the EudraVigilance database. Therefore, where reports of suspected adverse reactions are 1079 1080 sent directly to other authorities, bodies, organisations and/or institutions within a Member State, the 1081 competent authority in that Member State shall have data exchange agreements in place so that these 1082 reports are brought to its attention and are made available to EudraVigilance in a timely manner[DIR 1083 Art 107a(5)]. This applies as well to reports of suspected adverse reactions arising from an error associated with the use of a medicinal product. Those error reports of suspected adverse reactions for 1084 1085 which a competent authority in a Member State is made aware of, including those received from the 1086 EudraVigilance database in accordance with Article 24(4) of Regulation (EC) No 726/2004, shall also be 1087 brought to the attention of other authorities, bodies, organisations and/or institutions responsible for 1088 patient safety within that Member State [DIR Art 107a(5)]. within that Member State [DIR Art 1089 107a(5)]

1090 To facilitate such reporting, it may be necessary to implement data exchange agreements or other1091 arrangements, as appropriate.

1092 Unless there are justifiable grounds resulting from pharmacovigilance activities, individual Member
1093 States shall not impose any additional obligations on marketing authorisation holders for the reporting
1094 of suspected adverse reactions [DIR Art 107a(6)].

1095 VI.C.2.2. Responsibilities of the marketing authorisation holder in the EU

Each marketing authorisation holder shall have in place a system for the collection and recording of all 1096 1097 reports of suspected adverse reactions which are brought to its attention, whether reported 1098 spontaneously by healthcare professionals or consumers or occurring in the context of a post-1099 authorisation study [DIR Art 104(1), Art 107(1)]. Marketing authorisation holders shall establish 1100 procedures in order to obtain accurate and verifiable data for the scientific evaluation of suspected 1101 adverse reaction reports [Dir Art 107(4)]. They shall not refuse to consider reports of suspected 1102 adverse reactions received electronically or by any other appropriate means from patients and 1103 healthcare professionals [Art 107(2)]. All those reports shall be accessible at a single point within the 1104 Union [Dir Art 107(1)].

- All these reports of suspected adverse reactions shall be accessible at a single point within the Union
 [Dir Art 107(1)]. Marketing authorisation holders shall also collect follow-up information on these
 reports and submit the updates to the Eudravigilance database [Dir Art 107(4)]. In support of the
 operation of the follow-up procedures, a business process map and a process description are provided
 in VI.App.1.1. General guidance on the following-up of reports of suspected adverse reactions is
- 1110 provided in VI.B.3. Marketing authorisation holders shall establish mechanisms enabling the
- 1111 traceability and follow-up of adverse reaction reports while complying with the data protection
- 1112 legislation [IR Art 12 (1)]. Pharmacovigilance data and documents relating to individual authorised
- 1113 medicinal products shall be retained as long as the product is authorised and for at least 10 years after
- 1114 the marketing authorisation has ceased to exist. However, the documents shall be retained for a longer
- 1115 period where Union law or national law so requires [IR Art 12 (2)].
- 1116 With regard to the collection and recording of reports of suspected adverse reactions, marketing
- authorisation holders responsibilities apply to reports related to medicinal products (see VI.A.2.2.) for
- 1118 which ownership cannot be excluded on the basis of one the following criteria: medicinal product
- 1119 name, active substance name, pharmaceutical form, batch number or route of administration.
- 1120 Exclusion based on the primary source country or country of origin of the adverse reaction is possible if
- 1121 the marketing authorisation holder can demonstrate that the suspected medicinal product has never
- been supplied or placed on the market in that territory or that the product is not a travel medicine
- 1123 (e.g., anti-malarial medicinal product).
- The marketing authorisation holder shall ensure that any information on adverse reactions, suspected to be related to at least one of the active substances of its medicinal products authorised in the EU, is brought to its attention by any company outside the EU belonging to the same mother company (or group of companies) ³⁶. The same applies to the marketing authorisation holder when having concluded a commercial agreement with a company outside the EU for one of its medicinal product authorised in the EU. Pursuant to Dir Art 107(1), those reports of suspected adverse reactions shall also be accessible at a single point within the EU. The clock for reporting (see <u>VI.B.7.</u>) starts when a
- 1131 valid ICSR is first received by one of these companies outside the EU.
- 1132 In addition to the requirements presented in this Section, the general principles detailed in Section
- 1133 <u>VI.B.</u>, together with the reporting modalities presented in <u>VI.C.3.</u>, <u>VI.C.4.</u> and <u>VI.C.6.</u> should be
- 1134 applied by marketing authorisation holders to all reports of suspected adverse reactions.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

³⁶ As outlined in the Commission Communication on the Community Marketing Authorization Procedures for Medicinal Products (<u>98/C 229/03</u>).

1135 VI.C.2.2.1. Spontaneous reports

1136 Marketing authorisation holders shall record all reports of suspected adverse reactions originating from

1137 within or outside the EU, which are brought to their attention spontaneously by healthcare

- 1138 professionals, or consumers. This includes reports of suspected adverse reactions received
- electronically or by any other appropriate means [DIR Art 107(1), Art 107(2)]. In this context,
- 1140 marketing authorisation holders may consider utilising their websites to facilitate the collection of
- 1141 reports of suspected adverse reactions by providing adverse reactions forms for reporting, or
- 1142 appropriate contact details for direct communication (see VI.B.1.1.4.).

1143 VI.C.2.2.2. Solicited reports

- 1144 In accordance with Art 107(1) of Directive 2001/83/EC, marketing authorisation holders shall record all 1145 reports of suspected adverse reactions originating from within or outside the EU, which occur in post-
- 1146 authorisation studies, initiated, managed, or financed by them³⁷. For non-interventional post-
- authorisation studies, this requirement applies to study designs based on primary data collection and
- the guidance provided in VI.C.1.2.1. should be followed. For all solicited reports (see VI.B.1.2.),
- 1149 marketing authorisation holders should have mechanisms in place to record and document complete
- and comprehensive case information and to evaluate that information, in order to allow meaningful
- assessment of individual cases and reporting of valid ICSRs (see <u>VI.B.2.</u>) related to the studied (or
 supplied) medicinal product. Marketing authorisation holders should therefore exercise due diligence in
- establishing such system, in following-up those reports (see <u>VI.B.3.</u>) and in seeking the view of the
 primary source as regard the causal role of the studied (or supplied) medicinal product on the notified
- adverse event. Where this opinion is missing, the marketing authorisation holder should exercise its
- 1156 own judgement based on the information available in order to decide whether the report is a valid
- 1157ICSR, which should be reported
submitted to the competent authorities. This requirement does not1158apply to study designs based on secondary use of data since reporting of ICSRs is not required (see
- 1159 <u>VI.C.1.2.1.</u>). Safety data from solicited reports to be presented in the relevant sections of the periodic
 1160 safety update report of the authorised medicinal product are detailed in GVP <u>Module VII</u>.

1161 VI.C.2.2.3. Case reports published in the scientific literature

General principles in relation to the monitoring for individual cases of suspected adverse reactions
described in the scientific and medical literature are provided in <u>VI.B.1.1.2.</u>. AsDetailed guidance on
the monitoring of the scientific and medical literature is provided in <u>VI.App.2</u>. Electronic reporting
recommendations for ICSRs published in the scientific and medical literature are provided in
VI.C.6.2.3.2.

With regards the screening of the scientific and medical literature, the requirements provided in this
Module are part of the reporting of individual cases of suspected adverse reactions as well as wider
literature searches which need to be conducted for periodic safety update reports (see GVP Module
VII).

1171 VI.C.2.2.3.1 Monitoring of medical literature by the European Medicines Agency

1172 The Agency shall monitor selected medical literature for reports of suspected adverse reactions to
1173 medicinal products containing certain active substances. It shall publish a list of active substances
1174 being monitored and the medical literature subject to this monitoring. The Agency shall enter into the

³⁷ This does not concern donation of a medicinal product for research purpose if the marketing authorisation holder has no control on the study.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

1175	EudraVigilance database relevant information from the selected medical literature. The Agency shall, in
1176	consultation with the European Commission, Member States and interested parties, draw up a detailed
1177	guide regarding the monitoring of medical literature and the entry of relevant information into the
1178	EudraVigilance database [REG Art 27].

The medical literature and the active substances subject to the monitoring by the Agency are published at a dedicated webpage³⁸ of the Agency's website together with supporting documents. Further
information is also provided in the Detailed Guide Regarding the Monitoring of Medical Literature and the Entry of Relevant Information into the EudraVigilance Database by the European Medicines
Agency³⁹, which defines the different steps of the medical literature monitoring (MLM) business
processes.

1185 In accordance with Article 107(3) of Directive 2001/83/EC, in order and to avoid the reporting of 1186 duplicate ICSRs, marketing authorisation holders shall only report those ICSRs described in the 1187 scientific and medical literature which is not reviewed by the Agency, for all medicinal products 1188 containing active substances which are not included in the list monitored by the Agency pursuant to 1189 Article 27 of Regulation (EC) No 726/2004. Until such lists of scientific and medical literature and 1190 active substance names are published by the Agency, marketing authorisation holders should monitor all the active substances for which they hold a marketing authorisation in the EU by accessing a widely 1191 1192 used systematic literature review and reference database, in line with the principles detailed in VI.B.1.1.2. and in VI. Appendix 2. 1193

Articles can be excluded from the reporting of ICSRs by the marketing authorisation holder if another
 company's branded medicinal product is the suspected medicinal product. In the absence of a specified
 medicinal product source and/or invented name, ownership of the medicinal product should be
 assumed for articles about an active substance, unless alternative reasons for exclusion detailed
 hereafter apply:

1199 VI.C.2.2.3.2 Exclusion criteria for the reporting of ICSRs published in the scientific literature

1200 The following exclusion criteria for ICSR reporting by marketing authorisation holders apply for1201 individual cases published in the scientific literature:

- a. where ownership of the medicinal product by the marketing authorisation holder can be excluded
 on the basis of the criteria detailed in VI.C.2.2....: medicinal product name, active substance
 name, pharmaceutical form, batch number or route of administration;
- b. for individual case safety reports identified in the scientific and medical literature that
 originatewhich originates in a country where a company holds a marketing authorisation but has
 never commercialised the medicinal product;
- 1208 c. for literature ICSRs which areis based on an analysis from a competent authority database within
 1209 the EU. TheHowever, the reporting requirements remain for those ICSRs which are based on the
 1210 analysis from a competent authority database outside the EU;
- d. for literature articles, which present presents aggregated data analyses or line listings from
 publicly available databases or, e.g. poison control centres,
- e. which summarises unmarises results from post-authorisation studies (see <u>VI.C.1.2.</u>). This type of
 literature article or literature reviews,

³⁸ Monitoring of medical literature and entry of adverse reaction reports into EudraVigilance

³⁹ Ref.: (Doc Ref. <u>EMA/161530/2014</u>)

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

f. which describes suspected adverse reactions, which occur in a group of patients with a designated
 medicinal product with the aim of and individual patients cannot be identified for creating valid
 case reports.

For points d to f, this type of literature aims at identifying or quantifying a safety hazard related to a medicinal product, and aggregated data on patients are often presented in tables or line listings. The main objective of those studies is to detect/evaluate specific risks that could affect the overall riskbenefit balance of a medicinal product.

New and significant safety findings presented in these articles, for which reporting is not required,
should however be discussed in the relevant sections of the concerned periodic safety update report
(see GVP Module VII) and analysed as regards their overall impact on the medicinal product riskbenefit profile. In addition, any new safety information, which may impact on the risk-benefit profile of
a medicinal product, should be notified immediately to the competent authorities in Member States
where the medicinal product is authorised and to the Agency in accordance with the recommendations
provided in VI.C.2.2.6.

- A detailed guidance on the monitoring of the scientific and medical literature has been developed in
 accordance with Article 27(3) of Regulation (EC) No 726/2004; it is included in <u>VI. Appendix 2.</u>
- 1231 The electronic reporting recommendations regarding suspected adverse reactions reports published in
 1232 the scientific and medical literature are provided in <u>VI.C.6.2.3.2.</u>.

1233 VI.C.2.2.4. Suspected adverse reactions related to quality defect or falsified medicinal 1234 products

When a report of suspected adverse reactions is associated with a suspected or confirmed falsified medicinal product or(see GVP Annex I) or with a quality defect of a medicinal product, a valid ICSR should be reportedsubmitted. The seriousness of the ICSR is linked to the seriousness of the reported suspected adverse reactions in accordance with the definitions provided in <u>VI.A.2.4.</u>. Electronic reporting recommendations provided in <u>VI.C.6.2.3.5.</u> should be followed.

- 1240 In addition in order to protect public health, it may become necessary to implement urgent measures
- such as the recall of one or more defective batch(es) of a medicinal product from the market.
- 1242 Therefore, marketing authorisation holders should have a system in place to ensure that reports of
- 1243 suspected adverse reactions related to falsified medicinal products or to quality defects of a medicinal
- 1244 products are investigated in a timely fashion and that confirmed quality defects are notified separately 1245 to the manufacturer and to competent authorities in accordance with the provisions described in Article
- 1246 13 of Directive 2003/94/EC.

1247 VI.C.2.2.5. Suspected transmission via a medicinal product of an infectious agent

- For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal product (including vaccines) should be considered as a serious adverse reaction and such cases should be reported submitted within 15 days in accordance with the requirements outlined in VI.C.4.-⁴⁰. If no other criterion is applicable, the seriousness of this ICSR should be considered as important medical event (see VI.A.2.4.). This also applies to vaccines. Electronic reporting recommendations provided in VI.C.6.2.3.6.VI.C.6.2.3.6. should be followed.
- 1254 In the case of medicinal products derived from human blood or human plasma, haemovigilance 1255 procedures may also apply in accordance with <u>Directive 2002/98/EC</u>. Therefore the marketing

⁴⁰ See <u>VI.C.6.2.3.6.</u> for electronic reporting recommendations.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

- 1256 authorisation holder should have a system in place to communicate suspected transmission via a
- medicinal product of an infectious agent to the manufacturer, the relevant blood establishment(s) and national competent authorities in Member States.
- Any organism, virus or infectious particle (e.g. prion protein transmitting transmissible spongiform
 encephalopathy), pathogenic or non-pathogenic, is considered an infectious agent.
- A transmission of an infectious agent may be suspected from clinical signs or symptoms, or laboratoryfindings indicating an infection in a patient exposed to a medicinal product.
- 1263 Emphasis should be on the detection of infections/infectious agents known to be potentially
- transmitted via a medicinal product, but the occurrence of unknown agents should also always beconsidered.
- 1266 In the context of evaluating a suspected transmission of an infectious agent via a medicinal product,
- 1267 care should be taken to discriminate, whenever possible, between the cause (e.g. injection/
- administration) and the source (e.g. contamination) of the infection and the clinical conditions of thepatient at the time of the infection (immuno-suppressed /vaccinee).
- 1270 Confirmation of contamination (including inadequate inactivation/attenuation of infectious agents as
- 1271 active substances) of the concerned medicinal product increases the evidence for transmission of an
- infectious agent and may therefore be suggestive of a quality defect for which the procedures detailed
 in <u>VI.C.2.2.4.</u> should be applied.
- 1274 Medicinal products should comply with the recommendations provided in the Note for Guidance on
- 1275 Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and
- 1276 Veterinary Products⁴¹. For advanced therapy medicinal products, Article 14(5) of Regulation (EC) No
- 1277 1394/2007 and the Guideline on Safety and Efficacy Follow-up Risk Management of Advanced
- 1278 Therapy Medicinal Products⁴², should also be followed as appropriate.

1279 VI.C.2.2.6. Emerging safety issues

- Events may occur, which do not fall within the definition of reportable valid ICSRs, and thus are not
 subject to the reporting requirements, even though they may lead to changes in the known risk-benefit
 balance of a medicinal product and/or impact on public health. Examples include:
- 1283 major safety findings from a newly completed non-clinical study;
- 1284 major safety concerns identified in the course of a non-interventional post-authorisation study or of
 1285 a clinical trial;
- 1286 signal of a possible teratogen effect or of significant hazard to public health;
- 1287 safety issues published in the scientific and medical literature;
- safety issues arising from the signal detection activity (see <u>Module IX</u>) or emerging from a new
 ICSR and which impact on the risk-benefit balance of the medicinal product and/or have
 implications for public health;
- 1291 <u>safety issues related to the use outside the terms of the marketing authorisation;</u>
- 1292 safety issues due to misinformation in the product information;

⁴¹ Latest revision. (Ref.: <u>EMA/410/01</u>)

⁴² Ref.: EMEA/149995/2008

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

- 1293 marketing authorisation withdrawal, non-renewal, revocation or suspension outside the EU for
 1294 safety-related reasons;
- 1295 urgent safety restrictions outside the EU;
- 1296 safety issues in relation to the supply of raw material;
- 1297 lack of supply of medicines.

1298 These events/observations, which may affect the risk-benefit balance of a medicinal product, are not to 1299 be submitted as ICSRs. They should be notified as emerging safety issues in writing to the competent 1300 authorities in Member States where the medicinal product is authorised and to the Agency via email 1301 (P-PV-emerging-safety-issue@ema.europa.eu); this should be done immediately when becoming 1302 aware of them. The document should indicate the points of concern and the actions proposed in 1303 relation to the marketing application/authorisation for the concerned medicinal product. Those safety 1304 issues should also be analysed in the relevant sections of the periodic safety update report of the 1305 authorised medicinal product They should be notified as emerging safety issues in accordance with the 1306 requirements provided in GVP Module IX.

1307 VI.C.2.2.7. Period between the submission of the marketing authorisation application and 1308 the granting of the marketing authorisation

1309 In the period between the submission of the marketing authorisation application and the granting of

the marketing authorisation, information (quality, non-clinical, clinical) that could impact on the risk-

benefit balance of the medicinal product under evaluation may become available to the applicant⁴³. It

1312 is the responsibility of the applicant to ensure that this information is immediately submitted in

accordance with the modalities described in <u>VI.C.2.2.6.</u> to the competent authorities in the Member

- 1314 States where the application is under assessment (including Reference Member State and all
- 1315 concerned Member States for products assessed under the mutual recognition or decentralised1316 procedures) and to the Agency. For applications under the centralised procedure, the information
- 1317 should also be provided to the (Co-) Rapporteur.

1318 In the situation where a medicinal product application is under evaluation in the EU while it has already

been authorised in a third country, valid ICSRs from outside the EU, originating from unsolicited

1320 reports (see <u>VI.B.1.1.</u>) or solicited reports (see <u>VI.B.1.2.</u>), should be reported submitted in accordance

1321 with the requirements provided in <u>VI.C.3.</u>, <u>VI.C.4.</u> and <u>VI.C.6.</u>.

1322 VI.C.2.2.8. Period after suspension, revocation or withdrawal of marketing authorisation

1323 The marketing authorisation holder shall continue to collect any reports of suspected adverse reactions 1324 related to the concerned medicinal product following the suspension of a marketing authorisation. The 1325 reporting requirements outlined in VI.C.4 remain.

- 1326 Where a marketing authorisation is withdrawn or revoked, the former marketing authorisation holder is
- 1327 encouraged to continue to collect spontaneous reports of suspected adverse reactions originating
- 1328 within the EU to for example facilitate the review of delayed onset adverse reactions or of
- 1329 retrospectively notified cases.

⁴³ See also chapter 1, section 5.1.1 of Volume 2A (Notice to Applicants) of The Rules Governing Medicinal Products in the European Union-, accessible at http://ec.europa.eu/health/documents/eudralex/vol-2/index_en.htm.

1330 VI.C.2.2.9. Period during a public health emergency

A public health emergency is a public health threat duly recognised either by the World Health
Organization (WHO) or the Community in the framework of <u>Decision No. 2119/98/EC</u> as amended of

- 1333 the European Parliament and of the Council. In the event of a public health emergency, regular
- 1334 reporting requirements may be amended. Such arrangements will be considered on a case-by-case
- basis and will be appropriately notified on the Agency website.

1336 VI.C.2.2.10. Reports from class action lawsuits

Stimulated reports arising from class action lawsuits should be managed as spontaneous reports. Valid
 ICSRs should describe suspected adverse reactions related to the concerned medicinal product. They
 should be reported submitted in accordance with the time frames and modalities described in <u>VI.C.3.</u>,
 VI.C.4. and VI.C.6.

- 1340 <u>VI.C.4.</u> and <u>VI.C.6.</u>.
- 1341 Where large batches of potential ICSRs are received, marketing authorisation holders may request, in
- exceptional circumstances, for an exemption in order to submit serious cases of suspected adverse
- 1343 reactions within 30 days from their date of receipt instead of 15 days. The 90 days reporting time
- frame for non-serious ICSRs remains unchanged. It will be possible to apply for this exemption only once the functionalities of the EudraVigilance database specified in Article 24(2) of Regulation (EC) No
- once the functionalities of the EudraVigilance database specified in Article 24(2) of Regulation (EC) No
- 1346 726/2004 are established. The request should be made to the Agency's pharmacovigilance
- 1347 department.

1348 VI.C.2.2.11. Reports from patient support programmes and market research programmes

A patient support programme is an organised system where a marketing authorisation holder receives and collects information relating to the use of its medicinal products. Examples are post-authorisation patient support and disease management programmes, surveys of patients and healthcare providers, information gathering on patient compliance, or compensation/re-imbursement schemes.

- 1353 A market research programme refers to the systematic collection, recording and analysis by a
- 1354 marketing authorisation holder of data and findings about its medicinal products, relevant for
- 1355 marketing and business development.
- Safety reports originating from those programmes should be considered as solicited reports. Marketing
 authorisation holders should have the same mechanisms in place as for all other solicited reports (see
 <u>VI.C.2.2.2.</u>) to manage that information and report valid cases of adverse reactions, which are
- 1359 suspected to be related to the concerned medicinal product.
- 1360 Valid ICSRs should be reported submitted as solicited in accordance with the electronic reporting 1361 requirements provided in VI.C.6.2.3.7.

1362 VI.C.3. Reporting time frames

- 1363 The general rules in relation to the reporting of initial and follow-up reports, including those for 1364 defining the clock start are detailed in VI.B.7.
- According to Articles 107(3) and 107a(4) of Directive 2001/83/EC,
- serious valid ICSRs shall be reported submitted by competent authorities in Member States or by
 marketing authorisation holders within 15 days from the date of receipt of the reports;
- non-serious valid ICSRs shall be reportedsubmitted by competent authorities in Member States or
 by marketing authorisation holders within 90 days from the date of receipt of the reports.

1370 This should be done in accordance with the reporting modalities detailed in VI.C.4.

1371 ICH-E2B provides a mechanism to the sender to indicate whether the case fulfils the local expedited
1372 requirements. In line with ICH-E2B the following applies for all serious and non-serious ICSRs
1373 reportable in the EU based on the modalities detailed in VI.C.4.:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• Data element A.1.9 'Does this case fulfil the local criteria for an expedited report?' should be completed with the value 1 (YES).
ICH-E2B(R3)	• Data element C.1.7 'Does this Case fulfil the local criteria for an expedited report?' should be completed with the value TRUE.

1374 VI.C.4. Reporting modalities of ICSRs in EU

1375 In addition to the recommendations provided in VI.B.8., competent authorities in Member States and marketing authorisation holders shall use the formats, standards and terminologies for the electronic 1376 transmission of suspected adverse reactions as referred to in chapter IV of the Commission 1377 Implementing Regulation (EU) No 520/2012. ICSRs shall be used for reporting to the Eudravigilance 1378 1379 database suspected adverse reactions to a medicinal product that occur in a single patient at a specific point in time [IR Art 27]. Competent authorities in Member States and marketing authorisation holders 1380 1381 shall also ensure that all reported submitted electronic ICSRs are well documented and as complete as 1382 possible in accordance with the requirements provided in FIR Art 28. Art 28 of Commission 1383 Implementing Regulation (EU) No 520/2012.

The time frames for reporting serious and non-serious valid ICSRs are provided in <u>VI.C.3.</u>. The recommendations provided in <u>VI.C.6.</u> should be adhered to as regards the electronic exchange of pharmacovigilance information between competent authorities in Member States, marketing authorisation holders and the Agency.

1388 ICSRs reported electronically to the EudraVigilance database will be made accessible to stakeholders 1389 such as competent authorities, healthcare professionals, consumers, as well as marketing authorisation 1390 holders and research organisations in accordance with Article 24(2) of Regulation (EC) No 726/2004 1391 and the EudraVigilance Access Policy for Medicines for Human Use⁴⁴. This policy defines the overall 1392 principles of the provision of access to EudraVigilance data in line with the current legal framework, 1393 while guaranteeing personal data protection. As detailed in the EudraVigilance access policy, a 1394 selection of ICSRs could be downloaded by marketing authorisation holders in ICH E2B format and in 1395 accordance with the ICH M2 message specifications, to facilitate their pharmacovigilance activities.

1396 VI.C.4.1. Interim arrangements

1397 In accordance with the provisions set out in Article 2(4), Article 2(5) and Article 2(6) of Directive
1398 2010/84/EU, until the Agency can ensure the functionalities of the EudraVigilance database as
1399 specified in Article 24(2) of Regulation (EC) No 726/2004, 107(3) and 107a(4) of Directive
1400 2001/83/EC, the following reporting requirements shall apply to valid unsolicited and solicited ICSRs
1401 reported by healthcare professionals and non-healthcare professionals. This is independently of the
1402 condition of use of the suspected medicinal product and of the expectedness of the adverse reaction.

1403 a. Serious ICSRs

^{44 &}lt;u>http://www.ema.europa.eu</u>

1404 1405	 Marketing authorisation holders shall report all serious ICSRs that occur in the EU to the competent authority of the Member State on whose territory the suspected adverse reactions occurred.
1406 1407 1408 1409	 Marketing authorisation holders shall report to the EudraVigilance database all serious ICSRs that occur outside the EU, including those received from competent authorities. If required by Member States, those reports shall also be submitted to the competent authorities in the Member States in which the medicinal product is authorised.
1410 1411 1412 1413 1414	 Competent authorities in Member States shall ensure that all serious ICSRs that occur in their territory and that are reported to them, including those received from marketing authorisation holders, are made available to the EudraVigilance database. Competent authorities in Member States should also make available, to the marketing authorisation holders of the suspected medicinal products, all serious ICSRs reported directly to them.
1415	b. Non-Serious ICSRs
1416 1417 1418	 If required by Member States, marketing authorisation holders shall report all non-serious ICSRs that occur in the EU to the competent authority of the Member State on whose territory the suspected adverse reactions occurred.
1419 1420 1421	Overviews of the reporting requirements of serious and non-serious reports during the interim period, applicable to marketing authorisation holders or competent authorities in Member States, are presented in VI.App3.1, together with a detailed business process map.
1422 1423	Member States reporting requirements for serious non-EU-ICSRs and for non-serious EU-ICSRs are also included in this Appendix.
1424	VI.C.4.2. Final arrangements
1425 1426 1427 1428 1429 1430	Once the functionalities of the EudraVigilance database specified in Article 24(2) of Regulation (EC) No 726/2004 are established, the following requirements, detailed in Articles 107(3) and 107a(4) of Directive 2001/83/EC, shall apply within 6 months of the announcement by the Agency to valid unsolicited and solicited ICSRs reported by healthcare professionals and non-healthcare professionals. This is independently irrespective of the condition of use of the suspected medicinal product and of the expectedness of the adverse reaction.
1431	a. Serious ICSRs
1432 1433 1434	• Marketing authorisation holders shall submit all serious ICSRs that occur within or outside the EU, including those received from competent authorities outside the EU, to the EudraVigilance database only.
1435	
1436	 Competent authorities in Member States shall submit to the EudraVigilance database all serious ICSRs that occur in their territory and that are directly reported to them.
1436 1437	
	ICSRs that occur in their territory and that are directly reported to them.
1437 1438	ICSRs that occur in their territory and that are directly reported to them. b. Non-Serious ICSRs • Marketing authorisation holders shall submit all non-serious ICSRs that occur in the EU to the

1444 implemented, are are presented in <u>VI.App3App.3.2</u>, together with a detailed business process map
1445 and a process description.

In accordance with the requirement detailed in Article 24(4) of Regulation (EC) No 726/2004 for the
final arrangements, the ICSRs submitted to the EudraVigilance database by marketing authorisation
holders shall be automatically transmitted upon receipt, to the competent authority of the Member
State where the reaction occurred. A detailed Relevant business process map is and process description
are included in VI.App3App.3.3...

In accordance with Article 24(2) of Regulation (EC) No 726/2004, data submitted to the EudraVigilance
 database are made accessible to stakeholders such as competent authorities, healthcare professionals,
 consumers, as well as marketing authorisation holders and research institutions. This is made based on
 the latest version of the EudraVigilance Access Policy for Medicines for Human Use⁴⁵. This policy
 defines the overall principles of the provision of access to EudraVigilance data in line with the current
 legal framework, while guaranteeing personal data protection. VI.C.5.

1457 Additionally, the EudraVigilance database shall also be accessible to marketing authorisation holders to1458 the extent necessary for them to comply with their pharmacovigilance obligations [Reg. Art 24(2)].

1459 VI.C.5. Collaboration with bodies outside the EU regulatory network

1460 VI.C.5.1. Collaboration with the World Health Organization and the 1461 European Monitoring Centre for Drugs and Drug Addiction

1462 The Agency shall make available to the WHO (in practice the Uppsala Monitoring Centre (UMC) as the 1463 WHO Collaborating Centre for International Drug Monitoring) all suspected adverse reaction reports 1464 occurring in the EU [REG Art 28c(1)]. This will taketakes place on a weekly basis after their transmission to the EudraVigilance database by competent authorities in Member States or marketing 1465 1466 authorisation holders. It will replace in line with the latest version of the EudraVigilance Access Policy for Medicines for Human Use⁴⁵. It replaces the requirements of Member States participating in the 1467 WHO Programme for International Drug Monitoring to directly report to WHO suspected adverse 1468 1469 reactions reports occurring in their territory. This will be implemented once the functionalities of the 1470 EudraVigilance database specified in Article 24(2) of Regulation (EC) No 726/2004 are established.

- 1471 A detailed business process map and a process description for the reporting of ICSRs, from the
 1472 EudraVigilance database to the WHO Collaborating Centre for International Drug Monitoring, isare
 1473 presented in <u>VI. AppendixApp 4</u>.
- The Agency and the European Monitoring Centre for Drugs and Drug Addiction shall also exchange
 information that they receive on the abuse of medicinal products including information related to illicit
 drugs [REG Art 28c(2)].

1477 VI.C.6. Electronic exchange of safety information in the EU

1478 VI.C.6. highlights the requirements, as defined in Articles 24(1) and 24(3) of Regulation (EC) No
1479 726/2004, for the establishment and maintenance of the European database and data processing
1480 network (the EudraVigilance database) in order to collate and share pharmacovigilance information
1481 electronically between competent authorities in Member States, marketing authorisation holders and
1482 the Agency, in ways which ensure the quality and integrity of the data collected.

⁴⁵ Ref.: <u>EMA/ 759287/2009</u>

1483 The information provided here is relevant for the electronic exchange of ICSRs in the EU between all 1484 stakeholders and for the electronic submission of information on medicinal products to the Agency.

1485 VI.C.6.1. Applicable guidelines, definitions, international formats, 1486 standards and terminologies

For the classification, retrieval, presentation, risk-benefit evaluation and assessment, electronic
exchange and communication of pharmacovigilance and medicinal product information, Member
States, marketing authorisation holders and the Agency shall adhere to the legal requirements
provided in chapter IV of the Commission Implementing Regulation (EU) No 520/2012.

- 1491 In addition the following guidelines should be applied:
- 1492 Note for guidance EudraVigilance Human Processing of Safety Messages and Individual Case
 1493 Safety Reports (ICSRs) (EMA/H/20665/04/Final Rev. 2) (EudraVigilance Business Rules);
- Note for Guidance on the Electronic Data Interchange (EDI) of Individual Case Safety Reports
 (ICSRs) and Medicinal Products (MPRS) in Pharmacovigilance during the pre- and post authorisation phase in the European economic area (EEA) (EMEA/115735/2004);
- 1497 The ICH guidelines Guidelines detailed in VI.B.8.;

The ICH-M5 guideline Guideline 'Routes of Administration Controlled Vocabulary' (CHMP/ICH/175860/2005), which provides standard terms for routes of administration;

1500 • The guidelines applicable based on ICSRs ICH-E2B format:

		Guidelines	
	ICH-E2B(R2)	 Note for guidance - EudraVigilance Human - Processing of Safety Messages and Individual Case Safety Reports (ICSRs) (<u>EMA/H/20665/04/Final Rev. 2</u>) (also referred as EudraVigilance Business Rules); 	
		• Note for Guidance on the Electronic Data Interchange (EDI) of Individual Case Safety Reports (ICSRs) and Medicinal Products (MPRS) in Pharmacovigilance during the pre- and post-authorisation phase in the European economic area (EEA) (EMEA/115735/2004).	
	ICH-E2B(R3)	• EU ICSR Implementation Guide (EMA/51938/2013);	
		• EU ICSR Implementation Guide Business Rules Spreadsheet;	
		EU Backwards Forwards Conversion Element Mapping <u>Spreadsheet;</u>	
		• EU E2B(R3) code lists;	
		EU reference instances;	
		• EU example <u>instances</u> .	
The I	he latest version of these documents should always be considered taken into account.		

1503 VI.C.6.2. Electronic reporting of individual case safety reports

The reporting of valid ICSRs electronically, by competent authorities in Member States and marketing authorisation holders, is mandatory for all medicinal products authorised in the EU [DIR Art 107(3), Art

1502

1506 107a(4)]. Non-adherence to this requirement constitutes a non-compliance with EU legislation. 1507 Responsibilities

during the Pre- and Post-authorisation Phase in the European Economic Area (EEA)

The responsibilities in case of communication failure (including adherence to compliance for reporting) are detailed in-chapter IV of the Note for Guidance on the Electronic Data Interchange (EDI) of Individual Case Safety Reports (ICSRs) and Medicinal Product Reports (MPRs) in Pharmacovigilance

1511

1512 (EMEA/115735/2004).:

Reference	Guidelines
EudraVigilance database (current)	Chapter IV of the Note for Guidance on the Electronic Data Interchange (EDI) of Individual Case Safety Reports (ICSRs) and Medicinal Product Reports (MPRs) in Pharmacovigilance during the Pre- and Post-authorisation Phase in the European Economic Area (EEA) (EMEA/115735/2004).
EudraVigilance database (new functionalities) Applicable six months following the announcement by the Agency that the new functionalities specified in Article 24(2) of Regulation (EC) No 726/2004 are established.	• Chapter I.C.2.1.6 of the EU ICSR Implementation Guide (<u>EMA/51938/2013</u>).

1514 Technical tools (EVWEB) have been made available by the Agency to interested electronic data

1515 interchange partners, including small and medium-sized enterprises, to facilitate compliance with the

- 1516 electronic reporting requirements as defined in EU legislation. Information is available on
- 1517 EudraVigilance website⁴⁶.

1518 VI.C.6.2.1. EudraVigilance Database Modules

- Two modules are available in the EudraVigilance database to address the collection of reports of
 suspected adverse reactions related to medicinal products for human use, in accordance with EU
 legislation:
- EudraVigilance Post-Authorisation Module (EVPM), implemented based on the requirements defined
 in Regulation (EC) No 726/2004 and Directive 2001/83/EC; and
- EudraVigilance Clinical Trial Module (EVCTM), implemented based on the requirements defined in
 Directive 2001/20/EC.

1526VI.C.6.2.1.1. Adverse reaction data collected in the EudraVigilance Post-Authorisation1527Module

1528 The adverse reaction reports collected in the EudraVigilance Post-Authorisation Module (EVPM) refer to 1529 unsolicited reports and solicited reports which do not fall under the scope of the Clinical Trials Directive

⁴⁶ <u>http://eudravigilance.ema.europa.eu</u>

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

1530 1531	2001/20/EC (see <u>VI.C.1.</u>). The ICSRs should be submitted with the value 'EVHUMAN' in the data element 'Message receiver identifier' (ICH M2 M.1.6). VI.C.1.1.).		
1531	In line with ICH-E2B the ICSRs should be submitted with the following value:		
1032			
	Reference E2B(R2)/(R3) requirements ICH-E2B(R2) • 'EVHUMAN' in the data element M.1.6 'Message receiver identifier' (ICH M2).		
	 ICH-E2B(R3)) • 'EVHUMAN' in the data elements N.1.4 'Batch Receiver Identifier' and 'N.2.r.3 Message Receiver Identifier'. 		
1534			
1535 1536	Depending on their type, these ICSRs should be classified withbased on one of the following options, in accordance with the EudraVigilance Business Rules ⁴⁷ .		
1537	Data element 'Type of report' (ICH-E2B(R2) A.1.4):		
1538	spontancous report;		
1539	other;		
1540	not-available to sender (unknown); or		
1541	report from study.		
1542 1543 1544	In addition, when the value in the data element ICH-E2B(R2) A.1.4 is 'Report from study', the data element 'Study type in which the reaction(s)/event(s) were observed' (ICH-E2B(R2) A.2.3.3) should be populated line with ICH-E2B:		
1545	 - individual patient use, e.g. compassionate use or named-patient basis; or 		
1546			
	Reference E2B(R2)/(R3) requirements		
	ICH-E2B(R2) • Data element A.1.4 'Type of report'		
	 spontaneous report; 		
	– other;		
	 not available to sender (unknown); or 		
	 report from study. 		
	 When the value of the data element A.1.4 is 'Report from study', the data element A.2.3.3 'Study type in which the reaction(s)/event(s) were observed' should be populated with: 		
	 individual patient use, e.g. compassionate use or named-patient basis; or 		
	 other studies, e.g. pharmacoepidemiology, pharmacoeconomics, intensive monitoring, PMS. 		
	ICH-E2B(R3) • Data element C.1.3 'Type of report'		
	 spontaneous report; 		
	– other;		

⁴⁷-Note for guidance - EudraVigilance Human - Processing of Safety Messages and Individual Case Safety Reports (ICSRs) (<u>EMA/H/20665/04/Final Rev. 2</u>).

-	Reference E2B(R2)/(R3) requirements
	 not available to sender (unknown); or
	 report from study.
	 When the value of the data element C.1.3 is 'Report from study', the data element C.5.4 'Study type in which the reaction(s)/event(s) were observed' should be populated with:
	 individual patient use, e.g. compassionate use or named-patient basis; or
	 other studies, e.g. pharmacoepidemiology, pharmacoeconomics, intensive monitoring, PMS.
1547	VI.C.6.2.1.2. Adverse reaction data collected in the EudraVigilance Clinical Trial Module
1548 1549 1550 1551 1552 1553 1554 1555	Only cases of suspected unexpected serious adverse reactions (SUSARs), related to investigational medicinal products (IMPs) or non-investigational medicinal products (NIMPs) ⁴⁸ studied in clinical trials which fall under the scope of Directive 2001/20/EC (see <u>VI.C.1.</u>), VI.C.1.1.), should be reported submitted by the sponsor to the EudraVigilance Clinical Trial Module (EVCTM). The requirements provided in chapter II of EudraLex Volume 10 of The Rules Governing Medicinal Products in the European Union should be applied. The ICSRs should be submitted with the value 'EVCTMPROD' in the data element 'Message receiver identifier' (ICH M2 M.1.6) and should be classified as followed, in accordance with the EudraVigilance Business Rules ⁴⁹ .
1556	 data element 'Type of report' (ICH-E2B(R2) A.1.4);
1557	
1558	 data element 'Study type in which the reaction(s)/event(s) were observed' (ICH-E2B(R2) A.2.3.3):
1559	
1560	The ICSRs should be submitted with the following value in line with ICH-E2B:
	Reference E2B(R2)/(R3) requirements
	ICH-E2B(R2) • 'EVCTMPROD' in the data element M.1.6 'Message receiver identifier' (ICH M2).
	ICH-E2B(R3) 'EVCTMPROD' in the data elements N.1.4 'Batch Receiver Identifier' and 'N.2.r.3 Message Receiver Identifier'.
1561 1562	Depending on their type, ICSRs submitted to EVCTM should be classified based on one of the following options in line with ICH-E2B:
	Reference E2B(R2)/(R3) requirements
-	ICH-E2B(R2) • Data element A.1.4 'Type of report'
	 report from study.
	• When the value of the data element A.1.4 is 'Report from study', the data

⁴⁸ For guidance on these terms, see The Rules Governing Medicinal Products in the European Union, Volume 10, Guidance Applying to Clinical Trials, Guidance on Investigational Medicinal Products and Non-Investigational Medicinal Products (NIMPs) (Ares(2011)300458 - 18/03/2011), and the Detailed guidance on the collection, verification and presentation of adverse event/reaction reports arising from clinical trials on medicinal products for human use ('CT-3'), (2011/C 172/01). ⁴⁹-See Footnote 38.

Reference	E2B(R2)/(R3) requirements
	element A.2.3.3 'Study type in which the reaction(s)/event(s) were observed' should be populated with: - clinical trials
ICH-E2B(R3)	 Data element C.1.3 'Type of report' report from study. When the value of the data element C.1.3 is 'Report from study', the data element C.5.4 'Study type in which the reaction(s)/event(s) were observed' should be populated with: clinical trials

1563 VI.C.6.2.2. Preparation of individual case safety reports

1564 VI.C.6.2.2.1. General principles

The content of each valid ICSR transmitted electronically between all stakeholders should comply with the legal requirements and guidelines detailed in the Commission Implementing Regulation (EU) No 520/2012 and in VI.C.6.1., particularly:

- the requirements provided in chapters IV and V of the Commission Implementing Regulation (EU)
 No 520/2012;
- the latest version of the <u>ICH-Endorsed Guide for MedDRA Users MedDRA Term Selection: Points</u>
 to Consider Document (see GVP Annex IV);
- the EudraVigilance business rules for the electronic transmission of ICSRs detailed in the Note for Guidance - EudraVigilance Human - Processing of Safety Messages and Individual Case Safety Reports (ICSRs) (EMA/H/20665/04/Final Rev. 2).and EU ICSR Implementation Guide as referred to in VI.C.6.1.
- 1576
 1577 It is recognised that it is often difficult to obtain all the details on a specific case. However, the
 1578 complete information (medical and administrative data) for a valid ICSR that is available to the sender
 1579 should be reported submitted in a structured manner in the relevant ICH-E2B(R2) data elements (see
 1580 GVP Annex IV) (which should be repeated as necessary when multiple information is available) and in
 1581 the narrative section for serious cases (see VI.C.6.2.2.4.). This applies to all types of ICSRs, such as
 1582 reports with initial information on the case, follow-up information and cases highlighted for
 1583 amendment⁵⁰ or nullification⁵¹.

1584 In the situation where it is evident that the sender has not transmitted the complete information 1585 available on the case, the receiver may request the sender to re-transmit the ICSR within 24 hours 1586 with the complete case information in electronic format in accordance with the requirements applicable 1587 for the electronic reporting of ICSRs. This should be seen in the light of the qualitative signal detection 1588 and evaluation activity, where it is important for the receiver to have all the available information on a 1589 case to perform the medical assessment (see VI.C.6.2.4.).

Where the suspected adverse reactions reported in a single ICSR impact on the known risk-benefit balance of a medicinal product, this should be considered as an emerging safety issue (see VI.C.2.2.6.), which should be immediately notified in writing to the competent authorities of the

⁵⁰ See also <u>VI.C.6.2.2.8.</u> on amendment of individual cases.

⁵¹ See also <u>VI.C.6.2.2.109</u>, on nullification of individual cases.

Member States where the medicinal product is authorised and to the Agency. This is in addition to the reporting requirements detailed in <u>VI.C.4.</u>. A summary of the points of concerns and the action
proposed should be recorded in the ICSR as follows in data element 'Sender's comments' (line with
ICH-E2B(R2) B.5.4).:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	Data element B.5.4 'Sender's comments'.
ICH-E2B(R3)	Data element H.4 'Sender's comments'.

1597 VI.C.6.2.2.2. Information on suspect, interacting and concomitant medicinal products

1598 1599 1600 1601	medicinal products should be provided in accordance with IR Art Article 28-(3) (g) to (i),) of the Commission Implementing Regulation (EU) No 520/2012, ICH-E2B (R2) (((see GVP Annex IV) ar			
1602	The characterisation of medicinal products as suspect, interacting or concomitant is based on the			
1603	information provided by primary source.			
1604	For-combination medicinal products, which contain more than one active substance, each active			
1605	substance needs to be reflected individually the following applies in the data element 'Active substance			
1606	name(s)' (line with ICHE2B(R2) B.4.k.2.2), which needs to be repeated for each active substance			
1607	contained in the combination medicinal product.:			
	Reference			
	ICH-E2B(R2)	• In addition to the information included in the data element B.4.k.2.1 'Proprietary medicinal product name', each active substance needs to be reflected individually in the data element B.4.k.2.2 'Active substance name(s)', which needs to be repeated for each active substance contained in the medicinal product.		
	ICH-E2B(R3)	• In addition to the information included in the mandatory data element G.k.2.2 'Medicinal Product Name as Reported by the Primary Source', each active substance needs to be reflected individually in the section G.k.2.3.r. 'Substance / Specified Substance Identifier and Strength', which should be repeated for each active substance contained in the medicinal product. This applies where there is no Medicinal Product Identifier (MPID), Pharmaceutical Product Identifier (PhPID)		

When the primary source reports a suspect or interacting branded/proprietary medicinal product name
without indicating the active substance(s) of the medicinal product and where the proprietary
medicinal product can be one of two or more possible generics, which have a different composition
depending on the country where the medicinal product is marketed, the ICSR should be populated as
follows in line with ICH-E2B:

the EU ICSR Implementation Guide (EMA/51938/2013).

or where no Substance/Specified Substance TermID is available as referred to in

1613 • data element 'Proprietary medicinal product name' (ICH-E2B(R2) B.4.k.2.1) should be populated
 1614 with the proprietary/branded medicinal product name as reported by the primary source;

R	eference	E2B(R2)/(R3) requirements
IC	CH-E2B(R2)	• Data element B.4.k.2.1'Proprietary medicinal product name' should be populated with the proprietary/branded medicinal product name as reported by the primary source;
		• Data element B.4.k.2.2 'Active substance name(s)' should be completed with the active substance(s) that correspond(s) to the composition of the proprietary/branded medicinal product of the country where the reaction/event occurred.
		• Where there is more than one active substance contained in the medicinal product, data element B.4.k.2.2 'Active substance name(s)' should be repeated accordingly.
10	CH-E2B(R3)	• Data element G.k.2.2 'Medicinal Product Name as Reported by the Primary Source' should be populated with the proprietary/branded medicinal product name as reported by the primary source;
		• The data element G.k.2.3.r.1 'Substance/Specified Substance Name' should be completed with the active substance(s) that correspond(s) to the composition of the proprietary/branded medicinal product of the country where the reaction/event occurred.
		• Where there is more than one active substance contained in the medicinal product, section G.k.2.3.r 'Substance/Specified Substance Identifier and Strength' should be repeated accordingly.
Но	wever if the in	formation is available on:
•	the 'Identifica B.4.k.2.3),	ation of the country where the drug was obtained' (data element ICH E2B(R2)
•	-the 'Authoriza	ation/application number' (data element ICH-E2B(R2) B.4.k.4.1),
•	-the 'Country	of authorization/application' (data element ICH-E2B(R2) B.4.k.4.2), and/or
•	-the 'Batch/lo	t-number' (data element ICH-E2B(R2) B.4.k.3),
	•	n with regard the active substance(s) of the proprietary medicinal product should be ngly-, if information is available on the following ICH-E2B data elements:
R	eference	E2B(R2)/(R3) requirements
IC	CH-E2B(R2)	• The data element B.4.k.2.3'Identification of the country where the drug was obtained',
		• The data element B.4.k.4.1'Authorization/application number',
		• The data element B.4.k.4.2 'Country of authorization/application', and/or
		The data element B.4.k.3 'Batch/lot number' .

Refer		E2B(R2)/(R3) requirements
ICH-E	2B(R3)	The data element G.k.2.4 'Identification of the Country Where the Drug Was Obtained'
		• The data element G.k.3.2 'Country of Authorisation/Application' and/or
		The data element G.k.4.r.7 'Batch/lot number'

1626 1627 1628 1629 1630 1631 1632 1633 1634 1635	 without indicating the pharmaceutical form/presentation of the product and where the proprietary/branded medicinal product can be one of two or more possible pharmaceutical forms/presentations, which have different compositions in a country, the ICSR should be populated follows in line with ICH-E2B: data element 'Proprietary medicinal product name' (ICH-E2B(R2) B.4.k.2.1) should be populated with the medicinal product name as reported by the primary source; data element 'Active substance name(s)' (ICH-E2B(R2) B.4.k.2.2) should be completed with the active substances which are in common to all pharmaceutical forms/presentations in the count 	
	Reference	E2B(R2)/(R3) requirements
	ICH-E2B(R2)	• Data element B.4.k.2.1'Proprietary medicinal product name' should be populated with the medicinal product name as reported by the primary source;
		 Data element B.4.k.2.2 'Active substance name(s)' should be completed with those active substances, which are in common to all pharmaceutical forms/presentations in the country of authorisation. Where there is more than one active substance contained in the medicinal
		product, data element B.4.k.2.2 'Active substance name(s)' should be repeated accordingly.
	ICH-E2B(R3)	• Data element G.k.2.2 'Medicinal Product Name as Reported by the Primary Source' should be populated with the proprietary/branded medicinal product name as reported by the primary source;
		• The data element G.k.2.3.r.1 'Substance/Specified Substance Name' should be completed with the active substance(s) that correspond(s) to the composition of the proprietary/branded medicinal product of the country where the reaction/event occurred.
		• Where there is more than one active substance contained in the medicinal product, section G.k.2.3.r 'Substance/Specified Substance Identifier and Strength' should be repeated accordingly.
1636	a. Reporting	of a therapeutic class of medicines

Where medicinal products cannot be described on the basis of the active substances or the invented names, for example when only the therapeutic class is reported by the primary source, or in case of other administered therapies that cannot be structured, this information should only be reflected in the case narrative (data element ICH-E2B(R2) B.5.1). The information should not be included in the structured data elements 'Proprietary' related to the medicinal product name' (ICH-E2B(R2))

1642 B.4.k.2.1) name and 'Active/or the active substance name(s)' (ICH-E2B(R2) B.4.k.2.2) should not be 1643 populated.). The same applies if a suspected food interaction is reported (e.g. to grapefruit juice).

1644 Where a case of adverse reactions is reported suspected to be related only to a therapeutic class, it is considered incomplete and does not qualify for reporting (see VI.B.2.). Efforts should be made to 1645 1646 follow-up the case in order to collect the missing information regarding the suspected medicinal 1647 product (see VI.B.3.).

Reporting of interactions 1648 b.

1649 As regards the reporting of drug interactions, which concerns drug/drug (including biological products), drug/food, drug/device, and drug/alcohol interactions, the coding of the interaction should be 1650 1651 performed in the following ICH-E2B section 'Reactions/Events' (ICH-E2B(R2) B.2) in line with the latest

version of the ICH-Endorsed Guide for MedDRA Users - MedDRA Term Selection: Points to Consider 1652 1653 Document (see GVP Annex IV)...) along with any adverse reactions resulting from the suspected 1654 interaction:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	Section B.2 'Reactions/Events'
ICH-E2B(R3)	Section E.i.1'Reaction/Events'

1656

1655 In addition, for instances of drug/drug interactions, information on the active substances/proprietary medicinal product names the following applies in line with ICH-E2B:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	 Section B.4 'Drug information' should be completed with information on the active substances/proprietary medicinal products concerned Data element B.4.k.1 'Characterisation of drug role' is to be completed as 'interacting'.
ICH-E2B(R3)	 Section G.k 'Drug(s) Information' should be completed with information on the active substances/proprietary medicinal products concerned Data element G.k.1 'Characterisation of Drug Role' is to be completed as 'interacting' for all suspected interacting medicines.

1657 If an interaction is suspected with food or other non-drug compounds, 'interacting' should be selected 1658 for the suspect medicine, however information concerning the interacting food should be provided in 1659 the section 'Drug information' (ICH-E2B(R2) B.4), which should be characterised as interacting in the 1660 data element 'Characterisation of drug role' (ICH-E2B(R2) B.4.k.1). case narrative.

Reporting of excipients/adjuvants 1661 .с.

1662 If the primary source suspects a possible causal role of one of the ingredients (e.g., excipient or 1663 adjuvant) of the suspected medicinal product, this information should be provided sent in the section 1664 'Drug information' (line with ICH-E2B(R2) B.4) as a separate entry in addition to the information given 1665 regarding the suspected medicinal product. This should also be specified in the case narrative (data 1666 element ICH-E2B(R2) B.5.1). If available, tests results (positive or negative) in relation to the causal 1667 role of the suspected ingredient should be included in the section 'Results of tests and procedures relevant to the investigation of the patient' (ICH E2B(R2) B.3).follows: 1668

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	 In the section B.4 'Drug information' - as a separate entry specifying the suspected excipient/adjuvant, in addition to the information given regarding the suspected medicinal product. This should also be specified in the case narrative. If available, tests results (positive or negative) in relation to the causal role of the suspected ingredient should be included in the section B.3 'Results of tests and procedures relevant to the investigation of the patient'.
ICH-E2B(R3)	 In the section G.k 'Drug(s) Information' - as a separate entry in addition to the information given regarding the suspected medicinal product. This should also be specified in the case narrative. If available, tests results (positive or negative) in relation to the causal role of the suspected ingredient should be included in the section F.r.3 'Test Result'.

1669d.Additional Information on Drug

Often, additional information on the medicine(s) is provided in individual cases, which is important for
the purpose of data analysis and case review, for example in the context of counterfeit, overdose, drug
taken by father, drug taken beyond expiry date, batch and lot tested and found within specifications,
batch and lot tested and found not within specifications, medication error, misuse, abuse, occupational
exposure and off label use.

1675 The following applies in line with ICH-E2B to capture this information:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	 As a general principle, additional characteristics related to the medicines and pertinent to the case should be provided in free text. Data element B.4.k.19 'Additional information on drug' should be used to specify any additional information (e.g., beyond expiration date, batch and lot tested and found to be within specifications). Additional information concerning the indication for the drug, which cannot be described in data element B.4.k.11 'Indication for use in the case' should also be provided as applicable in the data element B.4.k.19. An appropriate MedDRA term should be provided in the data element B.2.i.1 'Reaction/event in MedDRA terminology (Lowest Level Term)' where applicable in line with the latest version of the <u>ICH-Endorsed Guide for MedDRA Users, MedDRA Term Selection: Points to Consider</u>. Data elements 'B.5.3 Sender's diagnosis/syndrome and/or reclassification of
	reaction/event' and B.5.4 Sender's comments can also be used to combine reported signs and symptoms into a succinct diagnosis, or to provide the sender's assessment of the drug role.
ICH-E2B(R3)	• As a general principle, additional characteristics related to the medicines and pertinent to the case should be coded and further information provided in free text.
	 Data element G.k.10.r 'Additional Information on Drug (coded)' should be completed using one or more of the following values as applicable: Counterfeit, Overdose, Drug taken by father, Drug taken beyond expiry date, Batch and lot

Reference	E2B(R2)/(R3) requirements	
	specifications, Medication error label use. The value(s) should	ications, Batch and lot tested and found not within r, Misuse, Abuse, Occupational exposure and Off be used where the primary source has made a additional characteristics of the drug.
	'Reaction/Event (MedDRA cod	should be provided in the data element E.i.2.1b e)' where applicable in line with the latest version MedDRA Users, MedDRA Term Selection: Points to
	 Section H.3.r 'Sender's Diagnosis' and data element H.4 'Sender's Comments' can also be used to combine reported signs and symptoms into a succinct diagnosis, or to provide the sender's assessment of the drug role. If the primary source did not provide an explicit statement about the drug characterisation which would clearly transpose into a MedDRA term in the reaction section but there is an indication in the context of the clinical course description, the sender may also choose the most applicable value(s) of G.k.10.r 'Additional Information on Drug (coded)' at their discretion. The case should be followed up to obtain further information. Data element G.k.11 'Additional Information on Drug (free text)' should be used to capture any additional drug information in free text format not described in G.k.10.r, e.g. expiry date for the lot number. 	
		nt G.k.10.r 'Additional Information on Drug
	• Counterfeit ⁵²	This is to indicate that the medicine was suspected or confirmed to be a falsified medicinal product in line with the definition provided in Article 1, paragraph 33 of Directive 2001/83/EC.
	Drug taken beyond expiry date	This is to indicate that the medicine administered to or taken by the patient was beyond its expiry date as indicated in the SmPC or on the packaging of the medicine.
	Batch and lot tested and found within specifications	This is to indicate that a batch or lot of a medicine was tested and found within the specifications of the marketing authorisation.
	 Batch and lot tested and found not within specifications 	This is to indicate that a batch or lot of a medicine was tested and found outside the specifications of the marketing authorisation.

⁵² This value should not been used to refer to medicines that do not comply with EU law on intellectual and industrial property rights, such as registered trademarks or patent rights, as defined for counterfeit medicines in <u>Q&A: Directive on falsified medicines</u>.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

1676 VI.C.6.2.2.3. Suspected adverse reactions

All available information as described in [IR ArtArticle 28-(3) (j)]) of Commission Implementing
 Regulation (EU) No 520/2012 shall be provided for each individual case. The coding of diagnoses and
 provisional diagnoses with signs and symptoms in the data element 'Reaction/event in MedDRA
 terminology (Lowest Level Term)' (ICH-E2B(R2) B.2.i.1) should be performed in line with the latest
 version of the ICH-Endorsed Guide for MedDRA Users, MedDRA Term Selection: Points to Consider (see

1682 GVP Annex IV).

1683 In practice, if a diagnosis is reported with characteristic signs and symptoms, the preferred option is to 1684 select a term for the diagnosis only and to MedDRA code it in the ICH-E2B(R2) section B.2 1685 'Reaction(s)/event(s)'. If no diagnosis is provided, all reported signs and symptoms should be listed 1686 and MedDRA--coded in the ICH-E2B(R2) section B.2 'Reaction(s)/event(s)'. If these signs and 1687 symptoms are typically part of a diagnosis, the diagnosis can be MedDRA--coded in addition by 1688 competent authorities in Member States or marketing authorisation holders in the ICH-E2B(R2) data 1689 element B.5.3 'Sender's as part of the sender's diagnosis/syndrome and/or reclassification of reaction/event'event in the ICSR. 1690

1691 If in the narrative other events have been reported, which are not typically signs or symptoms of the
 primary source's diagnosis or provisional diagnosis, and those events are suspected to be adverse
 1693 reactions, they should also be listed and MedDRA-coded in the ICH-E2B(R2) section B.2
 1694 'Reaction(s)/event(s)'-coded.

In caseWhere a competent authority in a Member State or a marketing authorisation holder disagrees
 with the diagnosis reported by the primary source, an alternative diagnosis can be provided in the ICH E2B(R2) data element B.5.3 'Sender's diagnosis/syndrome and/or reclassification of reaction/event' in
 addition to the reported diagnosis provided in the ICH-E2B(R2) section B.2 'Reaction(s)/event(s)'.
 this situation, a-reasoning should be included in the data element 'Sender's comments' (ICH-E2B(R2)
 B.5.4)as additional comment (see VI.C.6.2.2.4.).

1701

In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• Section B.2 'Reaction(s)/event(s)' should be used and the data element B.2.i.1 'Reaction/event in MedDRA terminology (Lowest Level Term)' completed.
	• Section B.5.3 'Sender's diagnosis/syndrome and/or reclassification of reaction/event' should be used where the sender would like to combine signs and symptoms that were reported into a succinct diagnosis whereby the reasoning should be included in the data element B.5.4 'Sender's comments'.
	 Section B.5.3 'Sender's diagnosis/syndrome and/or reclassification of reaction/event' should also be used, if there is disagreement with the diagnosis reported by the primary source and to provide an alternative diagnosis. Reasoning should be included in the in the data element B.5.4 'Sender's comments'.
ICH-E2B(R3)	• Section E.i 'Reaction(s)/Event(s)' should be used and the data element E.i.2.1b 'Reaction/Event (MedDRA code)' completed.
	• Section H.3.r 'Sender's Diagnosis' should be used where the sender would like to combine signs and symptoms that were reported into a succinct diagnosis whereby the reasoning should be included in the data element H.4 'Sender's

Comments'.

Section H.3.r 'Sender's Diagnosis' should also be used, if there is disagreement with the diagnosis reported by the primary source and to provide an alternative diagnosis. Reasoning should be included in the in the data element H.4 'Sender's Comments'.

1702 In the event of death of the patient, the date, cause of death including autopsy-determined causes 1703 shall be provided as available [IR 28 (3) (I)]. If the death is unrelated to the reported suspected 1704 adverse reaction(s) and is linked for example to disease progression, the seriousness criterion of the 1705 ICSR should not be considered as fatal; the recommendation provided in the EudraVigilance Business Rules Eudra Vigilance Business Rules⁵³ and the EU ICSR Implementation Guide⁵⁴ should be followed. 1706

1707 VI.C.6.2.2.4. Case narrative, causality assessment and comments

1708 In accordance with [IR ArtArticle 28 (3) (m];) of Commission Implementing Regulation (EU) No 1709 520/2012, a case narrative (data element ICH-E2B(R2) B.5.1) shall be provided, where possible⁵⁵, for 1710 all cases with the exception of non-serious cases. The information shall be presented in a logical time 1711 sequence, in the chronology of the patient's experience including clinical course, therapeutic measures, 1712 outcome and follow-up information obtained. Any relevant autopsy or post-mortem findings shall also 1713 be summarised.

1714 The narrative should be presented in line with the recommendations described in chapter 5.2 of ICH-E2D (see GVP Annex IV). In this aspect, it should serve as a comprehensive, stand-alone "medical 1715 1716 report" containing all known relevant clinical and related information, including patient characteristics, 1717 therapy details, medical history, clinical course of the event(s), diagnosis, adverse reactions and their 1718 outcomes, relevant laboratory evidence (including normal ranges) and any other information that 1719 supports or refutes the suspected adverse reactions- (see VI.C.6.2.2.11. for handling of languages). With regards to the identifiability of the patient, information should be provided in accordance with 1720 local data protection laws⁵⁶. Case narratives should not include information that could lead to the 1721 identification of the patient, including references to healthcare professionals or treatment centres. 1722

- 1723 An example of a standard narrative template is available in the Report of the CIOMS Working Group V⁵⁷. 1724
- The information provided in the narrative should be consistent with the data appropriately reflected in 1725 1726 all the other relevant ICH-E2B(R2) data elements of the ICSR (see GVP Annex IV). In line with ICH-
- 1727 E2B the following applies:

ICH-E2B(R2)

• Section B.5 'Narrative case summary and further information' should be used and the data element B.5.1 'Case narrative including clinical course, therapeutic

Ref.: (EMA/51938/2013)

See VI.C.6.2.2.10. for the processing of personal data in ICSRs in the EU.

⁵³ Note for guidance – EudraVigilance Human – Processing of safety messages and individual case safety reports (ICSRs) (EMA/H/20665/04/Final Rev. 2)

⁵⁵ 'Where possible' should be interpreted as having received sufficient information from the primary source to prepare a concise clinical summary of the individual case.

⁵⁷ Council for International Organizations of Medical Sciences (CIOMS). Current Challenges in Pharmacovigilance: Pragmatic Approaches (CIOMS V). Geneva: CIOMS; 2001. Accessible at: http://www.cioms.ch/.

Reference	E2B(R2)/(R3) requirements
	measures, outcome and additional relevant information' completed.
ICH-E2B(R3)	• Section H 'Narrative Case Summary and Further Information' should be used and the data element H.1 'Case Narrative Including Clinical Course, Therapeutic Measures, Outcome and Additional Relevant Information' completed.

During the interim arrangements (see <u>VI.C.4.1.</u>), the case narratives included in the ICSRs submitted to the competent authorities in Member States by marketing authorisation holders, should not be modified or deleted when the ICSRs are forwarded to the EudraVigilance database by the competent

1731 authorities.

1747 1748 1749

Where available, comments from the primary source on the diagnosis, causality assessment or other
relevant issue, issues should be provided in the data element 'Reporter's comments' (following ICHE2B(R2) B.5.2).- data elements:

- ReferenceE2B(R2)/(R3) requirementsICH-E2B(R2)• Data element B.5.2 'Reporter's comments'ICH-E2B(R3)• Data element H.2 'Reporter's Comments'
- 1735 Competent authorities in Member States and marketing authorisation holders may provide an 1736 assessment of the case and describe a disagreement with, and/or alternatives to the diagnoses given 1737 by the primary source (see VI.C.6.2.2.3.). This should be done in the data element 'Sender's comments' (ICH-E2B(R2) B.5.4), where discrepancies Discrepancies or confusions in the information 1738 notified by the primary source may also be highlighted. Where applicable, a summary of the points of 1739 1740 concerns and actions proposed should also be included in the data element 'Sender's comments' (ICH-1741 E2B(R2) B.5.4), if the ICSRICSR where it leads to notification of an emerging safety issue (see 1742 VI.C.2.2.6.). The degree of suspected relatedness of each medicinal product to the adverse reaction(s) 1743 may be indicated in the data element 'Relatedness of drug to reaction(s)/event(s)' (ICH-E2B(R2) 1744 B.4.k.18), which should be repeated as necessary. This also allows presenting the degree of 1745 relatedness from different sources or with different methods of assessment.
- 1746 In line with ICH-E2B this information should be provided in the following data elements:

Reference	E2B(R2)/(R3) requirements	
ICH-E2B(R2)	Data element B.5.4 'Sender's comments'	
ICH-E2B(R3)	Data element H.4 'Sender's Comments'	
The degree of suspected relatedness of each medicinal product to the adverse reaction(s) may be used to . present the degree of relatedness from different sources or with different methods of assessment. In line with ICH-E2B the following applies:		
Reference		
ICH-E2B(R2)	 Section B.4.k.18 'Relatedness of drug to reaction(s)/event(s) should be completed and repeated as applicable. 	
ICH-E2B(R3)	• Section G.k.9.i 'Drug-reaction(s)/Event(s) Matrix' should be completed and	

repeated as applicable.

1750 VI.C.6.2.2.5. Test results

1751 Results of tests and procedures relevant to the investigation of the patient shall be provided [IR Art 28
1752 (3) (k)].

As described in ICH-E2B(R2) (see CVP Annex IV), the section B.3 'Results of tests and procedures
relevant to the investigation of the patient' should capture the This includes tests and procedures
performed to diagnose or confirm the reaction/event, including those tests done to investigate
(exclude) a non-drug cause, (e.g., serologic tests for infectious hepatitis in suspected drug-induced
hepatitis). Both positive and negative results should be reported.-included in the ICSR.

The coding of investigations should be performed in line with the latest version of the <u>ICH-Endorsed</u>
Guide for MedDRA Users, MedDRA Term Selection: Points to Consider (see GVP Annex IV). If it is not
possible to provide information on tests and test results in a structured manner, provisions have been
made to allow for the transmission of the information as free text-in the data element ICH-E2B(R2)
B.3.2. 'Results of tests and procedures relevant to the investigation'.

1763 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• Section B.3 'Results of tests and procedures relevant to the investigation of the patient' should be completed and repeated as applicable.
	• Data element B.3.1 'Structured information' should be used to structure the information on the test, the outcome and the date the test was performed. Where several tests or procedures were performed, the section should be completed accordingly.
	• Data element B.3.2 'Results of tests and procedures relevant to the investigation' should be used to provide information on tests and procedures, which cannot be captured in section B.3.1.
ICH-E2B(R3)	• Section F.r 'Results of Tests and Procedures Relevant to the Investigation of the Patient' should be used to structure the information on the test, the outcome and the date the test was performed. Where several tests or procedures were performed, the section should be completed accordingly.
	• Data element F.r.2.1 'Test Name (free text)' should be used for the description of a test when an appropriate MedDRA code is unavailable.
	• Data element F.r.3.4 'Result Unstructured Data (free text)' should be used when 'results' and 'units' cannot be split, often because a Unified Code for Units of Measure (UCUM) code is not available for the test unit.
	• Data element F.r.6 'Comments (free text)' should be used to capture any relevant comments made by the reporter about the test result.
VI.C.6.2.2.6. St	upplementary records/information
Key information from supplementary records should be provided in the relevant section of the ICSR, and their availability should be mentioned-in the data element 'List of documents held by sender' (ICH- E2B(R2) A.1.8.2).	

1768 In line with ICH-E2B the following applies:

1764

1765 1766 1767

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• Data element A.1.8 'Additional available documents held by sender' should be completed as applicable.
ICH-E2B(R3)	 Data element C.1.6.1 'Are Additional Documents Available' should be completed. Section C.1.6.1.r 'Documents Held by Sender' should be completed, where the data element C.1.6.1.r.1 'Documents Held by Sender' should provide a description of the nature of documents (e.g. clinical records, hospital records, autopsy reports) and C.1.6.1.r.2 'Included Documents' should contain the actual document, if the sender chooses to send the document or is required to do so. The processing of personal data should be done in accordance with local data protection law (see <u>VI.C.2.2.10.</u>).

1769 Other known case identifiers relevant for the detection of duplicates should be presented 1770 systematically-in the data element 'Other case identifiers in previous transmissions' (ICH-E2B(R2) A.1.11).

1771

1772 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• Data element A.1.11 'Other case identifiers in previous transmissions' should be completed.
ICH-E2B(R3)	• Section C.1.9.1 'Other Case Identifiers in Previous Transmissions' should be completed as applicable.

1773 VI.C.6.2.2.7. Follow-up information

1774 In addition to the guidance in VI.B.3., the following guidance should be followed:

1775 ICSRs are sent at different times to multiple receivers. Therefore the initial/follow-up status is 1776 dependent upon the receiver. For this reason an item to capture follow-up status is not included in the 1777 ICH-E2B(R2) data elements. However, the data element 'Datedate of receipt of the most recent 1778 information for this report' (ICH-E2B(R2) A.1.7)-report taken together with the data element 'Sender 1779 identifier' (ICH E2B(R2) A.3.1.2) and the data element 'Sender's sender's (case) report unique 1780 identifier' (ICH-E2B(R2) A.1.0.1) identifier provide a mechanism for each receiver to identify whether 1781 the report being transmitted is an initial or a follow-up report. For this reason these items are considered critical for each transmission and a precise date should always be used (i.e. day, month, 1782 1783 year). The data element 'Datedate of receipt of the most recent information for this report' (ICH-1784 E2B(R2) A.1.7)-report should therefore always be updated each time a-follow-up information is received by a competent authority or a marketing authorisation holder, independently irrespective 1785 1786 whether the follow-up information received is significant enough to be reported submitted. The data 1787 element 'Date date the report was first received from the source' (ICH-E2B(R2) A.1.6) source should 1788 remain unchanged to the date the competent authority or the marketing authorisation holder became 1789 aware of the initial report.

1790 New information should be clearly identifiable in the case narrative (data element ICH-E2B(R2) B.5.1) 1791 and should also be provided in a structured format-in the applicable ICH-E2B(R2) data elements.

1792 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	 The following data elements should always be completed: Data element A.1.0.1 'Sender's (case) safety report unique identifier' Data element A.1.6 'Date report was first received from source' Data element A.1.7 'Date of receipt of the most recent information for this report' Data element A.1.10 'Worldwide unique case identification number' Data element A.3.1.2 'Sender identifier' Data element B.5.1 'Case narrative including clinical course, therapeutic measures, outcome and additional relevant information' (for serious reports of suspected adverse reactions)
ICH-E2B(R3)	 The following data elements should always be completed: Data element C.1.1 'Sender's (case) Safety Report Unique Identifier' Data element C.1.4 'Date Report Was First Received from Source' Data element C.1.5 'Date of Most Recent Information for this Report' Section C.1.8 'Worldwide Unique Case Identification' Data element H.1 'Case narrative including clinical course, therapeutic measures, outcome and additional relevant information' (for serious reports of suspected adverse reactions)

1793 Competent authorities in Member States or marketing authorisation holders should report follow-up
1794 information if significant new medical information has been received. Significant new information
1795 relates to, for example, a new suspected adverse reaction(s), reactions, a change in the causality
1796 assessment, and any new or updated information on thea case that impacts on its medical
1797 interpretation. Therefore, the identification of significant new information requiring to be
1798 reported submitted always necessitates medical judgement.

Situations where the seriousness criteria and/or the causality assessment are downgraded (e.g. followup information leads to a change of the seriousness criteria from serious to non-serious; causality
assessment is changed from related to non-related) should also be considered as significant changes
and thus reported submitted as ICSR (see VI.B.7.1. for reporting time frames).

1803 In addition, competent authorities in Member States or marketing authorisation holders should also 1804 report follow-up information, where submit a new version of an ICSR, when new administrative 1805 information is available, that could impact on the case management; for example, if new case 1806 identifiers have become known to the sender, which may have been used in previous transmissions 1807 (data element 'Other case identifiers in previous transmissions' (ICH-E2B(R2) A.1.11)).. This 1808 information may be specifically relevant to manage potential duplicates. Another example refers to 1809 data element 'Additional available documents held by sender' (ICH-E2B(R2) A.1.8), whereby new 1810 documents that have become available to In this context, the sender may following data 1811 elements/sections should be relevant for the medical assessment of the case, completed in line with 1812 ICH-E2B:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• Data element A.1.11 'Other case identifiers in previous transmissions'

Reference	
ICH-E2B(R3)	Section C.1.9.1 'Other Case Identifiers in Previous Transmissions'

1813 1814

1815

Another example refers to additional documents held by sender, whereby new documents that have become available to the sender may be relevant for the medical assessment of the case. In this context, the following data elements/sections should be completed in line with ICH-E2B :

Reference	E2B(R2)/(R3) requirements	
ICH-E2B(R2)	Section A.1.8 'Additional available documents held by sender'	
ICH-E2B(R3)	Section C.1.6 'Additional Available Documents Held by Sender'	

1816 In contrast, a follow-up report which contains non-significant information does not require to be 1817 reported submitted. This may refer, for example, to minor changes to some dates in the case with no 1818 implication for the evaluation or transmission of the case, or corrections of typographical errors in the 1819 previous case version. Medical judgement should be applied since a change to the birth date may 1820 constitute a significant modification (e.g. with implications on the age information of the patient). 1821 Similarly, a change of the status of a MedDRA code/term from current to non-current, due to a version 1822 change of MedDRA, can be considered as a non-significant change as long as this change has no 1823 impact on the medical content of a case. However, an amendment of the MedDRA coding due to a 1824 change in the interpretation of a previously reported suspected adverse reaction may constitute a 1825 significant change and therefore should be reported.

1826 In situations where the case is modified without impacting on its medical evaluation, while no new
1827 follow-up is received (e.g., for correcting a mistake or typographical error), the date of receipt of the
1828 most recent information reported in the data element 'Date of receipt of the most recent information
1829 for this report' (ICH-E2B(R2) A.1.7) should not be changed. This data element should however be
1830 updated in any other situations, to the date when new follow-up information is received (independently
1831 whether it is significant or not) or to the date when changes are made which impact on the
1832 interpretation of the case.

1833 Where follow-up information of a case initially reported submitted by a marketing authorisation holder
1834 is received directly by a competent authority, the 'Worldwide worldwide unique case identification
1835 number' (ICH-E2B(R2) A.1.10)number of the initial report should be maintained, in adherence with
1836 ICH-E2B(R2) (see GVP Annex IV). The same principle should be applied if a follow-up is received by a
1837 marketing authorisation holder of a case initially reported submitted by a competent authority.

1838 VI.C.6.2.2.8. Amendment Report

1839 Serious and non-serious cases may need to be amended when, after an internal review or according to
1840 an expert opinion some items have been corrected, without receipt of new information that would
1841 warrant for the submission of a follow-up report. For example, an amendment of the MedDRA coding
1842 due to a change in the interpretation of a previously submitted ICSR may constitute a significant
1843 change and therefore should be sent as amendment report.

Additionally, for reports for which case translations shall be provided by marketing authorisation
holders when request by the Agency or other Member States (see <u>VI.C.6.2.2.11.</u>), the translations
should be submitted in the form of amendment reports. The same would apply where documentations
or articles mentioned in the ICSRs are requested by the Agency or other Member States and are
further sent as attachments in ICH E2B(R3) C.4.r.2.

However when new information (significant or non-significant) is received, it should be considered as follow-up report and the guidance provided in <u>VI.C.6.2.2.7.</u> should be followed.

1851 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	The principle of amending a report as such is not supported. In situations, where the amendment of a report is necessary, the same principles as for a follow-up report can be applied, even where there is no receipt of new information. It should be noted that this can lead to situations, where these reports may appear as "late reports" i.e. do not meet the established reporting timelines.
	In situations where the case is modified without impacting on its medical evaluation, while no new follow-up is received (e.g., for correcting a mistake or typographical error), the date of receipt of the most recent information included in the data element A.1.7 'Date of receipt of the most recent information for this report' should not be changed.
ICH-E2B(R3)	• The data element C.1.11.1 'Report Nullification/Amendment' should be set to 'Amendment'.
	• The data element C.1.11.2 'Reason for Nullification/Amendment' should be completed to indicate the reason why a previously transmitted ICSR is amended.
	• The same 'Sender's (case) Safety Report Unique Identifier' (data element C.1.1) previously submitted should be used (see exceptions in ICH ICSR Implementation Guide for C.1.1).
	• The same 'Worldwide Unique Identifier' (data element C.1.8) previously submitted should be used.
	• The data element C.1.5 'Date of Most Recent Information for This Report' should remain unchanged. For example MedDRA coding needs to be changed following internal quality review; in this example the date should remain unchanged
VI.C.6.2.2.9. Ni	ullification of cases
that a previously	E2B (see GVP Annex IV), the nullification of individual cases should be used to indicate transmitted report should be considered completely void (nullified), for example when as found to be erroneous or in case of duplicate reports.
The following pri	nciples should be followed:
• The nullification reason should be clear and concise to explain why this case is no longer considered to be a valid report. For example a nullification reason stating, 'the report no longer meets the reporting criteria' or 'report sent previously in error' are not detailed enough explanations;	
An individual case can only be nullified by the sending organisation;	
• Once an indiv	idual case has been nullified, the case cannot be reactivated;
 Individual versions (i.e. follow-up reports) of a case cannot be nullified, only the entire individual case to which they refer; 	

A nullified case is one that should no longer be considered for scientific evaluation. The process of the nullification of a case is by means of a notification by the sender to the receiver that this is no longer a valid case. However, the case should be retained in the sender's and receiver's pharmacovigilance database for auditing purposes.

1869 In line with ICH-E2B the following should be applied:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• The data element A.1.13 'Report nullification' should be set to "Yes".
	• The data element A.1.13.1 'Reason for nullification' should be completed to indicate the reason why a previously transmitted ICSR is considered completel void.
	• The same 'Worldwide unique case identification number' (data element A.1.10) previously submitted should be used.
	• The data element A.1.7 'Date of receipt of the most recent information for this report' should either reflect the date when information was received that warrants the nullification of the report or otherwise should remain unchanged.
ICH-E2B(R3)	• The data element C.1.11.1 'Report Nullification/Amendment' should be set to 'Nullification'.
	• The data element C.1.11.2 'Reason for Nullification/Amendment' should be completed to indicate the reason why a previously transmitted ICSR is considered completely void.
	• The same 'Sender's (case) Safety Report Unique Identifier' (data element C.1. previously submitted should be used (see exceptions in ICH ICSR Implementation Guide for C.1.1).
	• The same 'Worldwide Unique Identifier' (data element C.1.8) previously submitted should be used.
	• The data element C.1.5 "Date of Most Recent Information for This Report" should either reflect the date when information was received that warrants the nullification of the report or otherwise should remain unchanged.
xamples of sce	narios for which ICSRs should be nullified are provided in VI.App.5.
it becomes ne	cessary to resubmit the case that has been previously nullified the following should b
Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• A new 'Sender's (case) safety report unique identifier' (data element A.1.0.1) and a new 'Worldwide unique case identification number' (data element A.1.10 should be assigned.
ICH-E2B(R3)	• A new 'Sender's (Case) Safety Report Unique Identifier' (data element C.1.1) and a new 'Worldwide Unique Case Identification' (Section C.1.8) should be

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

1870

1871 1872 1873

1874 VI.C.6.2.2.10. What to take into account for data privacyprotection laws

To detect, assess, understand and prevent adverse reactions and to identify, and take actions to
reduce the risks of, and increase the benefits from medicinal products for the purpose of safeguarding
public health, the processing of personal data concerning the patient or the primary source within the
EudraVigilance database is possible while respecting EU legislation in relation to data protection
(Directive 95/46/EC, Regulation (EC) No 45/2001).

Where in accordance with applicable national legislation, information related to personal data cannot 1880 be transferred to the EudraVigilance database, pseudonymisation may be applied by competent 1881 authorities in Member States and by marketing authorisation holders, thereby replacing identifiable 1882 1883 personal data such as name and address with pseudonyms or key codes, for example in accordance with the ISO Technical Specification DD ISO/TS 25237: 2008, Health informatics - Pseudonymization 1884 1885 [IR Recital 17]. The application of pseudonymisation will facilitate the ability of the EudraVigilance 1886 system to adequately support case processing and detect duplicates. ThisAlternatively where 1887 pseudonymisation is not feasible, the following may be applied in line with ICH-E2B:

	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• In certain data elements which can identify an individual such as in the reporter's name, initials, address, or in the patient's name, initials, medical record number, where the information cannot be transmitted for data protection reasons, the data element should be populated with the value 'PRIVACY'.
ICH-E2B(R3)	• The nullflavor 'MSK' (see <u>VI.A.2.6.</u>) should be used if personal information is available but cannot be provided by the sender due to local privacy legislation. It informs the receiver that the information does exist without providing personal details such as birth date or name.

Pseudonymisation or the use of the nullflavor 'MSK' should however be doneapplied without impairing
the information flow in the EudraVigilance database and the interpretation and evaluation of safety
data relevant for the protection of public health; given the high-level nature of the information, data
elements such as patient's age, age group and gender should in principle be kept un-redacted/visible.

1892 VI.C.6.2.2.911. Handling of languages

The ICH-E2B(R2) (see GVP Annex IV) concept for the The electronic reporting of ICSRs is based on the fact that structured and coded information is used for data outputs of pharmacovigilance systems (e.g. listings) and for signal detection. However, for scientific case assessment and signal evaluation, the medical summary provided in the data element 'Case narrative including clinical course, therapeutic measures, outcome and additional relevant information' (ICH-E2B(R2) B.5.1) a medical summary is normally required (see VI.6.2.2.4.).

1899 Where suspected adverse reactions are reported by the primary source in narrative and textual
1900 descriptions in an official language of the Union other than English, the original verbatim text and the
1901 summary thereof in English shall be provided by the marketing authorisation holder⁵⁸. Member States
1902 may report case narratives in their official language(s). For those reports, case translations shall be
1903 provided when requested by the Agency or other Member States for the evaluation of potential signals.

⁵⁸ In practice, the original verbatim text reported by the primary source in an official language of the Union other than English should be included in the ICSR, if it is requested by the Member State where the reaction occurred or by the Agency.

- 1904 For suspected adverse reactions originating outside the EU, English shall be used in the ICSR [IR 281905 (4)].
- Additional documents held by the sender, which may be only available in a local language, should onlybe translated if requested by the receiver.

1908 In line with ICH-E2B the following applies:

Reference	
ICH-E2B(R2)	• Data element B.5.1 'Case narrative including clinical course, therapeutic measures, outcome and additional relevant information' should be used to capture the original verbatim text and the English summary thereof.
ICH-E2B(R3)	• Section H.5.r 'Case Summary and Reporter's Comments in Native Language (repeat as necessary)' should be used to provide information on the clinical course of the case, therapeutic measures, outcome and other relevant information, as well as the reporter's comments on the case in a language different from that used in sections H.1, H.2, and H.4.
VI.C.6.2.2.10. 	Nullification of cases
In line with ICH-	E2B(R2) (see GVP Annex IV), the nullification of individual cases should be used to
	reviously transmitted report should be considered completely void (nullified), for
•	he whole case was found to be erroneous or in case of duplicate reports. It is essentia
to use the same	case report numbers previously submitted in the data element 'Sender's (case) safet
report unique ide	entifier' (ICH-E2B(R2) A.1.0.1) and in the data element 'Worldwide unique case
identification nur	mber' (ICH-E2B(R2) A.1.10).
A nullified case in	s one that should no longer be considered for scientific evaluation. The process of the
	case is by means of a notification by the sender to the receiver that this is no longer
	ever, the case should be retained in the sender's pharmacovigilance database for
auditing purpose	
The principles to	be considered when nullifying a case are detailed in VI. Appendix 5.
VI.C.6.2.3. Spe	ecial situations
VI.C.6.2.3.1. U	se of a medicinal product during pregnancy or breastfeeding
General recomm	endations are provided in VI.B.6.1.
With regard to the	he electronic reporting of parent-child/foetus cases, the following should be adhered
to:	
a. In the situat	tion where If a foetus or nursing infant is exposed to one or several medicinal produc
through the	parent and experiences one or more suspected adverse reactions (other than early
spontaneou	s abortion/foetal demise), information on both the parent and the child/foetus should
be provided	hin the same report. These cases are referred to as parent-child/foetus reports. The
information	provided in the section 'Patients characteristics' (ICH-E2B(R2) B.1) applies only to the
	. The characteristics concerning the parent (mother or father), who was the source of
•	the suspect medicinal product should be provided in the data element 'For a parent-
child/fetus r	report, information concerning the parent' (ICH-E2B(R2) B.1.10). If both parents are
	of the suspect drug(s) then the case should reflect the mother's information in the da

1935 element 'For a parent-child/fetus report, information concerning the parent' (ICH E2B(R2) B.1.10).
 1936 The data element 'Case narrative including clinical course, therapeutic measures, outcome and
 1937 additional relevant information' (ICH-E2B(R2) B.5.1) should describe the entire case, including the
 1938 father's information.):

1939 Information on both the parent and the child/foetus should be provided in the same report. This 1940 case is referred to as a parent-child/foetus report. The information provided for the patient's 1941 characteristics applies only to the child/foetus. The characteristics concerning the mother or 1942 father, who was the source of exposure to the suspect medicinal product, should be captured as part of the information concerning the parent. If both parents are the source of the suspect 1943 1944 drug(s), the structured parent information in the case should reflect the mother's characteristics; information regarding the father should be provided in the narrative together with all other 1945 1946 relevant information.

1947 In line with ICH-E2B the following applies:

		E2B(R2)/(R3) requirements
	ICH-E2B(R2)	• Section B.1 'Patient characteristics' should be completed for the child/fetus.
		• Section B.1.10 'For a parent-child/fetus report, information concerning the parent' should be completed for the mother or the father as applicable.
		• Data element B.5.1 'Case narrative including clinical course, therapeutic measures, outcome and additional relevant information' should be used to provide the medical summary for the entire case and where both parents are the source of the suspected drug(s), the father's characteristics should be also reflected here.
	ICH-E2B(R3)	• Section D 'Patient Characteristics' should be completed for the child/fetus.
		• Section D.10 'For a Parent-child / Foetus Report, Information Concerning the Parent' should be completed for the mother or the father as applicable.
		• Section H.5.r 'Case Summary and Reporter's Comments in Native Language (repeat as necessary)' should be used to provide the medical summary for the entire case and where both parents are the source of the suspected drug(s), the father's characteristics should be also reflected here.
b.	If both the pare	ent and the child/foetus experience suspected adverse reactions , two :
Two separate reports, i.e. one for the parent (mother or father) and one for the child, should be created but they. Both reports should be linked by using the data element number of the report which is linked to this report' (in ICH-E2B(R2) A.1.12) in each reformed followed:		ed but they. Both reports should be linked by using the data element 'Identification
	Reference	E2B(R2)/(R3) requirements
	ICH-E2B(R2)	• Section A.1.12 'Identification number of the report which is linked to this report' should be used to identify cases that warrant being evaluated together e.g. a mother-child pair where both had reactions.
	ICH-E2B(R3)	• Section C.1.10.r 'Identification Number of the Report Linked to this Report (repeat as necessary)' should be completed for all linked reports. For example, if a sender wishes to reference (link) an ICSR A to ICSR B, then

		Reference E2B(R2)/(R3) requirements
		the sender populates C.1.10.r in both reports.
1953	C.	If there has been no reaction affecting the child , the :
1954 1955 1956		The parent-child/foetus report does not apply; i.e. the section 'Patients characteristics' (ICH- E2B(R2) B.1) applies the parent's characteristics only apply to the parent (mother or father) who experienced the suspected adverse reaction.
1957		For those cases describing In line with ICH-E2B the following applies:
		Reference E2B(R2)/(R3) requirements
		ICH-E2B(R2) • Section B.1 'Patient characteristics' should be completed for the mother or father as applicable.
		ICH-E2B(R3) • Section D 'Patient Characteristics' should be completed for the mother or father as applicable.
1958	d.	If there has been a miscarriage or early spontaneous abortion, only:
1959 1960 1961 1962 1963		Only a parent report is applicable , i.e. with the section 'Patients characteristics' (ICH-E2B(R2) B.1) applypatient's characteristics to be provided for the mother. However, if the suspect medicinal product was taken by the father, the data element 'Additionalthis information on drug' (ICH- E2B(R2) B.4.k.19) should specify that the medication was taken by the father should also be recorded.
1964		In line with ICH-E2B the following applies:
		Reference E2B(R2)/(R3) requirements
		ICH-E2B(R2) • Section B.1 'Patient characteristics' should be completed for the characteristics of the mother.
		• The data element B.4.k.19 'Additional information on drug' should be completed if suspect drug(s) were taken by the father.
		ICH-E2B(R3) • Section D 'Patient Characteristics' should be completed for the characteristics of the mother.
		• Data element G.k.10.r 'Additional Information on Drug (coded)' should be completed if suspect drug(s) were taken by the father. The value to be selected is 'Drug taken by father'.
		 completed if suspect drug(s) were taken by the father. ICH-E2B(R3) Section D 'Patient Characteristics' should be completed for the characteristics of the mother. Data element G.k.10.r 'Additional Information on Drug (coded)' show completed if suspect drug(s) were taken by the father. The value to be completed if suspect drug(s) were taken by the father.

1965 VI.C.6.2.3.2. Suspected adverse reaction reports published in the scientific literature

EU requirements in relation to the monitoring of suspected drug reactions reported in the scientific and
medical literature are provided in <u>VI.C.2.2.3.</u>, VI.C.2.2.3.1.
With regard to the electronic reporting of
ICSRs published in the scientific and medical literature, the following applies recommendation should be
followed:

1970 The literature references shall be included in the data element 'Literature reference(s)' (ICH-E2B(R2))
 1971 A.2.2)provided in the Vancouver Convention (known as "Vancouver style"), developed by the
 1972 International Committee of Medical Journal Editors [IR Art 28 (3) (b)]. The standard format as well as

- those for special situations can be found in the following reference: <u>International Committee of Medical</u>
 Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med.
- 1975 1997; 336: 309-16, which is in the Vancouver style)]⁵⁹.

1976 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• The data element A.2.2 'Literature reference(s)' should be populated with the literature reference. The Digital Object Identifier (DOI) for the article should be included where available, e.g.: "International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997; 336:309-15. doi:10.1056/NEJM199701233360422"
ICH-E2B(R3)	• Section C.4.r 'Literature Reference(s)' should be populated with the literature reference reflected in the data element C.4.r.1 'Literature Reference(s)'. The Digital Object Identifier (DOI) for the article should be included where available e.g.:" International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997; 336:309-15. doi:10.1056/NEJM199701233360422"

- A comprehensive English summary of the article shall be provided inas part of the data element 'Case
 narrative including clinical course, therapeutic measures, outcome and additional relevant information'
 (ICH-E2B(R2) B.5.1)information [IR Art 28 (3) (b)].
- 1980 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• Data element B.5.1 'Case narrative including clinical course, therapeutic measures, outcome and additional relevant information' should be used to provide the comprehensive English summary.
ICH-E2B(R3)	• Section H.1 'Case narrative including clinical course, therapeutic measures, outcome and additional relevant information' should be used to provide the comprehensive English summary.

Upon request of the Agency, for specific safety review, a full translation in English and a copy of the
relevant literature article shall be provided by the marketing authorisation holder that transmitted the
initial report, taking into account copyright restrictions [IR 28 (3)]. The recommendations detailed in
<u>VLApp2.10</u>, regarding the mailing of the literature article, should be adhered to.

1985 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• The recommendations detailed in <u>VI.App2.10</u> , regarding the mailing of the literature article, should be adhered to.

⁵⁹ The Vancouver recommendations are also available on the International Committee of Medical Journal Editors website <u>http://www.icmje.org.</u> See International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med. 1997; 336: 309-16.

Reference	
ICH-E2B(R3)	 The electronic version of the document (i.e. the journal article and a copy of the translation where applicable) should be attached to the ICSR in C.4.r.2. If the article and/or translation are not provided at the time of ICSR reporting, attachments can be transmitted separately from the ICSR transmission. When the sender transmits an attachment later, the original ICSR along with all the same medical information captured in E2B(R3) data elements is retransmitted as an 'amendment' (see <u>V1.C.2.2.8.</u>). If new additional information is provided, then the ICSR with attachment is transmitted as a follow-up.

1986 Recommendations presented in VI.App2.10, for the reporting of several individual cases when they 1987 are published in the same literature article, should be followed.

1988 VI.C.6.2.3.3. Suspected adverse reactions related to overdose, abuse, off-label use, misuse, 1989 medication error or occupational exposure

1990 General principles are provided in VI.B.6.3.

If a case of overdose, abuse, off-label use, misuse, medication error or occupational exposure is
reported with clinical consequences, the MedDRA Lowest Level Term code, corresponding to the term
closest to the description of the reported overdose, abuse, off-label use, misuse, medication error or
occupational exposure should be added to the observed suspected adverse reaction(s) in the data
element 'Reaction/event in MedDRA terminology (Lowest Level Term)' (ICH-E2B(R2) B.2.i.1), in-line
with recommendations included in the latest version of the ICH-Endorsed Guide for MedDRA Users
'MedDRA Term Selection: Points to Consider' (see GVP Annex IV).

1998 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	 Data element B.4.k.19 'Additional information on drug' can be used to specify any additional information (e.g., overdose, abuse, off-label use, misuse, medication error or occupational exposure). Additional information concerning the indication for the drug should be provided as applicable. Likewise, the appropriate MedDRA term should be provided in the data element B.2.i.1 'Reaction/event in MedDRA terminology (Lowest Level Term)' or in the data element 'B.5.3 Sender's diagnosis/syndrome and/or reclassification of reaction/event' (in line with ICH-Endorsed Guide for MedDRA Users 'MedDRA Term Selection: Points to Consider').
ICH-E2B(R3)	 Data element G.k.10.r 'Additional Information on Drug (coded)' should be completed using one or more of the following values as applicable:, Overdose, Medication error, Misuse, Abuse, Occupational exposure and Off label use. The value(s) should be used where the primary source has made a clear statement related to the additional characteristics of the drug. Likewise, an appropriate MedDRA term should be provided in the data element E.i.2.1b 'Reaction/Event (MedDRA code)'. Alternatively, section H.3.r 'Sender's Diagnosis' should be completed (in line with ICH-Endorsed Guide for MedDRA Users 'MedDRA Term Selection: Points to Consider').

	E2B(R2)/(R3) req	uirements
•	characterisation which wo reaction section but there description, the sender m	not provide an explicit statement about the drug uld clearly transpose into a MedDRA term in the is an indication in the context of the clinical course ay choose the most applicable value(s) of G.k.10.r at should be followed up to obtain further information.
•		itional Information on Drug (free text)' should be ional drug information in free text format not
•	with the value 'Drug not a not receive the actual pre- information provided by the by the sender. This applie prescribed drug. There is Information' should be co- drug (including the fact th	Characterisation of Drug Role' should be populated administered' for medication errors if the patient did scribed drug but another one, based on the he primary source or, if this information is missing, as where the patient did not receive the actual no equivalent in ICH-E2B(R2). Sections G 'Drug(s) mpleted with the information about the prescribed hat it was not administered), as well as the sed drug as the 'suspect' drug.
	/alues definition for data ele [coded)'	ement 'G.k.10.r Additional Information on Drug
•	Overdose	This is to indicate that the medicine may have been subject to an overdose as defined in chapter VI.A.2.1.2.a.
•	Misuse	This is to indicate that the medicine may have been associated with misuse as defined in chapter VI.A.2.1.2.a.
•	Abuse	This is to indicate that the medicine may have been associated with abuse as defined in chapter VI.A.2.1.2.a.
•	Occupational exposure	This is to indicate that the medicine may have been associated with occupational exposure as defined in chapter VI.A.2.1.2.a.
•	Off label use	This is to indicate that the medicine may have been associated with off label use as defined in chapter VI.A.2.1.2.a.
•	Medication error	This is to indicate that the medicine may have been associated with a medication error as defined in chapter VI.A.2.1.2.a.

1999 VI.C.6.2.3.4. Lack of therapeutic efficacy

2000 General principles are provided in VI.B.6.4.

If the primary source suspects a lack of therapeutic efficacy, the MedDRA Lowest Level Term code,
 corresponding to the term closestmost closely to the description of the reported lack of therapeutic
 efficacy, should be provided in the data clement 'Reaction/event in MedDRA terminology (Lowest Level

Term)' (ICH-E2B(R2) B.2.i.1), in lineaccordance with recommendations-included in the latest version of
 the ICH-Endorsed Guide for MedDRA Users 'MedDRA Term Selection: Points to Consider' (see GVP
 Annex IV).

2007 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• The appropriate MedDRA term should be provided in the data element B.2.i.1 'Reaction/event in MedDRA terminology (Lowest Level Term)'.
ICH-E2B(R3)	• The appropriate MedDRA term should be provided in the data element E.i.2.1b 'Reaction/Event (MedDRA code)'.

- 2008 Unless aggravation of the medical condition occurs, the indication for which the suspected medicinal 2009 product was administered should not be included in the data element 'Reaction/event in MedDRA 2010 terminology (Lowest Level Term).)' or 'Reaction/Event (MedDRA code)'.
- The same reporting modalities as for serious ICSRs (see <u>VI.C.4.</u>) should be applied for those cases related to classes of medicinal products where, as described in <u>VI.B.6.4.</u>, reports of lack of therapeutic
- 2013 efficacy should be reported submitted within a 15-day time frame. If no seriousness criterion is
- 2014 available, it is acceptable to submit the ICSR within 15 days as non-serious.

2015VI.C.6.2.3.5. Suspected adverse reactions related to quality defect or falsified medicinal2016products

EU requirements are provided in <u>VI.C.2.2.4</u>. In order to be able to clearly identify cases related to quality defect or falsified medicinal products (see <u>GVP Annex I</u>) when they are exchanged between stakeholders, the following recommendations should be applied:

2020 *a.* *a. Quality defect*

Where a report of suspected adverse reactions is associated with a suspected or confirmed quality defect of a medicinal product, the MedDRA Lowest Level Term code of the term corresponding most closely to the product quality issue, should be added to the observed suspected adverse reaction(s) in the data element 'Reaction/event in MedDRA terminology (Lowest Level Term)' (ICH-E2B(R2) B.2.i.1). accordance with the recommendations in the latest version of the ICH-Endorsed Guide for MedDRA Users 'MedDRA Term Selection: Points to Consider.

2027 **b-**In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	 As a general principle, additional characteristics related to the medicines and pertinent to the case should be coded and further information related to the quality defect provided in free text. Data element B.4.k.19 'Additional information on drug' should be used to specify any additional information (e.g., beyond expiration date, batch and lot tested and found to be within specifications); additional information concerning the indication for the drug should be provided as applicable. The appropriate MedDRA term should be provided in the data element B.2.i.1 'Reaction/event in MedDRA terminology (Lowest Level Term)'.
ICH-E2B(R3)	Data element G.k.10.r 'Additional Information on Drug (coded)' should be

Reference	E2B(R2)/(R3) requirements	
	tested and found within specifications. These values sh	of the following values as applicable: Batch and lot ications; Batch and lot tested and found not within hould be used where the primary source has made he additional characteristics of the drug.
	• Likewise, an appropriate MedDRA term should be provided in the data element E.i.2.1b 'Reaction/Event (MedDRA code)'. Alternatively, section H.3.r 'Sender's Diagnosis' should be completed.	
		al Information on Drug (free text)' should be used information in free text format not described in
	 Values definition for data elem (coded)' 	nent 'G.k.10.r Additional Information on Drug
	Drug taken beyond expiry date	This is to indicate that the medicine administered to or taken by the patient was beyond its expiry date as indicated in the SmPC or on the packaging of the medicine.
	Batch and lot tested and found within specifications	This is to indicate that a batch or lot of a medicine was tested and found within the specifications of the marketing authorisation.
	 Batch and lot tested and found not within specifications 	This is to indicate that a batch or lot of a medicine was tested and was found outside the specifications of the marketing authorisation.

2028 b. Falsified medicinal products

2029 Where a report of suspected adverse reactions is associated with a suspected or confirmed falsified⁶⁰ 2030 ingredient, active substance or medicinal product, the MedDRA Lowest Level Term code of the term 2031 corresponding most closely to the reported information should be added to the observed suspected 2032 adverse reaction(s) in accordance with the data element 'Reaction/eventrecommendations in MedDRA 2033 terminology (Lowest Level Term)' (ICH-E2B(R2) B.2.i.1). the latest version of the ICH-Endorsed Guide 2034 for MedDRA Users 'MedDRA Term Selection: Points to Consider. Information on the suspected 2035 medicinal product, active substance(s) or excipient(s) should be provided in the data elements 2036 'Proprietary medicinal product name' (ICH-E2B(R2) B.4.k.2.1) and/or 'Active substance name(s)' (ICH-2037 E2B(R2) B.4.k.2.2) as reported by the primary source. also provided.

2038

In line with ICH-E2B the following applies:

ICH-E2B(R2)	• As a general principle, additional characteristics related to the medicines and pertinent to the case should be coded and further information related to the falsified medicinal product provided in free text. Data element B.4.k.19 'Additional information on drug' should be used to specify any additional information (e.g., falsified medicine); additional information concerning the

⁶⁰ As presented in EU legislation (<u>Directive 2011/62/EU</u>).

Reference	E2B(R2)/(R3) requirements	
	indication for the drug should	be provided as applicable.
	'Reaction/event in MedDRA te	should be provided in the data element B.2.i.1 rminology (Lowest Level Term)' or the data losis/syndrome and/or reclassification of
		ietary medicinal product name' and/or B.4.k.2.2 reported by the primary source should be
ICH-E2B(R3)		nal characteristics related to the medicines and e coded and further information provided in the
	• An appropriate MedDRA term should be provided in the data element E.i.2.1b 'Reaction/Event (MedDRA code)'. Alternatively, section H.3.r 'Sender's Diagnosis' should be completed.	
	• Section G.k 'Drug(s) Information' should be completed; information should be captured in the data element G.k.2.2 'Medicinal Product Name as Reported by the Primary source' and/or G.k.2.3.r.1 'Substance/Specified Substance name'.	
	completed using the following	onal Information on Drug (coded)' should be value 'Counterfeit'. The value should be used ed or confirmed to be a falsified medicinal product.
	data element G.k.10.r should product is confirmed as a cou	to confirm the product is not a counterfeit, the be changed appropriately in a follow up. If the nterfeit, the appropriate MedDRA code should be 'Sender's Diagnosis' and information should be
		nal Information on Drug (free text)' should be used g information in free text format not described in sed over the internet.
	Values definition for data element	G.k.10.r 'Additional Information on Drug (coded)'
	Counterfeit ⁶¹	This is to indicate that the medicine was suspected or confirmed to be a falsified medicinal product in line with the definition provided in Article 1, paragraph 33 of Directive 2001/83/EC.

2039

2040

⁶¹ This value should not been used to refer to medicines that do not comply with EU law on intellectual and industrial property rights, such as registered trademarks or patent rights, as defined for counterfeit medicines in <u>Q&A: Directive on</u> falsified medicines.

2041 VI.C.6.2.3.6. Suspected transmission via a medicinal product of an infectious agent

2042 EU requirements are provided in VI.C.2.2.5.

The coding of a suspected transmission of an infectious agent via a medicinal product in the data
 clement 'Reaction/event in MedDRA terminology (Lowest Level Term)' (ICH-E2B(R2) B.2.i.1) should
 be performed in line with the latest version of the ICH-Endorsed Guide for MedDRA Users 'MedDRA
 Term Selection: Points to Consider' (see GVP Annex IV).

In addition, if the infectious agent is specified, the MedDRA Lowest Level Term code corresponding to
the infectious agent should also be included in the data element 'Reaction/event in MedDRA
terminology (Lowest Level Term)' (ICH-E2B(R2) B.2.i.1).

2050 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• The appropriate MedDRA term should be provided in the data element B.2.i.1 'Reaction/event in MedDRA terminology (Lowest Level Term)'.
ICH-E2B(R3)	• The appropriate MedDRA term should be provided in the data element E.i.2.1b 'Reaction/Event (MedDRA code)'.

VI.C.6.2.3.7. Reports of suspected adverse reactions originating from organised data collection systems and other systems

General safety reporting requirements in the EU for post-authorisation studies are provided in <u>VI.C.1.</u>
and <u>VI.C.2.2.2.</u>. Individual case safety reports originating from those studies shall contain information
on study type, study name and the sponsor's study number or study registration number [IR Art 28
(3)(c)]. This should be provided in ICH E2B(R2) section A.2.3 'Study identification'.

2057 In line with ICH-E2B the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• Section A.2.3 'Study identification' should be completed accordingly.
ICH-E2B(R3)	• Section C.5 'Study Identification' should be completed accordingly.

2058 Safety reporting requirements regarding patient support programmes or market research programmes 2059 are provided in <u>VI.C.2.2.11</u>.

All ICSRs which are reportable to the EudraVigilance database and which originate from organised data
 collection systems and other systems which do not fall under the scope of the clinical trials Directive
 2062 2001/20/EC , should be submitted to EVPM (see VI.C.6.2.1.). The same applies to cases of adverse
 reactions originating from clinical trials if they are suspected to be related to a medicinal product other
 than the IMP or NIMP and does not result from a possible interaction with the IMP or NIMP.

The following reporting rules should be applied based on (i) the type of data collection system and (ii) whether the suspected medicinal product is part of the scope of the data collection system.

2067
 1. For cases of suspected adverse reactions (i) in relation to those adverse events for which the
 2068
 2069 protocol of non-interventional post-authorisation studies does not provide differently and requires
 2069 their systematic collection (see <u>VI.C.1.2.1.</u>), (ii) originating from compassionate use or named
 2070 patient use conducted in Member States where the active collection of adverse events occurring in

2073 a). Where the adverse reaction is suspected to be related at least to the studied (or supplied) 2074 medicinal product: 2075 the report should be considered as solicited; -the ICH E2B(R2) data element A.1.4 'Type of report' should be populated with the value 'Report 2076 2077 from study'; 2078 the ICH E2B(R2) data element A.2.3.3 'Study type in which the reaction(s)/event(s) were 2079 observed' should be populated with the value 'Other studies' or 'Individual patient use'. 2080 in line with ICH-E2B the following applies: ICH-E2B(R2) Data element A.1.4 'Type of report' should be populated with the value 'Report from study'. Data element A.2.3.3 'Study type in which the reaction(s)/event(s) were observed' should be populated with the value 'Other studies' or 'Individual patient use'. ICH-E2B(R3) Data element C.1.3 'Type of Report' should be populated with the value • 'Report from study'. Data element C.5.4 'Study Type Where Reaction(s)/Event(s) Were Observed' should be populated with the value 'Other studies' or 'Individual patient use'. 2081 b). Where the adverse reaction is only suspected to be related to a medicinal product which is not 2082 subject to the scope of the organised data collection system and there is no interaction with the 2083 studied (or supplied) medicinal product: 2084 • the report should be considered as spontaneous report; as such it conveys the suspicion of the 2085 primary source; 2086 -The ICH E2B(R2) data element A.1.4 'Type of report' should be populated with the value 2087 'Spontaneous'. 2088 in line with ICH-E2B the following applies: Data element A.1.4 'Type of report' should be populated with the value ICH-E2B(R2) 'Spontaneous'. Data element C.1.3 'Type of Report' should be populated with the value ICH-E2B(R3) 'Spontaneous'. 2089 2. For suspected adverse reactions (i) in relation to those adverse events for which the protocol of 2090 non-interventional post-authorisation studies provides differently and does not require their 2091 systematic collection (see VI.C.1.2.1.) or (ii) originating from compassionate use or named patient 2092 use conducted in Member States where the active collection of adverse events occurring in these 2093 programmes is not required (see VI.C.1.2.2.):

these programmes is required (see VI.C.1.2.2.), or (iii) originating from patient support

programmes, or market research programmes (see VI.C.2.2.11.):

2071 2072

2094 2095	 the report should be considered as spontaneous report; as such it conveys the suspicion of the primary source; 		
2096 2097	 the ICH E2B(R2) data element A.1.4 'Type of report' should be populated with the value 'Spontaneous'. 		
2098	In line with ICH-E2B the following applies:		
	Reference E2B(R2)/(R3) requirements		
	ICH-E2B(R2) • Data element A.1.4 'Type of report' should be populated with the value 'Spontaneous'.		
	ICH-E2B(R3) • Data element C.1.3 'Type of Report' should be populated with the value 'Spontaneous'.		
2099 2100 2101 2102 2103	3. For clinical trialtrials conducted in accordance with Directive 2001/20/EC and where the adverse reaction is only suspected to be related to a non-investigational medicinal product (other than the IMP or another medicinal product which is NIMP and does not subject to the scope of the clinical trial) and there is no result from a possible interaction with the investigational medicinal product: IMP or NIMP (see VI.C.1.1.):		
2104 2105	 the report should be considered as spontaneous report; as such it conveys the suspicion of the primary source; 		
2106 2107	 the ICH E2B(R2) data element A.1.4 'Type of report' should be populated with the value 'Spontaneous'. 		
2108 2109 2110 2111 2112	All ICSRs which are reportable to the EudraVigilance database and which originate from post- authorisation studies which do not fall under the scope of the clinical trials Directive 2001/20/EC, should be submitted to EVPM (see <u>VI.C.6.2.1.</u>). The same applies to cases of adverse reactions originating in clinical trials if they are not suspected to be related to the investigational medicinal product.		
2113	in line with ICH-E2B the following applies:		
	Reference E2B(R2)/(R3) requirements		
	ICH-E2B(R2) • Data element A.1.4 'Type of report' should be populated with the value 'Spontaneous'.		
	ICH-E2B(R3) • Data element C.1.3 'Type of Report' should be populated with the value 'Spontaneous'.		

2114 VI.C.6.2.3.8. Receipt of missing minimum information

2115 When missing minimum information (see VI.B.2.) has been obtained about a non-valid ICSR, the 2116 following rules should be applied:

- the data element 'Datedate where the report was first received from source' (ICH-E2B(R2))
 A.1.6) source should contain reflect the date of receipt of the initial non-valid ICSR;
- the data element 'Datedate of receipt of the most recent information for this report' (ICH-E2B(R2))
 A.1.7)-should contain reflect the date when all the four elements of the minimum information
 required for reporting have become available;

- clarification should be provided in the case narrative (data element ICH-E2B(R2) B.5.1) that some of the four elements were missing in the initial report.;
- as for any reported submitted cases, compliance monitoring is performed against the data element
 2125 'Datedate of receipt of the most recent information for this report' (report.

2126 In line with ICH-E2B(R2) A.1.7). the following applies:

Reference	E2B(R2)/(R3) requirements
ICH-E2B(R2)	• The data element A.1.6 'Date report was first received from source' should capture the date of receipt of the initial non-valid ICSR;
	• The data element A.1.7 'Date of receipt of the most recent information for this report' should capture the date when all the four elements of the minimum information required for reporting have become available;
	• Clarification should be provided in the data element B.5.1 'Case narrative including clinical course, therapeutic measures, outcome and additional relevant information' that some of the four elements were missing in the initial report.
ICH-E2B(R3)	• The data element C.1.4 'Date Report Was First Received from Source' should capture the date of receipt of the initial non-valid ICSR;
	• The data element C.1.5 'Date of Most Recent Information for This Report' should capture the date when all the four elements of the minimum information required for reporting have become available;
	• Clarification should be provided in the data element H.1 'Case Narrative Including Clinical Course, Therapeutic Measures, Outcome and Additional Relevant Information' that some of the four elements were missing in the initial report.

VI.C.6.2.4. Data quality of individual case safety reports transmitted electronically and duplicate management

- 2129 The EudraVigilance database should contain all cases of suspected adverse reactions that are
- 2130 reportable according to Directive 2001/83/EC and Regulation (EC) No 726/2004 to support
 2131 pharmacovigilance activities. This applies to all medicinal products authorised in the EU independent of
- 2132 their authorisation procedure.
- The EudraVigilance database should also be based on the highest internationally recognised data quality standards.
- To achieve these objectives, all competent authorities in Member States and marketing authorisation holders should adhere to:
- the electronic reporting requirements as defined in EU legislation;
- the concepts of data structuring, coding and reporting in line with the EU legislation, guidelines,
 standards and principles referred to in <u>VI.C.6.2.2.1.</u>
- This is a pre-requisite to maintain a properly functioning EudraVigilance database intended to fully support the protection of public health.

2142 In addition, the Agency in collaboration with stakeholders that submit ICSRs to EudraVigilance, are
2143 responsible to contribute to the quality and integrity of the data. This is also reflected in legislation as
2144 follows:

The Agency shall, in collaboration with the stakeholder that submitted an ICSR to the
 EudraVigilance database, be responsible for operating procedures that ensure the highest quality
 and full integrity of the information collected in the EudraVigilance database [REG Art 24(3)]. This
 includes as well the monitoring of use of the terminologies referred to in chapter IV of the
 Commission Implementing Regulation (EU) No 520/2012 [IR Art 25(3)].

- 2150 Specific quality system procedures and processes shall be in place in order to ensure:
- the submission of accurate and verifiable data on serious and non-serious suspected adverse
 reactions to the Eudravigilance database within the 15 or 90-day time frame [IR Art 11 (1) (c)];
- Specific quality system procedures and processes shall be in place in order to ensure the quality,
 integrity and completeness of the information submitted on the risks of medicinal products,
 including processes to avoid duplicate submissions [IR Art 11 (1) (d)].
- Marketing authorisation holders shall collaborate with the Agency and the Member States in the detection of duplicates of suspected adverse reaction reports [DIR Art 107(5)].
- Member States shall collaborate with the Agency and the marketing authorisation holders in the detection of duplicates of suspected adverse reaction reports [DIR Art 107a (3)].
- In this regard, marketing authorisation holders and competent authorities in Member States should
 have in place an audit system, which ensures the highest quality of the ICSRs transmitted
 electronically to the EudraVigilance database within the correct time frames, and which enables the
 detection and management of duplicate ICSRs in their system. Those transmitted ICSRs should be
 complete, entire and undiminished in their structure, format and content.
- 2165 High level For the purpose of a systematic approach towards quality in accordance with the quality 2166 cycle as outlined in GVP Module I, managerial staff (i.e. staff with management responsibilities) in any organisation should be responsible for ensuring that adequate resources are available and that 2167 appropriate training is provided to their personnel for pharmacovigilance. Competent authorities in 2168 2169 Member States and marketing authorisation holders should regularly update their training plans based 2170 on an assessment of the training needs of their personnel for pharmacovigilance, which should be 2171 subject to monitoring. Records for documenting and developing the competences of personnel should 2172 be maintained and updated accordingly. To support the training of personnel for pharmacovigilance, the Agency has made available a detailed training plan and catalogue based on a modular training 2173 2174 approach focusing on adverse reactions reporting, signals management and EudraVigilance⁶².
- In support of the operation of the procedures that ensure the highest quality and full integrity of the
 information collected in EudraVigilance as well as the monitoring of use of the terminologies for the
 reporting of suspected adverse reactions, business process maps and process descriptions in relation
 to the quality review of ICSRs and the are provided in VI.App.6.

A review of the ICSRs quality, integrity and compliance with the reporting time frames will be
performed by the Agency at regular intervals for all organisations reporting to EudraVigilance in line
with the Agency's SOPs. Parameters upon which the review of organisations may be initiated, refer for
example to the volume of reports being submitted to EudraVigilance, major changes to
pharmacovigilance databases, quality issues identified as part of the signal management, requests

⁶² Accessible on EudraVigilance training webpage.

from pharmacovigilance inspectors and the time interval since the last review. For the purpose of the
monitoring of the 15 or 90 days reporting time frames, the Agency provides competent authorities in
Member States and marketing authorisation holders with monthly compliance reports.

The outcome of the quality reviews will be provided to the organisations on the basis of a report, which include the need for corrective measures where applicable and the time frames for these measures to be applied. The time frames and the method for corrective measures will depend on the quality issues identified (e.g. corrections of the MedDRA coding of ICSRs to be performed by means of amendment reports).

With regard to the monitoring by the Agency of selected medical literature for reports of suspected
adverse reactions to medicinal products containing certain active substances (see VI.C.2.2.3.1.) and
the entering of adverse reaction reports in EudraVigilance in accordance with Article 27 of Regulation
(EC) 726/2004, two-yearly audits are planned to ensure the quality and integrity of the reports. SOPs
and WINs for the routine quality review process are published at the Agency's dedicated medical
literature monitoring webpage.⁶³

2198 In support of the operation of procedures that ensure detection and management of duplicate ICSRs 2199 are provided in <u>VI. Appendix 6</u> and <u>VI. Appendix 7</u>. Further guidance, business process maps and process descriptions are provided in VI.App.7 taking into account various scenarios acknowledging that 2200 duplicates may be detected at various stages of the processing of ICSRs by numerous stakeholders 2201 2202 and in EudraVigilance. The collaboration between the Agency, competent authorities in Member States 2203 and marketing authorisation holders is required to ensure that potential duplicates of reports of 2204 suspected adverse reactions are reviewed, confirmed and processed as necessary. Guidance on the detection of duplicate ICSRs is available provided in the Guideline on the Detection and Management of 2205 2206 Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (EMA/13432/2009).

A review of the ICSRs quality, integrity and compliance with the reporting time frames will be
 performed by the Agency at regular intervals for all organisations reporting to the EudraVigilance
 database. Feedback from these reviews will be provided to those organisations.

2210 VI.C.6.2.5. Electronic re-transmission of ICSRs between multiple senders and receivers

2211 The electronic re-transmission of cases refers to the electronic exchange of ICSRs between multiple 2212 senders and receivers, for example where in case of contractual agreement, a third country ICSR is 2213 first reported submitted by a marketing authorisation holder outside the EU to another marketing 2214 authorisation holder in the EU and from there to the Agency. This applies as well for the interim 2215 arrangements period, where based on the reporting requirements detailed in VI.C.4.1., ICSRs 2216 originating in the EU are submitted by marketing authorisation holders to the competent authorities in 2217 the Member State where the reaction occurred and then re-transmitted to the EudraVigilance 2218 database.

- During this re-transmission process, information on the case should not in principle be omitted or
 changed if no new information on the case is available to the re-transmitting sender. Exceptions apply
 to the following ICH-E2B data elements or sections:
- 2222 Exceptions apply to the following data elements or sections:
- 2224 <u>'Date of this transmission' (ICH-E2B(R2) A.1.3);</u>

⁶³ Monitoring of medical literature and entry of adverse reaction reports into EudraVigilance

2225	•	was first received from source' (ICH-E2B(R2) A.1.6), for initial reports;		
2226	<u>'Date of rece</u>	ipt of the most recent information for this report' (ICH-E2B(R2) A.1.7);		
2227	<u>"Information"</u>			
2228	• <u>'Relatedness</u>	of drug to reaction(s)/event(s)' (ICH-E2B(R2) B.4.k.18);		
2229	• <u></u>	ignosis/syndrome and/or reclassification of reaction/event' (ICH-E2B(R2) B.5.3);		
2230	• 'Sender's cor	mments' (ICH-E2B(R2) B.5.4).		
	Reference	E2B(R2)/(R3) requirements		
	ICH-E2B(R2)	• Data element A.1.0.1 'Sender's (case) safety report unique identifier';		
		Data element A.1.3 'Date of this transmission';		
		• Data element A.1.6 'Date report was first received from source', for initial		

- Potential reports;
 Data element A.1.7 'Date of receipt of the most recent information for this report';
- Data element A.3 'Information on sender and receiver of case safety report';
- Data element B.4.k.18 'Relatedness of drug to reaction(s)/event(s)';
- Data element B.5.3 'Sender's diagnosis/syndrome and/or reclassification of reaction/event';
- Data element B.5.4 'Sender's comments'.

guideline

- ICH-E2B(R3) Data element C.1.1 'Sender's (case) Safety Report Unique Identifier';
 - Data element C.1.4 'Date Report Was First Received from Source, for initial reports';
 - Data element C.1.5 'Date of Most Recent Information for This Report';
 - Data element G.k.9.i.2 'Assessment of Relatedness of Drug to Reaction(s)/Event(s)';
 - Data element H.3.r 'Sender's Diagnosis (MedDRA code)';
 - Data element H.4 'Sender's Comments'.

In the interest of improving data quality, in case of errors or inconsistencies in the report, the re transmitters should go back to the originator of the report to correct the case accordingly. However, if
 this cannot be done within normal reporting time frame, the re-transmitter can correct information that
 has been incorrectly structured.

In addition, any electronic data interchange partner should adhere to the ICH-E2B(R2) rules regarding
the provision of follow-up information, whereby the 'Worldwide unique case identification number'
(ICH-E2B(R2) A.1.10) should be maintained in accordance with the ICH-E2B(R2) guideline (see GVP
Annex IV)-principles set out in VI.C.6.2.2.7. Non-adherence to these administrative requirements
endangers the electronic case management and leads to the potential for unnecessary duplication of
reports in the receiver's database.

2241 VI.C.6.2.6. Electronic reporting through company's headquarters

- If a pharmaceutical company decides to centralise the electronic reporting of ICSRs (e.g. by reportingthrough the company's global or EU headquarter), the following should be taken into account:
- the central reporting arrangement should be clearly specified in the marketing authorisation
 holder's pharmacovigilance system master file and in the internal standard operating procedures;
- the company's headquarter designated for reporting the ICSRs should be registered with
 EudraVigilance*.

theThe same principles may be applied for reporting ICSRs from the competent authorities in Member
 States to the marketing authorisation holders during the interim arrangements period, that is the
 competent authorities in Member States report electronically to the company's headquarter instead of
 to the local affiliates.

2252 VI.C.6.3. Electronic submission of information on medicinal products

To support the objectives of Directive 2001/83/EC and Regulation (EC) No 726/2004, the provisions provided in second sub-paragraph of Article 57(2) of Regulation (EC) No 726/2004, regarding the electronic submission and update of information on medicinal products for human use authorised or registered in the EU, shall be followed by marketing authorisation holders. In this aspect marketing authorisation holders shall apply the internationally agreed formats and terminologies described in chapter IV of the Commission Implementing Regulation (EU) No 520/2012. Recommendations related to the electronic submission of information on medicines are provided on the Agency's website⁶⁴.

⁶⁴ See EMA documents for electronic submission of information on medicines:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000336.jsp&murl=m enus/regulations/regulations.jsp&mid=WC0b01ac0580410138&jsenabled=true


Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

VI. Appendix 1 HentificationFollow-up process of biological medicinal productsICSRs

2262 VI.App.1.1 Follow-up of ICSRs by marketing authorisation holders

Figure VI.2. Business process map - Follow-up of ICSRs by marketing authorisation holders

2264 2265



2266 **Table VI.2.** Process description - Follow-up of ICSRs by marketing authorisation holders

	Start	Receipt of a report of a suspected adverse reaction related to a medicine (ADR report)	
1	Receive report of suspected drug adverse reaction(s) from primary source	Day 0. Receipt of the information	МАН
2	Is the report valid?	Is the report received from the primary source a valid ICSR in accordance with VI.B.2.? If Yes, go to step 3. If No, go to step 10.	MAH
3	The report received is valid	The report received from the primary source is a valid ICSR in accordance with chapter VI.B.2	
3.1	Record the report	Record the valid ADR report received from the primary source in the pharmacovigilance database	MAH
3.2	Report ICSR to EudraVigilance (EV)	Report the valid ICSR to EudraVigilance in accordance with the principles set out in chapter VI.C.6.2 NOTE: the MAH can organise the reporting of the initial report and the follow-up report in accordance with the reporting timelines set out in the pharmacovigilance legislation i.e. if time permits and follow-up information can be obtained and processed within the initial reporting timeframes, the MAH is not required to report the initial and the follow- up report separately	MAH
3.3	Is follow-up required for the valid ICSR?	If Yes, go to step 4 If No, go to step 9	МАН
4	Follow-up required for valid ICSR		
4.1	Request information from primary source	Contact the primary source to obtain additional information pertinent to the valid case in accordance with the principles set out	МАН

No	Step	Description	Responsible Organisation
		in chapters VI.B.3 and VI.C.6.2.2.7	
		Note: MAHs should define in their SOPs how many attempts to obtain follow-up information are made	
4.2	Has new information on the case be obtained from the primary source?	If Yes, go to point 5. If No, go to point 8.	МАН
5	Additional information has been obtained		МАН
5.1	Record outcome of follow- up	Record the outcome of the follow-up and record information obtained in the pharmacovigilance database	МАН
5.2	Is new information significant and reportable?	Determine if information obtained is significant enough to be submitted in accordance with VI.C.6.2.2.7. If Yes, go to point 6. If No, go to point 7.	MAH
6	New information is significant and reportable		
6.1	Report ICSR to EudraVigilance	Report the ICSR with the follow-up information to EudraVigilance in accordance with VI.C.6.	MAH
7	New information is not significant and not reportable	The new information is not significant enough to be sent in accordance with VI.C.6.2.2.7.	
7.1	End		MAH
8	No information has been obtained	The follow-up with the primary source is unsuccessful and no additional information on the case can be obtained	
8.1	Record the outcome of follow-up	Record the fact that no further information has been obtained from the primary source in the pharmacovigilance database	МАН
8.2	End		
9	Follow-up is not required for valid ICSR	ICSR is valid. Follow-up is not performed	МАН
9.1	End		
10	The report received from the primary source is NOT a valid ICSR	The report received is not a valid report in accordance with VI.B.2.	

No	Step	Description	Responsible Organisation
10.1	Record non-valid ICSR	Record the non-valid ICSR in pharmacovigilance database	МАН
10.2	Request missing info from primary source	Request missing information for non-valid ICSR from the primary source through follow- up in line with VI.B.3. and VI.C.6.2.2.7.	MAH
10.3	Missing info has been obtained?	Has missing information been obtained for non-valid ICSR? If Yes, go to 11. If No, go to 14.	MAH
11	Missing information has been obtained for non- valid ICSR		МАН
11.1	Record the outcome of follow-up with primary source	Record the outcome of the follow-up of missing information in the pharmacovigilance database	MAH
11.2	Is the ICSR valid?	Is the report now valid taking into account the follow-up information obtained from the primary source? If Yes, go to 12. If No, go to 13.	MAH
12	ICSR is valid		
<u>12.1</u>	Report ICSR to EudraVgilance	Report the valid ICSR to EudraVigilance in line with the principles set out in VI.C.6.	МАН
13	ICSR is not valid		MAH
13.1	End		
14	Missing information has not been obtained for non-valid ICSR	No further information is obtained from the primary source in the pharmacovigilance database	
14.1	Record the outcome of the follow-up	Record the fact that no further information has been obtained from the primary source in the pharmacovigilance database	МАН
14.2	End		

VI.App.1.2 Follow-up of ICSRs by competent authorities in Member States involving consumers or healthcare professionals

2269 2270 **Figure VI.3.** Business process map - Follow-up of ICSRs by competent authorities in Member States involving consumers or healthcare professionals




Table VI.3. Process description - Follow-up of ICSRs by competent authorities in Member States involving consumers or healthcare professionals

	Start	Receipt of a report of a suspected adverse reaction related to a medicine (ADR report)	
1	Receive report of suspected drug adverse reaction(s) from primary source	Day 0. Receipt of the information	NCA
2	Is the report valid?	Is the report received from the primary source a valid ICSR in accordance with chapter VI.B.2? If Yes, go to step 3. If No, go to step 10.	NCA
3	The report received is valid	The report received from the primary source is a valid ICSR in accordance with chapter VI.B.2	
3.1	Record the report	Record the valid ADR report received from the primary source in the pharmacovigilance database	NCA
3.2	Report ICSR to EudraVigilance (EV)	Report the valid ICSR to EudraVigilance in accordance with the principles set out in VI.C.6.2. NOTE: the NCA can organise the reporting of the initial report and the follow-up report in accordance with the reporting timelines set out in the pharmacovigilance legislation i.e. if time permits and follow-up information can be obtained and processed within the initial reporting timeframes, the MAH is not required to report the initial and the follow- up report separately	NCA
3.3	Is follow-up required for the valid ICSR?	If Yes, go to step 4 If No, go to step 9	NCA
4	Follow-up required for valid ICSR		
4.1	Request information from primary source	Contact the primary source to obtain additional information pertinent to the valid	NCA

No	Step	Description	Responsible Organisation
		case in accordance with the principles set out in VI.B.3. and VI.C.6.2.2.7.	
		Note: NCAs should define in their SOPs how many attempts to obtain follow-up information are made	
4.2	Has new information on the case be obtained from the primary source?	If Yes, go to point 5. If No, go to point 8.	NCA
5	Additional information has been obtained		NCA
5.1	Record outcome of follow- up	Record the outcome of the follow-up and record information obtained in the pharmacovigilance database	NCA
5.2	Is new information significant and reportable?	Determine if information obtained is significant enough to be reportable in accordance with VI.C.6.2.2.7. If Yes, go to point 6. If No, go to point 7.	NCA
6	New information is significant and reportable		NCA
6.1	Report ICSR to EudraVigilance	Report the ICSR with the follow-up information to EudraVigilance in accordance with VI.C.6.	NCA
7	New information is not significant and not reportable	The new information is not reportable in accordance with VI.B.3. and VI.C.6.2.2.7.	
7.1	End		NCA
8	No information has been obtained	The follow-up with the primary source is unsuccessful and no additional information on the case can be obtained	
8.1	Record the outcome of follow-up	Record the fact that no further information has been obtained from the primary source in the pharmacovigilance database	NCA
8.2	End		
9	Follow-up is not required for valid ICSR	ICSR is valid. Follow-up is not performed	NCA
9.1	End		
10	The report received from the primary source is NOT	The report received is not a valid report in	

	a valid ICSR	accordance with VI.B.2.	
10.1	Record non-valid ICSR	Record the non-valid ICSR in pharmacovigilance database	NCA
10.2.	Request missing info from primary source	Request missing information for non-valid ICSR from the primary source through follow- up in line with VI.B.3. and VI.C.6.2.2.7.	NCA
10.3	Missing info has been obtained?	Has missing information been obtained for non-valid ICSR?	NCA
		If Yes, go to 11.	
11	Missing information has	If No, go to 14.	
11	Missing information has been obtained for non- valid ICSR		NCA
11.1	Record the outcome of follow-up with primary source	Record the outcome of the follow-up of missing information in the pharmacovigilance database	NCA
11.2	Is the ICSR valid?	Is the report now valid taking into account the follow-up information obtained from the primary source?	NCA
		If Yes, go to 12.	
		If No, go to 13.	
12	ICSR is valid		NCA
<u>12.1</u>	Report ICSR to EudraVgilance	Report the valid ICSR to EudraVigilance in line with the principles set out in VI.C.6	NCA
13	ICSR is not valid		MAH
13.1	End		NCA
14	Missing information has not been obtained for non-valid ICSR	No further information is obtained from the primary source in the pharmacovigilance database	NCA
14.1	Record the outcome of the follow-up	Record the fact that no further information has been obtained from the primary source in the pharmacovigilance database	NCA
14.2	End		NCA

VI.App.1.3 Follow-up of ICSRs by competent authorities in Member States with involvement of marketing authorisation holders

Figure VI.4. Business process map - Follow-up of ICSRs by competent authorities in Member States
 with involvement of marketing authorisation holders




 Table VI.4.
 Process description - Follow-up of ICSRs by competent authorities in Member States with involvement of marketing authorisation holders

	Start	Receipt of a report of a suspected adverse reaction related to a medicine (ISCR)	orgunisation
1	Receive report of suspected drug adverse reaction(s) from primary source	Day 0. Receipt of the information	МАН
2	Report ICSR to EudraVigilance	Report the valid ICSR to EudraVigilance in line with the principles set out in VI.C.6	MAH
3	Re-route ICSR to NCA	MAH ICSR is rerouted from EudraVigilance to the NCA of the country of the primary source for regulatory purposes	Agency
4	Is follow-up required with involvement of MAH?	If Yes, go to point 5. If No, go to point 12.	NCA
5	Follow-up is required		
5.1	Contact MAH to request follow- up information	Send email to QPPV or local contact person to request follow-up information	NCA
		Indicate reference to individual case(s) using World Wide Unique Case Identifier(s) for cases that require follow-up	
		Indicate criterion/criteria for request to involve MAH in follow-up	
		Indicate timeframe by when follow-up is to be provided	
5.2	Is follow-up already in progress?	If Yes, progress to point 6. If No progress to point 7.	МАН
6	Follow-up is already in progress	Follow-up has already been initiated by the MAH	МАН
6.1	Inform NCA that follow-up is in progress	Inform NCA via e-mail that follow-up is already in progress using functional mailbox MAH.followup@ema.europa.eu	МАН
		Provide reference to individual case(s) using World Wide Unique Case Identifier	
		Indicate timeline by when follow-up info	

No			
		has been requested	
6.2	End		
7	Follow-up has not been initiated		МАН
7.1	Contact primary source	Contact primary source to obtain follow- up information as per request of NCA	МАН
		Note: When contacting the primary source(s), MAH is allowed to indicate that the follow-up is performed upon request of a NCA	
7.2	Did primary source provide	If Yes, proceed to point 9	
	requested info?	If No, proceed to point 8	
8	Primary source did not provide follow-up information		МАН
8.1	Record that no follow-up info was obtained	Record that primary source did not provide follow-up information	MAH
8.2	Inform NCA	Inform NCA via e-mail that it was not possible to obtain follow-up information from primary source using functional mailbox MAH.followup@ema.europa.eu	МАН
		Provide reference to individual cases using World Wide Unique Case Identifier	
8.3	End		
9	Primary source did provide follow-up information		
9.1	Record follow-up information	Record follow-up information in pharmacovigilance database	MAH
9.2	Is new information significant and reportable?	Determine if follow-up information is significant enough to be reportable in accordance with principles set out in VI.C.6.2.2.7	
		If Yes, proceed to point 10.	
		If No, proceed to point 11.	
10	Follow-up info is significant and reportable		

10.1	Send follow-up ICSR to EudraVigilance	Send follow-up ICSR to EudraVigilance in accordance with principles set out in VI.C.6	МАН
10.2	Inform NCA that follow-up info was received	Inform NCA via e-mail that follow-up information from primary source was received using functional mailbox <u>MAH.followup@ema.europa.eu</u> Indicate reference to individual cases using World Wide Unique Case Identifier	MAH
10.3	End		
11	Follow-up information is not significant and not reportable		
11.1	Inform NCA	Inform NCA that no significant new information has been obtained in accordance with VI.C.6.2.2.7.	МАН
11.2	End		
12	MAH does NOT need to be involved in follow-up	There is no need to involve the MAH in the follow-up process	NCA
12.1	End		

VI.App.1.4 Follow-up of ICSRs for identification of biological medicinal products



2287

2288 2289




Figure VI.2.- Figure VI.5. Business process map - Identification of biological medicinal products⁶⁵

⁶⁵ Mandatory when they are the subject of reports of suspected adverse reactions [DIR Art 102(e) and IR Art 28 (3)].

Table VI.2. Table VI.5. Process description - Identification of biological medicinal products

No.	Step	Description	Responsible Organisation
1	Start. Receive report.	Day 0. Receipt of the information for the case that indicates that one of the suspect drugs is of biological origin.	MAH/NCA
2	Does report concern a biological medicinal product?	If Yes, go to step 3 If No, go to step 4	
3	Are batch number, brand name & active substance all present and identifiable?	 If Yes, create the case and send it to the correct receiver (step 34). If there is more than one batch number, structure the batch number that coincided with the adverse reaction-in the Drug section (ICH-E2B(R2) B.4) and enter the other batch numbers in the case narrative.: ICH-E2B(R2) in the Drug section B.4, data element B.4.k.3 "Batch/lot number" and enter the other batch numbers in the case narrative. ICH-E2B(R3) in the Drug section G.k, and repeat the data element G.k.4.r.7 "Batch/Lot Number" as necessary. If No, create the case and send it to the correct receiver (step 34) and follow-up with the reporter (step 3.1). 	MAH/NCA
3.1	Follow-up with reporter.	Follow-up with the reporter to attempt to identify the missing information.	MAH/NCA
3.2	Was reporter able to provide the missing information?	If Yes, return to step 1 – the information should be treated as follow-up and a new version created & transmitted. If No, document this (step 3.3).	MAH/NCA
3.3	Document the required missing information in the case.	Document in the case that the missing required information has been sought but the reporter was not able or willing to provide it.	MAH/NCA
4	Send to receiver, where applicable.	If the case requires transmission to a receiver, transmit the case electronically, in ICH-E2B(R2) format within the relevant timelines (15 or 90 days), to the relevant receiver.	MAH/NCA
5	Receive in PharmacoVigilance DataBase	Receive the case electronically and load it into the PharmacoVigilance DataBase.	Receiver
	(PhV DB).		

No.	Step	Description	Responsible Organisation
	substances	ensure that the brand name, active substance & batch number are all present and identifiable. This validation should be complementary to the usual business rules validations.	
7	Was validation successful?	If Yes, store the case in the PharmacoVigilance DataBase (step 8). If No, contact the sender (Step 7.1).	Receiver
7.1	Contact sender.	Contact the sender regarding the missing or not identifiable information.	Receiver
7.2	Is required data in the case file?	Upon receipt of communication from the receiver, check in the case file to see if the missing or unidentifiable information is already on file. If it is on file, correct the case (step 7.3). If the information is not on file, contact the reporter to request the missing information (step 3.1).	MAH/NCA
7.3	Correct case.	Correct the case to include the missing information & send updated version to receiver (step 4).	MAH/NCA
8	Store case in PharmacoVigilance DataBase (PhV DB).	The case should now be stored in the pharmacovigilance database.	Receiver
9	End.	The case is now available for signal detection and data quality analyses.	

VI. Appendix 2 Detailed guidance on the monitoring of scientific literature

VI. App2App. 2.1. When to start and stop searching in the scientific Iiterature

EU specific requirements, as regards the monitoring of scientific and medical literature are provided in VI.C.2.2.3.

2298 In addition to the reporting of serious and non-serious ICSRs or their presentation in periodic safety 2299 update reports, the marketing authorisation holder has an obligation to review the worldwide 2300 experience with medicinal product in the period between the submission of the marketing authorisation 2301 application and the granting of the marketing authorisation. The worldwide experience includes 2302 published scientific and medical literature. For the period between submission and granting of a marketing authorisation, literature searching should be conducted to identify published articles that 2303 provide information that could impact on the risk-benefit assessment of the product under evaluation. 2304 2305 For the purpose of the preparation of periodic safety update reports (see GVP Module VII) and the 2306 notification of emerging safety issues (see <u>VI.C.2.2.6.</u>), the requirement for literature searching is not 2307 dependent on a product being marketed. Literature searches should be conducted for all products with 2308 a marketing authorisation, irrespective of commercial status. It would therefore be expected that 2309 literature searching would start on submission of a marketing authorisation application and continue 2310 while the authorisation is active.

2311 VI.App2App.2.2 Where to look

Articles relevant to the safety of medicinal products are usually published in well-recognised scientific and medical journals; however, new and important information may be first presented at international symposia or in local journals. Although the most well-known databases (e.g. Medline) cover the majority of scientific and medical journals, the most relevant publications may be collated elsewhere in very specialised medical fields, for certain types of product (e.g. herbal medicinal products) or where safety concerns are subject to non-clinical research. A marketing authorisation holder should establish the most relevant source of published literature for each product.

Medline, Embase and Excerpta Medica are often used for the purpose of identifying ICSRs. These databases have broad medical subject coverage. Other recognised appropriate systems may be used. The database providers can advise on the sources of records, the currency of the data, and the nature of database inclusions. It is best practice to have selected one or more databases appropriate to a specific product. For example, in risk-benefit assessment, safety issues arising during non-clinical safety studies may necessitate regular review of a database that has a less clinical focus and includes more laboratory-based publications.

Relevant published abstracts from meetings and draft manuscripts should be reviewed for reportable
ICSRs and for inclusion in periodic safety update reports. Although it is not a requirement for
marketing authorisation holders to attend all such meetings, if there are company personnel at such a
meeting, or it is sponsored by a marketing authorisation holder, it is expected that articles of relevance
would be available to the marketing authorisation holder's pharmacovigilance system. In addition,
literature that is produced or sponsored by a marketing authorisation holder should be reviewed, so
that any reportable ICSRs can be reported submitted as required in advance of publication.

If ICSRs are brought to the attention of a marketing authorisation holder from this source, they shouldbe processed in the same way as ICSRs found on searching a database or reviewing a journal.

Abstracts from major scientific meetings are indexed and available in some databases, but posters and communications are rarely available from this source.

2337 VI.App2.3.Guidance in VI.C.2.2.3. should be followed for the searches of databases with broad medical
2338 coverage by the Agency in accordance with Article 27 of Regulation (EC) 726/2004 and the reporting
2339 obligations of marketing authorisation holders in accordance with Article 107 (3) of Directive
2340 2001/83/EC.

2341 VI.App.2.3 Database Searches

A search is more than a collection of terms used to interrogate a database. Decisions about the database selection, approach to records retrieval, term or text selection and the application of limits need to be relevant to the purpose of the search. For searches in pharmacovigilance, some of the considerations for database searching are described below.

2346 VI.App2App.2.3.1- Precision and recall

2347 Medical and scientific databases are a collection of records relating to a set of publications. For any 2348 given record, each database has a structure that facilitates the organisation of records and searching 2349 by various means, from simple text to complex indexing terms with associated subheadings. Search 2350 terms (text or indexed) can be linked using Boolean operators and proximity codes to combine 2351 concepts, increasing or decreasing the specificity of a search. In addition, limits to the output can be 2352 set. When searching, the application of search terms means that the output is less than the entire 2353 database of the records held. The success of a search can be measured according to precision and 2354 recall (also called sensitivity). Recall is the proportion of records retrieved ("hits") when considering 2355 the total number of relevant records that are present in the database. Precision is the proportion of 2356 "hits" that are relevant when considering the number of records that were retrieved. In general, the 2357 higher recall searches would result in low precision.

2358 VI.App2App.2.3.2- Search construction

Databases vary in structure, lag time in indexing and indexing policy for new terms. While some database providers give information about the history of a particular indexing term or the application of synonyms, other databases are less sophisticated. In addition, author abstracts are not always consistent in the choice of words relating to pharmacovigilance concepts or medicinal products/active substances names.

2364 When constructing a search for pharmacovigilance, the highest recall for a search would be to enter 2365 the medicinal product name and active substance name (in all their variants) only. In practice, 2366 additional indexing terms and text are added to increase precision and to reduce the search result to 2367 return records that are of relevance to pharmacovigilance. There is a balance to be achieved. It is₇ 2368 therefore, expected that complicated searches are accompanied by initial testing to check that relevant 2369 records are not omitted, however, there is no defined acceptable loss of recall when searching for pharmacovigilance purposes. Term selection should be relevant to the database used and the subject 2370 2371 of the search.

2372 VI.App2App.2.3.3- Selection of product terms

Searches should be performed to find records for active substances and not for brand names only. This
can also include excipients or adjuvants that may have a pharmacological effect. When choosing
search terms for medicinal products, there are a number of considerations.

- Is the active substance an indexed term?
- What spellings might be used by authors (particularly if the active substance is not indexed)?
- What alternative names might apply (numbers or codes used for products newly developed,
 chemical names, brand names, active metabolites)?
- Is it medically relevant to search only for a particular salt or specific compound for an active
 substance?

During searches for ICSRs, it may be possible to construct a search that excludes records for pharmaceutical forms or routes of administration different to that of the subject product, however, restrictions should allow for the inclusion of articles where this is not specified. Search construction should also allow for the retrieval of overdose, medication error, abuse, misuse, off-label use or occupational exposure information, which could be poorly indexed. Searches should also not routinely exclude records of unbranded products or records for other company brands.

2388 VI.App2App.2.3.4- Selection of search terms

As described previously, there is no acceptable loss of recall when searching published literature for pharmacovigilance. The use of search terms (free text or use of indexing) to construct more precise searches may assist in managing the output. Deficiencies that have been found frequently during Competent Authority inspections include:

- the omission of outcome terms, for example "death" as an outcome may be the only indexed term
 in a case of sudden death;
- the omission of pregnancy terms to find adverse outcomes in pregnancy for ICSR reporting;
- the omission of terms to include special types of reports which needs to be addressed as well in
 periodic safety update reports, for example,
- 2398 Reports of asymptomatic overdose, medication error, off-label use, misuse, abuse,
 2399 occupational exposure;
- 2400 Reports of uneventful pregnancy.

2401 VI.App2App.2.3.5- Limits to a search

Some databases apply indexing that allows the application of limits to a search, for example by subject
age, sex, publication type. The limits applied to a search are not always shown in the "search strategy"
or search string.

If limits are applied, they should be relevant to the purpose of the search. When searching a worldwide scientific and medical literature database, titles and abstracts are usually in English language. The use of limits that reduce the search result to only those published in the English language is generally not acceptable. Limits applied to patient types, or other aspects of an article, for example human, would need to be justified in the context of the purpose of a search.

Limits can be applied to produce results for date ranges, for example, weekly searches can be obtained by specifying the start and end date for the records to be retrieved. Care should be taken to ensure that the search is inclusive for an entire time period, for example, records that may have been added later in the day for the day of the search should be covered in the next search period. The search should also retrieve all records added in that period, and not just those initially entered or published during the specified period (so that records that have been updated or retrospectively added areretrieved). This should be checked with the database provider if it is not clear.

Although one of the purposes of searching is to identify ICSRs for reporting, the use of publication type limits is not robust. ICSRs may be presented within review or study publications, and such records may not be indexed as "case-reports", resulting in their omission for preparation of periodic safety update reports from search results limited by publication type.

2421 VI.App2App.2.4- Record keeping

Records of literature searches should be maintained in accordance with the requirements described in [IR Art 12]. Marketing authorisation holders should demonstrate due diligence in searching published scientific and medical literature. It is always good practice to retain a record of the search construction, the database used and the date the search was run. In addition, it may be useful to retain results of the search for an appropriate period of time, particularly in the event of zero results. If decision making is documented on the results, it is particularly important to retain this information.

2428 VI.App2App.2.5. Outputs

Databases can show search results in different ways, for example, titles only or title and abstract with or without indexing terms. Some publications are of obvious relevance at first glance, whereas others may be more difficult to identify. Consistent with the requirement to provide the full citation for an article and to identify relevant publications, the title, citation and abstract (if available) should always be retrieved and reviewed.

2434 VI.App2App.2.6. Review and selection of articles

It is recognised that literature search results are a surrogate for the actual article. Therefore, it is 2435 expected that the person reviewing the results of a search is trained to identify the articles of 2436 2437 relevance. This may be an information professional trained in pharmacovigilance or a 2438 pharmacovigilance professional with knowledge of the database used. Recorded confirmation that the 2439 search results have been reviewed will assist in demonstrating that there is a systematic approach to 2440 collecting information about suspected adverse reactions from literature sources. It is recommended 2441 that quality control checks are performed on a sample of literature reviews / selection of articles to check the primary reviewer is identifying the relevant articles. 2442

A common issue in selecting relevant articles from the results of a search is that often this process is conducted for the purposes of identification of ICSRs only. Whereas the review should also be used as the basis for collating articles for the periodic safety update report production, therefore relevant studies with no ICSRs should also be identified, as well as those reports of events that do not qualify for reporting.

Outputs from searches may contain enough information to be a valid ICSR, in which case the article should be ordered. All articles for search results that are likely to be relevant to pharmacovigilance requirements should be obtained, as they may contain valid ICSRs or relevant safety information. The urgency with which this occurs should be proportionate to the content of the material reviewed and the resulting requirement for action as applicable for the marketing authorisation holder.

Articles can be excluded from reporting by the marketing authorisation holder if another company's branded medicinal product is the suspected medicinal product. In the absence of a specified medicinal product source and/or invented name, ownership of the medicinal product should be assumed for articles about an active substance. Alternative reasons for the exclusion of a published article for the
 reporting of ICSRs are detailed in <u>VI.C.2.2.3.</u>

2458 VI.App2App.2.7. Day zero

2459 As described in <u>VI.B.7.</u>, day zero is the date on which an organisation becomes aware of a publication containing the minimum information for an ICSR to be reportable. Awareness of a publication includes 2460 any personnel of that organisation, or third parties with contractual arrangements with the 2461 organisation. It is sometimes possible to identify the date on which a record was available on a 2462 2463 database, although with weekly literature searching, day zero for a reportable adverse reaction present 2464 in an abstract is taken to be the date on which the search was conducted. For articles that have been 2465 ordered as a result of literature search results, day zero is the date when the minimum information for 2466 an ICSR to be valid is available. Organisations should take appropriate measures to obtain articles 2467 promptly in order to confirm the validity of a case.

2468 VI.App2App.2.8. Duplicates

Consistent with the requirements for reporting ICSRs, literature cases should be checked to prevent
reporting the submission of duplicates, and previously reported cases should be identified as such when
reported. It is, therefore, expected that ICSRs are checked in the organisation database to identify
literature articles that have already been reported submitted. Where applicable, this should include
ICSRs resulting from the Agency's activities in accordance with Article 27 of Regulation (EC) 726/2004.

2474 VI.App2App.2.9. Contracting out literature search services

2475 It is possible to use the services of another party to conduct searches of the published scientific and 2476 medical literature. In this event, the responsibility for the performance of the search and subsequent 2477 reporting still remains- with the exception of the provisions set out in Article 27 of Regulation EC) 2478 726/2004 and Article 107(3) of Directive 2001/83/EC. The transfer of a pharmacovigilance task or 2479 function should be detailed in a contract between the organisation and the service provider. The nature 2480 of third party arrangements for literature searching can range from access to a particular database 2481 interface only (access to a technology) to full literature searching, review and reporting (using the 2482 professional pharmacovigilance services of another organisation). It is recognised that more than one 2483 organisation may share services of a third party to conduct searches for generic active substances. In this instance, each organisation should satisfy itself that the search and service is appropriate to their 2484 2485 needs and obligations.

Where an organisation is dependent on a particular service provider for literature searching, it is
expected that an assessment of the service(s) is undertaken to determine whether it meets the needs
and obligations of the organisation. In any case, the arrangement should be clearly documented.

The clock start for the reporting of ICSRs begins with awareness of the minimum information by either the organisation or the contractual partner (whichever is the earliest). This also applies where a third party provides a review or a collated report from the published scientific and medical literature, in order to ensure that published literature cases are reported submitted as required within the correct time frames. That is, day zero is the date the search was run if the minimum criteria are available in the abstract and not the date the information was supplied to the organisation.

	Until standards for the electronic transmission of attachments (e.g. copies of literature articles) a developed in the framework of ICH, the sender should follow the rules outlined below for the
	submission of a copy of the literature article as detailed in VI.C.6.2.3.2.:
-	1:Mailing address and format of literature articles:
	Literature articles reportable to the Agency should be provided in PDF format and sent via e-r
	the following e-mail address: EVLIT@ema.europa.eu.
	In relation to copies of articles from the published scientific and medical literature, marketing
	authorisation holders are recommended to consider potential copyright issues specifically as
	regards the electronic transmission and handling of electronic copies in the frame of regulato
	activities.
-	2.—File name of literature articles sent in electronic format to the Agency:
	The file name of a literature article sent in PDF format should match exactly the 'World-Wide
	Unique Case Identification Number' (ICH-E2B(R2) A.1.10.1 or A.1.10.2 as applicable) assigned
	the individual case, which is described in the article and which is reported in the E2B(R2) ICS
	format.
	If there is a follow-up article to the individual case published in the literature, the file name w
	the World-Wide Unique Case Identification Number must be maintained but should include a
	sequence number separated with a dash.
+	Examples:
	Initial ICSR published in the literature: FR-ORGABC-23232321 (data element 'World-Wide Un
	Case Identification Number' (ICH-E2B(R2) A.1.10.1));
	File name of the literature article: FR-ORGABC-23232321.pdf.
1	 Follow-up information published in the literature in a separate article:
	remains unchanged (ICH-E2B(R2) A.1.10.1));
	File name: FR-ORGABC-23232321-1.pdf.
-	3.—Reporting of cases reported in the scientific and medical literature referring to more than one
	patient:
	When the literature article refers to the description of more than one patient, the copy of the
	literature article should be sent only once.
	The file name of a literature article sent in PDF format should match exactly the 'World-Wide
	Unique Case Identification Number' (data element ICH-E2B(R2) A.1.10.1 or A.1.10.2 as appli
	assigned to the first reportable individual case described in the article.
	In addition, all ICSRs which relate to the same literature article should be cross referenced in
	data element 'Identification number of the report which is linked to this report' (ICH-E2B(R2) A.1.12). The data element should be repeated as necessary to cross refer all related cases (s

Examples for the reporting of ICSRs In accordance with Article 28(3) of the Commission Implementing
 Regulation (EU) 520/2012 and upon request of the Agency, the marketing authorisation holder that
 transmitted the initial report shall provide a copy of the relevant article taking into account copyright
 restrictions, and a full translation of that article into English.

2538 2539 2540 **Table VI.6.** In line with ICH-E2B the following applies as regards the electronic submission of a copy of an article including a full translation where applicable: Electronic transmission of copies of literature articles/translations on suspected adverse reactions

Reference	
ICH-E2B(R2)	1. Mailing address and format of literature articles:
	Literature articles reportable to the Agency should be provided in PDF format and sent via e-mail to the following e-mail address: <u>EVLIT@ema.europa.eu</u> .
	In relation to copies of articles from the published scientific and medical literature, marketing authorisation holders are recommended to consider potential copyright issues specifically as regards the electronic transmission and handling of electronic copies in the frame of regulatory activities.
	2. File name of literature articles sent in electronic format to the Agency:
	The file name of a literature article sent in PDF format should match exactly the data element A.1.10.1 or A.1.10.2 'World-Wide Unique Case Identification Number' assigned to the individual case, which is described in the article and which is provided in the E2B(R2) ICSR format.
	If there is a follow-up article to the individual case published in the literature, the file name with the World-Wide Unique Case Identification Number must be maintained but should include a sequence number separated with a dash.
	Examples:
	Initial ICSR published in the literature: FR-ORGABC-23232321 data element A.1.10.1 'World-Wide Unique Case Identification Number';
	- File name of the literature article: FR-ORGABC-23232321.pdf.
	• Follow-up information published in the literature in a separate article:
	 ICSR: FR-ORGABC-23232321 data element A.1.10.1''World-Wide Unique Case Identification Number' remains unchanged;
	- File name: FR-ORGABC-23232321-1.pdf.
	3. Reporting of cases described in the scientific and medical literature referring to more than one patient:
	When the literature article refers to the description of more than one patient, the copy of the literature article should be sent only once.
	The file name of a literature article sent in PDF format should match exactly data element A.1.10.1 or A.1.10.2 as applicable 'World-Wide Unique Case Identification Number' assigned to the first reportable individual case described in the article.
	In addition, all ICSRs which relate to the same literature article should be cross

Reference	E2B(R2)/(R3) requirements
	referenced in data element A.1.12 'Identification number of the report which is linked to this report'. The data element should be repeated as necessary to cross refer all related cases.
ICH-E2B(R3)	• Information on how to attach documents to an ICSR is provided in section 3.5 'Document Attachments' of the ICH-E2B(R3) Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs) - Data Elements and Message Specification.
	• When a literature article is sent as an attachment, the literature citation in Vancouver style is captured in data element C.4.r.1 'Literature Reference(s)'. The Digital Object Identifier (DOI) for the article should be included where available. The example reference below highlighted how this should be done:
	"International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997; 336:309-15. doi:10.1056/NEJM199701233360422."
	• The electronic version of the document (i.e. the journal article and a copy of the translation where applicable) should be attached to the ICSR in data element C.4.r.2. 'Included Documents'.
	• If the article and/or translation are not provided at the time of ICSR reporting, attachments can be transmitted separately from the ICSR transmission. When the sender transmits an attachment later, the original ICSR along with all the same medical information captured in E2B(R3) data elements is retransmitted as an 'amendment' (see <u>VI.C.6.2.2.8.</u>). If new information has been received and the data elements in E2B(R3) have been updated, then the ICSR with attachment is transmitted as a follow-up.
	Examples for the reporting of suspected adverse reactions the scientific and medical literature and referring to more than

2541

2543

2544 one patient

Table VI.3. Table VI.7. Examples for the reporting of suspected adverse reactions described in the scientific and medical literature and referring to more than one patient 2545 2546

Ex.	Scenario	Action
+	A literature article describes suspected adverse reactions that have been experienced by up to 3 single patients. 3 ICSRs should be created and reported for each individual identifiable patient described in the literature article. Each ICSR should contain all the available information on the	 For Case 1 described in the literature article: ICH-E2B(R2) A.1.10.1 'World-Wide Unique Case Identification Number': UK-ORGABC-0001 ICH-E2B(R2) A.1.12 'Identification number of the report which is linked to this report': UK-ORGABC-0002 ICH-E2B(R2) A.1.12 'Identification number of the report which is linked to this report': UK-ORGABC-0003 ICH-E2B(R2) A.2.2 'Literature reference(s):

case. Literature reference in line with uniform requiremanuscripts submitted to biomedical journals N Engl J Med. 1997; 336:309-15. File name for the copy of literature article to lie-mail to EVLIT@ema.europa.eu: UK-ORGABC-0001.pdf For Case 2 described in the literature article: ICH-E2B(R2) A.1.10.1 'World-Wide Unique Caldentification Number': UK-ORGABC-0002 UK-ORGABC-0002 ICH-E2B(R2) A.1.12 'Identification number of which is linked to this report': UK-ORGABC-0001 ICH-E2B(R2) A.1.12 'Identification number of which is linked to this report': UK-ORGABC-0003 ICH-E2B(R2) A.1.12 'Identification number of which is linked to this report':	
 ICH-E2B(R2) A.1.10.1 'World-Wide Unique Candentification Number': UK-ORGABC-0002 ICH-E2B(R2) A.1.12 'Identification number of which is linked to this report': UK-ORGABC-0001 ICH-E2B(R2) A.1.12 'Identification number of which is linked to this report': UK-ORGABC-0003 ICH-E2B(R2) A.2.2 'Literature reference(s): Literature reference in line with uniform required 	S:
which is linked to this report': UK-ORGABC-0003 	
N Engl J Med. 1997; 336: 309-15. No copy of the literature article required since was already submitted for case 1.	uirements for s:
For Case 3 described in the literature article: ICH-E2B(R2) A.1.10.1 'World-Wide Unique Ca Identification Number': UK-ORGABC-0003 ICH-E2B(R2) A.1.12 'Identification number of which is linked to this report': UK-ORGABC-0001 ICH-E2B(R2) A.1.12 'Identification number of which is linked to this report': UK-ORGABC-0002	if the report
 UK-OKGABC-0002 ICH-E2B(R2) A.2.2 'Literature reference(s): Literature reference in line with uniform required manuscripts submitted to biomedical journals N Engl J Med. 1997; 336: 309-15. No copy of the literature article required since was already submitted for case 1. 	S:
 A literature article describes suspected adverse reactions that have been experienced by more than 3 single patients. ICSRs should be created and reported submitted for each For the ICSRs which relate to the same literature cross reference in the data element ICH (E2B(R2)) ICH-E2B(R3) C.1.10.r 'Identification number of the which is linked to this report' ICH (E2B(R2) field / should be conducted as follows: The first case should be linked to all other case to the same article; (1-n); All the other cases (n) should be only linked to the same article for each 	2) A.1.12/ he report A.1.12) ases related

	Ex.	Scenario	Action
		individual identifiable patient described in the literature article. Each ICSR should contain all the	one, as in the example below. Example for the reporting of cases originally reporteddescribed in the scientific and medical literature referring to a large number of patients:
		available information on the case. The cross reference with all the linked ICSRs from this literature article should only be provided in the first case, in the data element ICH-E2B(R2) A.1.12 'Identification number of the report which is linked to this report'. There is no need to repeat all the cross references in	 For Casecase 1 described in the literature article: data element ICHE2B(R2) A.1.10.1/ ICH-E2B(R3) C.1.8.1 'Worldwide Unique Case Identification Number': UK-ORGABC-0001 data element ICH-E2B(R2) A.1.12/ ICH-E2B(R3) C.1.10.r 'Identification number of the report which is linked to this report': UK-ORGABC-0002 data element ICH-E2B(R2) A.1.12/ ICH-E2B(R3) C.1.10.r 'Identification number of the report which is linked to this report': UK-ORGABC-0002
		the other ICSRs.	 UK-ORGABC-0003 data element ICH-E2B(R2) A.1.12/ ICH-E2B(R3) t C.1.10.r 'Identification number of the report which is linked to this report': UK-ORGABC-0004
1			 data element ICH-E2B(R2) A.1.12/ICH-E2B(R3) C.1.10.r 'Identification number of the report which is linked to this report': UK-ORGABC-000N data element ICH-E2B(R2) A.2.2/ ICH-E2B(R3) C.4.r. 'Literature reference(s)':
			 N Engl J Med. 1997; 336: 309-15. File name for the copyLiterature reference in line with uniform requirements for manuscripts submitted to biomedical journals including DOI if available: e.g. "N Engl J Med 1997; 336: 309-15. doi: 10.1056/NEJM199701233360422" Copy of literature article to be sent via e-mail to <u>EVLIT@ema.europa.eu</u>:/translation: follow steps as outlined in Table VI.6. UK-ORGABC-0001.pdf.
			 For Case 2 described in the literature article: data element ICHE2B(R2) A.1.10.1/ ICH-E2B(R3) C.1.8.1 'Worldwide Unique Case Identification Number': UK-ORGABC-0002 data element ICH-E2B(R2) A.1.12/ ICH-E2B(R3) C.1.10.r 'Identification number of the report which is linked to this report': UK-ORGABC-0001
I			 data element ICH-E2B(R2) A.2.2/ ICH-E2B(R3) C.4.r. 'Literature reference(s)':

Ex.	Scenario	Action
		 N Engl J Med. 1997; 336: 309-15. Literature reference in line with uniform requirements for manuscripts submitted to biomedical journals including DOI if available: e.g. "N Engl J Med 1997; 336: 309-15. doi: 10.1056/NEJM199701233360422" No copy of the literature article required since the copy was already submitted for case 1.
		 For Case N described in the literature article: data element ICH-E2B(R2) A.1.10.1/ ICH-E2B(R3) C.1.8.1 'Worldwide Unique Case Identification Number': UK-ORGABC-000N data element ICH-E2B(R2) A.1.12/ ICH-E2B(R3) C.1.10.r 'Identification number of the report which is linked to this report': UK-ORGABC-0001 data element ICH-E2B(R2) A.2.2/ ICH-E2B(R3) C.4.r. 'Literature reference(s)': N Engl J Med. 1997; 336:309-15. Literature reference in line with uniform requirements for manuscripts submitted to biomedical journals including DOI if available: e.g. "N Engl J Med 1997; 336:309-15. doi: 10.1056/NEJM199701233360422"
		• No copy of the literature article required since the copy was already submitted for case 1.

VI. Appendix 3 Modalities for reporting Reporting modalities of ICSRs in EU


2550

2548

2549

50 VI.App3.1. Interim arrangements

2551 Business process map - Suspected adverse reaction reporting in EU – Interim arrangements



2555

Table VI.4. Table VI.8. Process description - Suspected adverse reaction reporting in EU - Interim arrangements

4	Start. Receive report.	Marketing Authorisation Holder (MAH) receives information on a suspected adverse reaction from a patient, healthcare professional or other valid reporter. If the case has been received from an EU NCA, <u>do not</u> retransmit it to EudraVigilance (EV).	MAH
2	Open case.	Open and create an individual case safety report.	MAH
3	Is case from EEA?	Did the adverse reactions occur in the EU? If No, go to step 3.1. If Yes, got so step 5.	MAH
3.1	Is case serious?	If No, go to step 3.2. If Yes, got to step 4.	MAH
3.2	End.	The case is now stored in the MAHs pharmacovigilance database. Normal follow-up activities should continue and if any follow-up is received, return to step 1.	MAH
4	Send to EV & relevant NCAs.	Transmit the serious case electronically, in ICH E2B(R2) format as an xml message within the 15-day time frame to EV and to the relevant NCAs, where required. The case goes to step 4.1 & step 6.	ман
4.1	Receive in EV.	Receive the message in EV database from MAH or NCA.	EMA
4.2	Technical Validation (EV Business Rules).	 Every message that is received in EV is validated against the EudraVigilance Business Rules and an Acknowledgement message (ACK) is created specifying whether or not the message & the case(s) therein are valid. A valid message will have an ACK code 01. A non-valid message will have an ACK code 02 (if a case contained therein is non-valid) or 03 (if the message itself is not correctly formatted). 	EMA
4.3	Store in EV.	Once the case has been validated, it is stored in EV.	EMA
4.4	Send ACK.	The acknowledgement message created in step 4.2 is transmitted to the case sender, no later than 2 business days following receipt of the case. Go to step 16 for MAHs receiving the ACK.	EMA

No.	Step	Description	Responsible Organisation
			Grganisation
		Go to step 20 for NCAs receiving the ACK.	
4.5		Go to step 4.5 for the EMA's next step.	EN4
4.5	Was ACK code 01?	If No, go to step 4.6.	EMA
		If Yes, go to step 4.7.	EN4
4.6	Await corrected case.	The sender should correct every case with	EMA
		an error ACK and retransmit within the	
		regulatory reporting timelines. Periodically the EMA should assess all cases with an	
		error ACK for which a corrected case has	
		not been transmitted and contact the	
		Qualified Person responsible for	
		PharmacoVigilance (QPPV) to inform of	
		these missing corrected cases. If a sender	
		fails to correct cases, then this	
		information should be incorporated into	
		data quality assessments and the	
		appropriate committees should be	
		informed.	
		Go back to step 4.1 upon receipt of the	
		corrected case.	
4.7	End.	The case is now stored in EV &,	EMA
		following duplicate detection &	
		recoding will be available for signal	
		detection and data quality analyses.	
5	Send to relevant NCA.	Transmit the case (serious, and if	MAH
		required non-serious) electronically, in	
		ICH E2B(R2) format as an xml message	
		within the relevant time frames (15 or 90	
		days, as applicable), to the relevant NCA	
		for the Member State where the reaction	
		occurred. If country of occurrence has not	
		been encolfied then country of primary	
		been specified, then country of primary	
		source should normally be taken to be the	
	Dessitus in	source should normally be taken to be the occurrence country.	NGA
6	Receive in	source should normally be taken to be the occurrence country. Receive the message from MAH in the	NCA
6	PharmacoVigilance DataBase	source should normally be taken to be the occurrence country.	NGA
	PharmacoVigilance DataBase (PhV-DB).	source should normally be taken to be the occurrence country. Receive the message from MAH in the NCA's PhV DB.	
6 7	PharmacoVigilance DataBase (PhV DB). Technical Validation (EV	source should normally be taken to be the occurrence country. Receive the message from MAH in the NCA's PhV DB. Every message that is received in the	NGA NCA
	PharmacoVigilance DataBase (PhV-DB).	source should normally be taken to be the occurrence country. Receive the message from MAH in the NCA's PhV DB. Every message that is received in the NCA's PhV DB should be validated against	
	PharmacoVigilance DataBase (PhV DB). Technical Validation (EV	source should normally be taken to be the occurrence country. Receive the message from MAH in the NCA's PhV DB. Every message that is received in the NCA's PhV DB should be validated against the EudraVigilance Business Rules and an	
	PharmacoVigilance DataBase (PhV-DB). Technical Validation (EV	source should normally be taken to be theoccurrence country.Receive the message from MAH in theNCA's PhV DB.Every message that is received in theNCA's PhV DB should be validated againstthe EudraVigilance Business Rules and anAcknowledgement message (ACK) is	
	PharmacoVigilance DataBase (PhV-DB). Technical Validation (EV	source should normally be taken to be theoccurrence country.Receive the message from MAH in theNCA's PhV DB.Every message that is received in theNCA's PhV DB should be validated againstthe EudraVigilance Business Rules and anAcknowledgement message (ACK) iscreated specifying whether or not the	
	PharmacoVigilance DataBase (PhV-DB). Technical Validation (EV	source should normally be taken to be theoccurrence country.Receive the message from MAH in theNCA's PhV DB.Every message that is received in theNCA's PhV DB should be validated againstthe EudraVigilance Business Rules and anAcknowledgement message (ACK) iscreated specifying whether or not themessage & the case(s) therein are valid.	
	PharmacoVigilance DataBase (PhV-DB). Technical Validation (EV	source should normally be taken to be theoccurrence country.Receive the message from MAH in theNCA's PhV DB.Every message that is received in theNCA's PhV DB should be validated againstthe EudraVigilance Business Rules and anAcknowledgement message (ACK) iscreated specifying whether or not the	

No.	Step	Description	Responsible Organisation
		non-valid) or 03 (if the message itself is	
		not correctly formatted).	
8	Store in EV.	Once the case has been validated, it is stored in the NCA's PhV DB.	NCA
9	Send ACK.	The acknowledgement message created instep 7 is transmitted to the case senderno later than 2 business days followingreceipt of the case.Co to step 16 for MAHs receiving the ACK.Co to step 10 for the NCA's next step.	NCA
10	Was ACK code 01?	If No, go to step 10.1. If Yes, go to step 11.	NCA
10.1	Await corrected case.	The MAH should correct every case with an error ACK and retransmit it within the regulatory reporting timelines. Periodically the NCA should assess all cases with an error ACK for which a corrected case has not been transmitted and contact the QPPV to inform them of these missing corrected cases. If a sender fails to correct cases, then this information should be incorporated into any data quality assessments performed and the appropriate action can be taken. Go back to step 6 upon receipt of the corrected case.	NCA
11	Was case from NCA's MS?	Did the case occur in the territory of the receiving NCA? If No, go to step 11.1. If Yes, go to step 12.	NCA
11.1	End.	The case is now stored in the NCA's PharmacoVigilance DataBase &, following duplicate detection & recoding will be available for signal detection and data quality analyses.	NCA
12	Send to EV & MAH.	Transmit the serious case electronically,in ICH E2B(R2) format as an xml messagewithin the 15-day time frame to EV and tothe relevant MAH(s).Go to step 4.1 for reception of the case inEVGo to step 24 for reception of the case bythe relevant MAH(s).	NCA
13	Start. Receive report.	NCA receives information on a suspected adverse reaction from a patient, healthcare professional or	NCA

No.	Step	Description	Responsible
			Organisation
		other valid reporter concerning a	
		suspected adverse reaction occurring	
		in the territory of the receiving	
		competent authority.	
14	Open case.	Open and create an individual case safety report.	NCA
15	Is case serious?	If No, go to step 15.1	NCA
		If Yes, go to step 12	
15.1	End	The case is now stored in the NCA's	NCA
		PharmacoVigilance DataBase &,	
		following duplicate detection &	
		recoding will be available for signal	
		detection and data quality analyses.	
16	Receive ACK.	Receive the ACK message, associate it	MAH
		with the relevant case(s) and check to	
		ensure that the case was considered	
		valid.	
17	Was ACK code 01?	If yes, go to step 17.1.	MAH
		If no, then the regulatory timeline clock	
		has not stopped and the case should be	
		corrected and re-transmitted to EV within	
		the relevant regulatory reporting	
		timelines. Day 0 remains as the day that	
		the first information was received. A 02 or	
		03 ACK does not constitute new	
47.4	First.	information. Go to step 18 (Correct case).	
17.1	End.	End the process of transmitting this version of the case to EV or NCA.	MAH
		Normal follow-up activities should	
		continue and if any follow-up is received, return to step 1.	
18	Correct case.	Correct the case to remove the errors	MAH
-0	Confect case.	identified in the ACK.	
19	Retransmit to the organisation	Retransmit the corrected case to the	MAH
17	which rejected the case.	organisation which rejected the case with	
		ACK code 02 or 03.	
		Cot to step 4.1 &/or step 6 as	
		appropriate.	
20	Receive ACK.	Receive the ACK message, associate it	NCA
		with the relevant case(s) and check to	
		ensure that the case was considered	
		valid.	
21	Was ACK code 01?	If yes, go to step 23.	NCA
		If no, then the regulatory timeline clock	
		has not stopped and the case should be	

No.	Step	Description	Responsible Organisation
		the relevant regulatory reporting timelines. Day 0 remains as the day that the first information was received. A 02 or 03 ACK does not constitute new information. Go to step 22 (Correct case).	
22	Correct case.	Correct the case to remove the errors identified in the ACK and retransmit the case to EV and to the relevant MAH(s) (go back to step 12).	NCA
23	End.	End the process of transmitting this version of the case to EV and to the relevant MAH(s). Normal follow-up activities should continue and if any follow-up is received, return to step 6 or 13.	NCA
24	Receive report from NCA	MAH receives information on a suspected adverse reaction from an NCA. This case should not be retransmitted to EV and to the NCA which transmitted it to the MAH	MAH
25	End	The case is now stored in the MAH's PharmacoVigilance DataBase &, following duplicate detection & recoding will be available for signal detection and data quality analyses.	MAH


2557	VI.App3.1.1. Interim arrangements applicable to marketing authorisation
2558	holders
2559	Reporting requirements of individual case safety reports applicable to marketing authorisation holders
2560	during the interim period are detailed in the latest version of <u>Doc. EMA/321386/2012</u> available on EMA
2561	website.

2562 VI.App3.1.2. Interim arrangements applicable to competent authorities in 2563 Member States

2564 **Table VI.5.**-Reporting requirements applicable to competent authorities in Member States - Interim 2565 arrangements

 Centralised Mutual recognition, decentralised or subject to referral Purely national 	EU	All scrious	 EudraVigilance database Marketing authorisation holder of the suspected medicinal product 	15 day

2567 VI.App3.2. Final arrangements



2568 Figure VI.3. Figure VI.6. Business process map - Suspected adverse reaction-ICSRs reporting in EU
 2569 - Final arrangements

2570

Table VI.6. Table VI.9. Process description - Suspected adverse reaction ICSRs reporting in EU Final arra-gements

No.	Step	Description	Responsible Organisation
1	Start. Receive report.	National Competent Authority (NCA) or Marketing Authorisation Holder (MAH) receives information on a suspected adverse reaction from a patient, healthcare professional or other valid reporter. If the case has been received from an EU NCA, <u>do not</u> retransmit it to EudraVigilance (EV).	MAH/NCA
2	Open case.	Open and create an individual case safety report.	MAH/NCA
3	Is case serious?	If No go to step 3.1. If Yes, go to step 4.	
3.1	Is case from EEA?	If No go to step 11.1. If Yes, go to step 4.	
4	Send to EV.	Transmit the case (all serious and EU non-serious) electronically, in ICH E2B(R2/R3) format as an xmI XML message within the relevant time frame (15 or 90 days, as applicable), to EV.	MAH/NCA
5	Receive in EV.	Receive the message in the EV.	EMA
6	Technical Validation (EV Business Rules).	 Every message that is received in EV is validated against the EudraVigilance Business Rules and an Acknowledgement message (ACK) is created specifying whether or not the message & the case(s) therein are valid. E2B(R2) messages will receive an E2B(R2) acknowledgement and an E2B(R3) message will receive an E2B(R3) acknowledgement. 	EMA
		A valid messageE2B(R2) ICSR will have an E2B(R2) ACK code 01- (ACK_B.1.8). A non-valid E2B(R2) ICSR will have an E2B(R2) ACK code 02(ACK_B.1.8). A non-valid message will have an ACK receive an 03 transmision	
		 acknowledgement code 02(ACK_A.1.6) (if a case contained therein the message itself is not correctly formatted). A valid E2B(R3) ICSR will have an E2B(R2) ACK code "CA" (ACK B r 6) A 	
		E2B(R3) ACK code "CA" (ACK.B.r.6). A non-valid) or 03 E2B(R3) ICSR will have an E2B(R3) ACK code "CR" (ACK.B.r.6). A	

	No.	Step	Description	Responsible Organisation
			non-valid message will receive an "AR" transmision acknowledgement code (ACK.A.4) (if the message itself is not correctly formatted).	
	7	Store in EV.	Once the case has been validated, it is stored in the EV.	EMA
	8	Send ACK.	The acknowledgement message created in step 6 is transmitted to the case sender no later than 2 business days following receipt of the case. Go to step 9 for the EMA's next step. Go to step 10 for MAH/NCA's next step.	EMA
	9	Was a positive ACK code 01 received?	If No go to step 9.1. If Yes, go to step 9.2.	EMA
	9.1	Await corrected case.	The sender should correct every case with an error ACK and retransmit it within the regulatory reporting timelines. Periodically the EMA should assess all cases with an error ACK for which a corrected case has not been transmitted and contact the Qualified Person responsible for PharmacoVigilance (QPPV) to inform these missing corrected cases.sender. If a sender fails to correct cases, this information should be incorporated into data quality assessments and the appropriate committees should be informed. Go back to step 5 upon receipt of the corrected case.	EMA
1	9.2	End.	The case is now stored in EV &, following duplicate detection & recoding will be available for signal detection and data quality analyses. If the case occurred in the EU and was transmitted to EV by a MAH, it will be rerouted to the relevant NCA (see <u>VIAppendix-App.3.3</u>)	EMA
1	10	Receive ACK.	Receive the ACK message, associate it with the relevant case(s) and check to ensure that the case was considered valid.	MAH/NCA
	11	Was a positive ACK code 01received?	If yes, go to step 11.1. If no, then the regulatory timeline clock has not stopped and the case should be corrected and re-transmitted to EV within	MAH/NCA

No.	Step	Description	Responsible Organisation
		the relevant regulatory reporting timelines. Day 0 remains as the day that the first information was received. A Neither a non-valid ICSR (E2B(R2) ACK code 02 or E2B(R3) ACK code "CR") nor a non-valid message (E2B(R2) 03 ACK does not constituteor E2B(R3) "AR" transmision acknowledgement code) constitutes new information. Go to step 12 (Correct case)	
11.1	End.	End the process for this version of the case. Normal follow-up activities should continue and if any follow-up is received, return to step 1.	MAH/NCA
12	Correct case.	Correct the case to remove the errors identified in the ACK and retransmit the case to EV (go back to step 4).	MAH/NCA

VI.App3.2App.3.1. Final arrangements Requirements applicable to marketing authorisation holders

2576 Table VI.7. Table VI.10. Reporting requirements applicable to marketing authorisation holders 2577 Final arrangements

au	arketing Ithorisation ocedure	Origin	Adverse reaction type	Destination	Time frame
•	Centralised	EU	All serious	EudraVigilance database	15 days
•	Mutual recognition, decentralised or		All non-serious	EudraVigilance database	90 days
•	subject to referral Purely national	Non- EU	All serious	EudraVigilance database	15 days

2578

2579 VI.App3.2.2. Final arrangementsApp.3.2. Requirements applicable to 2580 competent authorities in Member States


Table VI.8. Table VI.11. Reporting requirements applicable to competent authorities in Member States - Final arrangements

Marketing authorisation procedure	Origin	Adverse reaction type	Destination	Time frame
Centralised	EU	All serious	EudraVigilance database	15 days
 Mutual recognition, decentralised or subject to referral 		All non-serious	EudraVigilance database	90 days
Purely national				

VI. App3App. 3.3 Transmission and rerouting of ICSRs to competent authorities in Member States ⁶⁶

2585 Figure VI.4. Figure VI.7. Business process map - Transmission and rerouting of ICSRs to competent authorities in Member States

- 2587
- 2588



⁶⁶ Once the functionalities of the EudraVigilance database specified in [REG Art 24(2)] are established.

Table VI.9. Table VI.12. Process description - Transmission and rerouting of ICSRs to competent authorities in Member States ⁶⁷

No.	Name	Description	Responsible Organisation
1	Start. Receive report.	Marketing Authorisation Holder (MAH) receives information on a suspected adverse reaction from a patient, healthcare professional or other valid reporter.	МАН
2	Open case.	Open and create an individual case safety report.	MAH
3	Send to EudraVigilance (EV).	Transmit the case electronically, in ICH E2B(R2/R3) format as an xmI XML message within the relevant time frames (15 or 90 days, as applicable), to EV.	MAH
4	Receive in EV.	Receive the message in the EV.	EMA
5	Technical Validation (EV Business Rules).	Every message that is received in EV is validated against the EudraVigilance Business Rules and an Acknowledgement message (ACK) is created specifying whether or not the message & the case(s) therein are valid. E2B(R2) messages will receive an E2B(R2) acknowledgement and an E2B(R3) message will receive an E2B(R3) acknowledgement. A valid messageE2B(R2) ICSR will have an E2B(R2) ACK code 01- (ACK_B.1.8). A non-valid messageE2B(R2) ICSR will have an E2B(R2) ACK code 02-(if a case contained therein is(ACK_B.1.8). A non- valid) or 03 message will receive an 03 transmision acknowledgement code (ACK_A.1.6) (if the message itself is not correctly formatted). A valid E2B(R3) ICSR will have an E2B(R3) ACK code "CA" (ACK.B.r.6). A	EMA
		non-valid E2B(R3) ICSR will have an E2B(R3) ACK code "CR" (ACK.B.r.6). A non-valid message will receive an "AR" transmision acknowledgement code (ACK.A.4) (if the message itself is not correctly formatted).	
6	Store in EV.	Once the case has been validated, it is stored in EV.	EMA

⁶⁷ Once the functionalities of the EudraVigilance database specified in [REG Art 24(2)] are established.

No.	Name	Description	Responsible Organisation
7	Send ACK.	The acknowledgement message created in step 5 is transmitted to the case sender no later than 2 business days following receipt of the case.	EMA
7.1	Receive ACK.	Receive the ACK message, associate it with the relevant case(s) and check to ensure that the case was considered valid.	МАН
7.2	Was a positive ACK code Offreceived?	If Yes, go to step 7.2.1. If no, then the regulatory timeline clock has not stopped and the case should be corrected and re-transmitted to EV within the relevant regulatory reporting timelines. Day 0 remains as the day that the first information was received. A Neither a non-valid ICSR (E2B(R2) ACK code 02 or E2B(R3) ACK code "CR") nor a non-valid message (E2B(R2) 03 ACK does not constituteor E2B(R3) "AR" transmision acknowledgement code) constitutes new information. Go to step 7.2.2 (Correct case).	MAH
7.2. 1	End.	End the process of transmitting this version of the case to EV. Normal follow-up activities should continue and if any follow-up is received, return to step 1.	МАН
7.2. 2	Correct case.	Correct the case to remove the errors identified in the ACK and retransmit the case to EV (go back to step 3).	MAH
8	Was a positive ACK code 01 received?	If yes, go to step 9. If no, perform no further processing on this version of the case and go to step 8.1	ЕМА
8.1	Await corrected case.	The sender should correct every case with an error ACK and retransmit it within the regulatory reporting timelines. Periodically the EMA should assess all cases with an error ACK for which a corrected case has not been transmitted and contact the Qualified Person responsible for PharmacoVigilance (QPPV)sender to inform of these missing corrected cases. If a sender fails to correct cases, his information should be incorporated into data quality assessments and the appropriate committees should be	EMA


No.	Name	Description	Responsible Organisation
		informed.	
9	Assess cases in message.	Whenever a message has passed the technical validation, the cases therein should be immediately assessed to determine the country where the reaction occurred for regulatory reporting purposes.	EMA
10	Was case from EU?	For every case, assess whether the country of occurrence is in the EU. If Yes, go to step 11. If No, go to step 10.1	EMA
10.1	End.	The case is now stored in EV &, following duplicate detection & recoding will be available for signal detection and data quality analyses.	EMA
11	Extract cases from message.	The cases occurring in the EU will be extracted from the message for processing prior to retransmission.	EMA
12	Technical Validation.	For the retransmission of E2B(R2) messages the 'Message sender identifieridentifier' (ICH M2E2B(R2) M.1.5) of reporting MAH is inserted in data element 'Sender organisation fieldorganisation' (ICH-E2B(R2) A.3.1.2) prior to retransmission. This is to permit the receiving National Competent Authority (NCA) to unambiguously identify the MAH responsible for transmitting the case to EV. For the retransmission of E2B(R3) messages the data element N.2.r.2 'Message sender identifier' will remain unchanged	EMA
13	Send to relevant NCA	The case is transmitted to the relevant NCA of the Member State where the reaction occurred with no other changes. Where a Member State has more than one NCA responsible for post-marketing reports, the cases occurring in that Member State are sent to all relevant NCAs.	EMA
14	Receive in PharmacoVigilance DataBase (PhV DB).	The relevant NCA receives the message in its PhV DB	NCA
15	Technical Validation (EV Business Rules).	Every message should be validated against the EudraVigilance Business Rules (the same business rules as in Step 5 and	NCA

No.	Name	Description	Responsible Organisation
		an Acknowledgement message (ACK) is created specifying whether or not the message & the case(s) therein are valid. A valid messageICSR will have an E2B(R2) ACK code 01- or E2B(R3) ACK code "CA". A non-valid messageICSR will have an E2B(R2) ACK code 02 (if a case	
14	Store in DharmaceVigilance	 contained therein isor E2B(R3) ACK code "CR". A non-valid) or 03 message will receive an E2B(R2) 03 or E2B(R3) "AR" transmision acknowledgement code (if the message itself is not correctly formatted). 	NCA
16	Store in PharmacoVigilance DataBase (PhV DB).	Once the case has been validated, it is stored in the PhV DB.	NCA
17	Send ACK.	The acknowledgement message created in step 15 is transmitted to EV no later than 2 business days following receipt of the case.	NCA
17.1	End	The case is now stored in the NCA's PharmacoVigilance DataBase &, following duplicate detection & recoding will be available for signal detection and data quality analyses.	NCA
18	Receive ACK	The acknowledgement message sent in step 17 is received & stored in EV.	EMA
19	End	The case has now been successfully retransmitted to the relevant NCA.	EMA

VI. Appendix 4 Transmission of ICSRs to the World Health Organization (WHO)⁶⁸

2594 Figure VI.5. Figure VI.8. Business process map - Transmission of ICSRs to the World Health
 2595 Organization (WHO) Collaborating Centre for International Drug Monitoring

- 2596
- 2597
- 2598



⁶⁸ Once the functionalities of the EudraVigilance database specified in [REG Art 24(2)] are established.

Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2 - Draft for public consultation

Table VI.10. Table VI.13. Process description - Transmission of ICSRs to the World Health Organisation (WHO) Collaborating Centre for International Drug Monitoring⁶⁹

No.	Step	Description	Responsible Organisation
1	Start. Receive report.	National Competent Authority (NCA) or Marketing Authorisation Holder (MAH) receives information on a suspected adverse reaction from a patient, healthcare professional or other valid reporter.	MAH/NCA
2	Open case.	Open and create an individual case safety report.	MAH/NCA
3	Send to EV.	Transmit the case electronically, in ICH E2B(R2/R3) format as an xmIXML message within the relevant time frames (15 or 90 days, as applicable), to EudraVigilance (EV).	MAH/NCA
4	Receive in EV.	Receive the message in EV.	EMA
5	Technical Validation (EV Business Rules).	 Every message that is received in EV is validated against the EudraVigilance Business Rules and an Acknowledgement message (ACK) is created specifying whether or not the message & the case(s) therein are valid. E2B(R2) messages will receive an E2B(R2) acknowledgement and an E2B(R3) message will receive an E2B(R2) acknowledgement. A valid messageE2B(R2) ICSR will have an E2B(R2) ACK code 01⁺ (ACK_B.1.8). A non-valid messageE2B(R2) ICSR will have an E2B(R2) ACK code 02-(if a case contained therein is(ACK_B.1.8). A non-valid) or 03 message will receive an 03 transmision acknowledgement code (ACK_A.1.6) (if the message itself is not correctly formatted). A valid E2B(R3) ICSR will have an E2B(R3) ACK code "CA" (ACK.B.r.6). A non-valid message will receive an "AR" transmision acknowledgement code (ACK.A.4) (if the message itself is not correctly formatted). 	EMA

⁶⁹ Once the functionalities of the EudraVigilance database specified in [REG Art 24(2)] are established.

No.	Step	Description	Responsible Organisation
6	Store in EV.	Once the case has been validated, it is stored in EV.	EMA
7	Send ACK.	The acknowledgement message created in step 5 is transmitted to the case sender no later than 2 business days following receipt of the case.	EMA
7.1	Receive ACK.	Receive the ACK message, associate it with the relevant case(s) and check to ensure that the case was considered valid.	MAH/NCA
7.2	Was a positive ACK code Offreceived?	If Yes, go to step 7.2.1. If no, then the regulatory timeline clock has not stopped and the case should be corrected and re-transmitted to EV within the relevant regulatory reporting timelines. Day 0 remains as the day that the first information was received. ANeither a non-valid ICSR (E2B(R2) ACK code 02 or E2B(R3) ACK code "CR") nor a non-valid message (E2B(R2) 03 ACK does not constituteor E2B(R3) "AR" transmision acknowledgement code) constitutes new information. Go to step 7.2.2 (Correct case).	MAH/NCA
7.2.1	End	End the process of transmitting this version of the case to EV. Normal follow-up activities should continue and if any follow-up is received, return to step 1.	MAH/NCA
7.2.2	Correct case	Correct the case to remove the errors identified in the ACK and retransmit the case to EV (go back to step 3).	MAH/NCA
8	Was a positive ACK code 01?received??	If yes, go to step 9 If no, perform no further processing on this version of the case and go to step 8.1	ЕМА
8.1	Await corrected case.	The sender should correct every case with an error ACK and retransmit within the regulatory reporting timelines. Periodically the EMA should assess all cases with an error ACK for which a corrected case has not been transmitted and contact the Qualified Person responsible for PharmacoVigilance (QPPV) to inform of these missing corrected cases. If a sender fails to correct cases, this information should be incorporated into data quality assessments and the appropriate	EMA

9Assess cases in message.Once a week, for every message that has passed the technical validation, the cases therein should be assessed to determine the country where the reaction occurred for regulatory reporting purposes.EMA10Was case from EU?For every case, assess whether the country of occurrence is in the EU. If Yes, go to step 10.1.EMA10.1End.The case is now stored in EV &, following duplicate detection & recoding will be available for signal detection and data quality analyses.EMA11Extract cases from messageThe cases occurring in the EU is extracted from the message for processing prior to retransmission.EMA12Redact & replaceExtract data in line with EV Data Access policy.Prior to sending the cases to the World Health Organization (WHO) Collaborating Centre for International Drug Monitoring, the cases are extracted epiles of the cases hole some data elements redacted and replaceE in line with the EV Data Access Policy.EMA13CopySend cases to physical mediasthrough the VigiBase API which returns a messageID for each file submittedEMA14Send to WHO:The cases are copied to physical mediastoring Centre collaborating Centre Cellaborating Centre receives the physical media cases.EMA1514Receive physical mediaCasesOnce the cases have been validated, they are stored in the Phy DB.WHO16EMA Checks status of ICSREMA uses the messageID to check theEMA	No.	Step	Description	Responsible Organisation
9Assess cases in message.Once a week, for every message that has passed the technical validation, the cases therein should be assessed to determine the country where the reaction occurred 			committees should be informed.	
Image: series of the series	9	Assess cases in message.	passed the technical validation, the cases therein should be assessed to determine the country where the reaction occurred	EMA
Image: series of the series	10	Was case from EU?	country of occurrence is in the EU. If Yes, go to step 11.	EMA
Image: series of the series	10.1	End.	following duplicate detection & recoding will be available for signal	ЕМА
Ine with EV Data Access policy.Health Organization (WHO) Collaborating Centre for International Drug Monitoring, the cases are extracted copies of the cases have some data elements redacted and replaced in line with the EV Data Access Policy in order to ensure personal data protection.EMA13CopySend cases to physical mediathrough the VigiBase API .The cases are copied to physical media.sent through the VigiBase API 	11	Extract cases from message	from the message for processing prior to	EMA
mediathrough the VigiBase API .media.sent through the VigiBase API which returns a messageID for each file submitted14Send to WHO.The physical media is sent to WHO Collaborating Centre.EMA1514Receive physical mediaCasesWHO Collaborating Centre receives the physical mediacases.WHO1615Store cases in PharmacoVigilance DataBase (PhV DB).Once the cases have been validated, they are stored in the PhV DB- a status code is recorded for each messageWHO	12		Health Organization (WHO) Collaborating Centre for International Drug Monitoring, the cases are extracted copies of the cases have some data elements redacted and replaced in line with the EV Data Access Policy in order to ensure personal	EMA
14Send to WHO.The physical media is sent to WHO Collaborating Centre.EMA1514Receive physical mediaCasesWHO Collaborating Centre receives the physical mediacases.WHO1615Store cases in PharmacoVigilance DataBase (PhV DB).Once the cases have been validated, they are stored in the PhV DB- a status code is recorded for each messageWHO	13	mediathrough the VigiBase	media.sent through the VigiBase API which returns a messageID for each file	EMA
mediaCasesthe physical mediacases.1615Store cases in PharmacoVigilance DataBase (PhV DB).Once the cases have been validated, they are stored in the PhV DB- a status code is 	14	Send to WHO.		EMA
PharmacoVigilance DataBase (PhV DB).are stored in the PhV DB- a status code is recorded for each message	15 14		-	WHO
16 EMA Checks status of ICSR EMA uses the messageID to check the EMA	16 15	PharmacoVigilance DataBase	are stored in the PhV DB- a status code is	WHO
Messages status code of each submitted message.	16		status code of each submitted	EMA
17 Was a positive status code If yes, go to step 19 EMA received? If no, go to step 18 EMA	17		If yes, go to step 19	EMA
18 Contact WHO to resolve technical issue WHO UMC is contacted to resolve technical issues. If a message needs to be retransmitted go to step 12, if this is not required go to step 19. EMA	18		WHO UMC is contacted to resolve technical issues. If a message needs to be retransmitted go to step 12, if this is not	EMA
	17 19	End.	Cases are stored in the WHO	WHO

No.	Step		Responsible Organisation
		Collaborating Centre's PharmacoVigilance DataBase &, following duplicate detection & recoding will be available for signal detection and data quality analyses.	

VI. Appendix 5 Nullification of cases

2603 2604	General principles regarding the nullification of cases are provided in <u>VI.C.6.2.2.10</u>. The following recommendationsoutlined in <u>VI.C.6.2.2.9</u> .			
2605	Exan	Examples of scenarios for which ICSRs should also be applied: be nullified, are provided in Table VI.13.		
2606 2607 2608 2609 2610 2611	t E F	 The value in the data element 'Report nullification' (ICH-E2B(R2) A.1.13) should be set to 'Yes' and the nullification reason should be provided in the data element 'Reason for nullification' (ICH- EB(R2) A.1.13.1). The nullification reason should be clear and concise to explain why this case is no longer considered to be a valid report. For example a nullification reason stating, 'the report no longer meets the reporting criteria' or 'report sent previously in error' are not detailed enough explanations. 		
2612	•	An individual case can only be nullified by the	e sending organisation.	
2613 2614		Once an individual case has been nullified, th f it becomes necessary to resubmit the case	e case cannot be reactivated. • that has been previously nullified, a new 'Sender's	
2615			2B(R2) A.1.0.1) and 'Worldwide unique case	
2616		dentification number' (ICH-E2B(R2) A.1.10)		
2617 2618		ndividual versions (i.e. follow-up reports) of ase to which they refer.	a case cannot be nullified, only the entire individual	
2619	Table VI.11. Table VI.14. Examples of scenarios for which ICSRs should be nullified			
	Ex.	Scenario	Action	
	1	An individual case has been identified as a duplicate of another individual case previously submitted- by the same sender.	 One of the individual cases should be nullified. The remaining valid case should be updated with any additional relevant information from the nullified case. NOTE: In case of duplicate reports where one report needs to be nullified, the update of the remaining case should be performed in the form of a follow-up report⁷⁰. Information on the identification of the nullified case(s) should be provided (ICH-E2B(R2) A.1.11/ICH-E2B(R3) C.1.11). 	
	2	A wrong 'Worldwide unique case identification number' (ICH-E2B(R2) A.1.10/ICH-E2B(R3) C.1.8.1) was accidentally used and does not refer to an existing case.	The case with the wrong 'Worldwide unique case identification number' (ICH-E2B(R2) A.1.10/ ICH- E2B(R3) C.1.8.1) should be nullified. A new case should be created with a correct 'Worldwide unique case identification number'.	
 	3	On receipt of further information it is confirmed that that the adverse reaction(s) occurred before the suspect	The case should be nullified.	

⁷⁰ See Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs), <u>EMA/13432/2009</u>.

	Ex.	Scenario	Action
		drug(s) was taken.	
	4	On receipt of further information on an individual case, it is confirmed that the patient did not receive the suspect drug _{τ} (s). Minimum reporting criteria for an ICSR as outlined in <u>VI.B.2</u> are no longer met.	The case should be nullified.
	5	On receipt of further information it is confirmed by the same reporter that the reported adverse reaction(s) did not occur to the patient. Minimum reporting criteria for an ICSR as outlined in VI.B.2 are no longer met.	The case should be nullified.
	6	On receipt of further information it is confirmed that there was no valididentifiable patient for the individual case. Minimum reporting criteria for an ICSR as outlined in VI.B.2 are no longer met.	If it is not possible to obtain confirmation of verify the patient's existence, then the case should be nullified.
2620 2621	 Individual cases that have been nullifiedExamples of scenarios for which ICSRs should notNOT be used for scientific evaluation, however, they should remain in the database for auditing purposes. 		
2622 2623 2624 2625 2626	rema ident the c	In addition, in case of duplicate reports where one report needs to be nullified, the update of the remaining case should be performed in the form of a follow-up report ⁷¹ . Information on the identification of the nullified case(s) should benullified, are provided in the data element 'Source(s) of the case identifier (e.g. name of the company, name of regulatory agency)' (ICH-E2B(R2) A.1.11.1.) and in the data element 'Case identifier(s)' (ICH-E2B(R2) A.1.11.2).	
2627	Tabl	e VI.12. Table VI.15. Examples of scenario	os for which ICSRs should NOT be nullified
·	Ex.	Scenario	Action
	7	A wrong 'Worldwide unique case identification number' (ICHE2B(R2) A.1.10/ ICH-E2B(R3) C.1.8.1) was accidentally used. This wrong ICH- E2B(R2) A.1.10-'Worldwide unique case identification number' referred to an a different existing case.	The report with the wrong 'Worldwide unique case identification number' (ICH-E2B(R2) A.1.10/ICH- E2B(R3) C.1.8.1) should not be nullified. A follow-upAn amendment report should be submitted to correct the information previously submitted. A new ICSR should be created and submitted with the correct 'Worldwide unique case identification
			number'.
	8	On receipt of further information on an	The case should not be nullified. A follow-up should

⁷¹ As presented in the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs), <u>EMA/13432/2009</u>.


Ex.	Scenario	Action
	individual case, it is confirmed that the patient did not receive the marketing authorisation holder's suspect drug. However, the patient received other suspect drugs and the minimum reporting criteria for an ICSR are still met.	 be submitted within the appropriate time frame with the updated information on the case. Further, it is recommended that the initial sender informs the other marketing authorisation holder about this case (including the 'Worldwide Unique Case Identification Number' (ICH-E2B(R2) A.1.10 / ICH-E2B(R3) C.1.8.1). The other concerned marketing authorisation holder should create a new case and specify the reference case number and the name of the initial sending marketing authorisation holder (ICH-E2B(R2) section A.1.11 / ICH-E2B(R3) section C.1.11).
9	On receipt of further information the reporter has confirmed that the reported adverse reaction is no longer considered to be related to the suspect medicinal product(s).	 The case should not be nullified. A follow-up report should be submitted within the appropriate time frame with the updated information on the case. ICH-E2B(R2): Section B.4.k.18 'Relatedness of drug to reaction(s)/event(s) (repeat B.4.k.18.1 through B.4.k.18.4 as necessary)' should be populated as necessary. ICH-E2B(R3): Section G.k.9.i 'Drug-reaction(s) / Event(s) Matrix (repeat as necessary)' should be populated as necessary.
10	Change of the individual case from serious to non-serious (downgrading).	 The case should not be nullified. A follow-up report or an amendment report (depending on whether new information was received or not) should be submitted-with: ICH-E2B(R2): the data element A.1.5.1 'Seriousness' (ICH-E2B(R2) A.1.5.1)should be populated with the value 'No' without selection of a value for the data element A.1.5.2 'Seriousness criteria'-(ICH-E2B(R2) A.1.5.2). The data element A.1.9 'Does this case fulfil the local criteria for an expedited report?' (ICH- E2B(R2) field A.1.9)should remain populated with the value 'Yes'. ICH-E2B(R3): the data element E.i.3.2 'Seriousness Criteria at Event Level' should not be populated if the reaction is not serious. The data element C.1.7 'Does This Case Fulfil the Local Criteria for an Expedited Report?' should

Ex.	Scenario	Action
		remain populated with the value 'Yes'.
11	The primary source country has changed, which has an impact on the ICH-E2B(R2) convention regarding the creation of the 'Worldwide unique case identification number' (ICH-E2B(R2) A.1.10)-/ICH-E2B(R3) C1.8.1).	The case should not be nullified. TheICH-E2B(R2): The data element A.1.0.1 'Sender's (case) safety report unique identifier' (ICH-E2B(R2) A.1.0.1) can be updated on the basis of the new primary source country code. However, the data element A.1.10 'Worldwide unique case identification number' (ICH-E2B(R2) A.1.10) should remain unchanged.
		• If, for some technical reason, the sender's local system is not fully ICH-E2B(R2) compliant and cannot followapply this policy, then the sender should nullify the original case. A new case should be created using the data element A.1.10 with a new 'Worldwide unique case identification number' (ICH-E2B(R2) A.1.10) reflecting the changed primary source country code. The 'Worldwide unique case identification number' (ICH-E2B(R2) A.1.10) of the case that was nullified should be reflected in the data elements A.1.11 'Other case identifiers in previous transmissions' (ICH-E2B(R2) A.1.11).
		• ICH-E2B(R3): The data element C.1.1 'Sender's (Case) Safety Report Unique Identifier' can be updated on the basis of the new primary source country code. However, the data element C.1.8.1 'Worldwide Unique Case Identification Number' should remain unchanged. If, for some technical reason the sender's local system cannot apply this policy, then the sender should nullify the original case. A new case should be created using the data element C.1.8.1 with a new 'Worldwide Unique Case Identification Number' reflecting the changed primary source country code. The 'Worldwide unique case identification number' of the case that was nullified should be reflected in the data elements C.1.9.1 'Other Case Identifiers in Previous Transmissions'.
12	The suspected medicinal product belongs to another marketing authorisation holder (e.g. a product with the same active substance but marketed under a different invented name).	The case should not be nullified. It is recommended that the initial sender informs the other marketing authorisation holder about this case (including the 'Worldwide unique case identification number'Unique Case Identification Number' (ICH-

Ex.	Scenario	Action
		E2B(R2) A.1.10) used /ICH-E2B(R3) C.1.8.1). The original organisation should also submit a follow-up report to provide this new information.
		The other concerned marketing authorisation holder should create a new case and specify the reference case number and the name of the initial sending marketing authorisation holder in the data elements 'Source(s) of the case identifier (e.g. name of the company name of regulatory agency)' (ICH-E2B(R2) A.1.11.1) and 'Case identifier(s)' (ICH-E2B(R2) A.1.11.2). This will allow grouping the cases in the EudraVigilance database.(ICH-E2B(R2) section A.1.11/ICH-E2B(R3) section C.1.11).
13	The suspected medicinal product taken does not belong to the marketing authorisation holder (same active substance, the invented name is unknown and the report originates from a country, where the marketing authorisation holder has no marketing authorisation for the medicinal product in question).	The case should not be nullified. The marketing authorisation holder should submit a follow-up report with this information within the appropriate time frame.
14	The case is mistakenly reportedsubmitted by the marketing authorisation holder A although the marketing authorisation holder B as co- marketer is responsible for reporting the case.	The case should not be nullified. An explanation should be sent by the marketing authorisation holder A to the co-marketer marketing authorisation holder B that the case has already been reportedsubmitted. The marketing authorisation holder B should provide any additional information on the case as a follow-up report with the same 'Worldwide unique case identification number' (ICH-E2B(R2) A.1.10)/ICH-E2B(R3) C.1.8.1).

VI. Appendix 6 Data quality monitoring of ICSRs transmitted electronically

Figure VI.6. Figure VI.9. Business process map - DataReview of quality monitoring and integrity of
 ICSRs transmitted electronically by the Agency in collaboration with NCAs and MAHs






Table VI.13. Process description - Data quality monitoring of ICSRs transmitted electronically

2636 2637 2638 2639

2640

Table VI.14. Table VI.16. The business map and process description describe a system where there is a separation between a PharmacoVigilance DataBase (PhV DB) holder, the PhV DB holder's data Quality Assessors (QA) and the PhV DB holder's auditors; however this is not mandatory and these functions may be performed by the same people or groups. Process description – Review of quality and integrity of ICSRs by the Agency in collaboration with NCAs and MAHs

No .	Step	Description	Responsible Organisation
4	Start . Decide upon Sender to evaluate.	Select one of the organisations that has transmitted ICSRs to your database: Inputs into this decision can include, but need not be limited to findings from previous assessments and requests from pharmacovigilance audits.Review of quality and integrity of ICSRs by the Agency in collaboration with NCAs and MAHs in EEA Member States	PhV DB holder
21	Sample ICSRs from Sender:Receive reports of suspected drug adverse reaction(s) from NCAs and MAHs	Take a sample of ICSRs that were transmitted by the selected senderICSRs are received in electronic format in EudraVigilance from sender organisations with reporting obligations of suspected adverse reactions related to medicines authorised in the EEA	QA EMA
32	Check for dataReview of ICSR quality errors.and integrity	Check the cases for data quality errors. The cases should be assessed against appropriate published standards and similar documents, for example the MedDRA Term Selection Points to Consider document. A review of the quality, integrity and monitoring of compliance with reporting timeframes as well as the use of terminologies is performed in accordance with: • 3194 SOP - EudraVigilance individual case safety report data quality checking (in draft) • 3201 WIN - EudraVigilance how to check the quality of the data (in draft)	QA EMA
4 3	WriteA EV quality review report and send is sent to PhV DB holder. organisation	The findings from the data quality assessment should be collated into a single report. These can include related	QA EMA

No .	Step	Description	Responsible Organisation
		checks, such as 15-day reporting compliance, whether error reports are corrected and similar statistical information. A draft report summarising the quality review outcome is sent to the organisation (EU QPPV for MAH/ Head of PhV Department of NCA) by e- mail	
5 3.1	Errors found? Are corrective actions required?	Were any errors found during the analysis of the cases? Are corrective actions required by the organisation being reviewed? If Yes, go to point 4. If No, go to step 5.1. If Yes go to steps 5.2, 5.3 & 6.point 10.	PhV DB holder
4.	Corrective actions are required by organisation being reviewed		
5 4.1	End.Review and comment	If there were no errors found, then no further action needs to be taken. The process can end until the next time the sender is assessed. The PhV DB holder may choose to share this information with the assessed sender and their auditors who may wish to factor this in to determinations of which sender to assess. Review draft quality review report and provide comments to EMA	PhV-DB holder Organisation being reviewed (NCA/MAH)
5.2	Highlight for PhV audit.	If the PhV-DB-holder's organisation has an audit department, any significant findings should always be shared with them.	PhV-DB-holder
5 .2.1	Prioritise for Audit. Is meeting required?	The audit or inspections department should use the information provided to them to feed into decisions about prioritising organisations for audit or inspection. If Yes, progress to 6. If No, progress to 7.	PhV DB holder's auditors Organisation being reviewed (NCA/MAH)
5.3 6	HNPUT: Findings from previous assessments. Meeting is required	Any errors found (or even lack thereof) should be incorporated into decisions about which senders to evaluate &	PhV-DB-holder

No .	Step	Description	Responsible Organisation
		should also inform the performance of the assessments (e.g. targeting particular types of case) and the report (documenting whether previously identified issues have been addressed). A review meeting is requested by the Sender Organisation or is proposed by EMA	
6.1	A meeting is organised	A meeting is organised (via TC or face- to-face)	EMA
6.2	Inform senderDraft minutes of findings.the meeting	Inform the sender of the findings, including requested remedial actions (e.g. retransmitting certain cases) and time frames for those actions Agreed actions and outcome of discussions to be summarised in draft meeting minutes	PhV-DB holder Organisation being reviewed (NCA/MAH)
6.3	Approve meeting minutes	Approve meeting minutes as final	EMA
6.4	Record final minutes	Record final meeting minutes	EMA/Organisation being reviewed (NCA/MAH)
6.5	End		
7	RequestA meeting? is NOT required	The sender should have the option to choose to request a meeting to discuss the findings and appropriate remedial action and time frames. If noNo review meeting is required (requested, go to step 7.1. If a meeting is requested go to step by the Sender Organisation or proposed by EMA) Proceed with point 8.	Sender
7.1 8	Address the findings & retransmit any required cases.Agree on corrective measures/timeframes	Address all findings, take necessary steps to prevent recurrence of such findings & retransmit any required cases.Reach agreement on corrective measures/timeframes; outcome of the agreement is to be reflected on the basis of the final quality review report, which is to be recorded	SenderOrganisation being reviewed (NCA/MAH)
8.1	Implement corrective measures	Implement the corrective measures in accordance with the agreed methods	Organisation being reviewed (NCA/MAH)

No .	Step	Description	Responsible Organisation
		and timeframes	
7 8.2	End.Inform EMA about outcome	Once all findings have been addressed, the necessary steps taken to prevent recurrence of such findings and any required cases have been retransmitted, the process can end until the next time the sender is assessed. Inform EMA when corrective measures have been implemented in line with final quality review report	Sender Deing reviewed (NCA/MAH)
8.3	Have meeting. Record and monitor outcome	Upon request from one party, a meeting should be held to discuss the findings of quality assessments and appropriate remedial and preventive actions to ensure that the cases in the database are correct and shall be so in the future. Record the final quality review report and monitor the implementation the agreed corrective measures	PhV DB holder & SenderEMA
9 8.4	End. Have corrective measures been applied?	Unless further action has Check if corrective measures have been specified (e.g. future meetings or assessments); implemented by the organisationIf Yes, the process can will end-until the next time the sender is assessedIf No, proceed to 9.	PhV DB holder
9	Send reminder to organisation being reviewed	Send reminder to organisation being reviewed to implement corrective measures and proceed with point 8.4	EMA
10	Corrective Measures are NOT required	The quality review did not reveal any corrective measures	
10.1	Record outcome		EMA/Organisation being reviewed
10.2	End		


VI. Appendix 7 Duplicate detection and management of ICSRs 2642


VI.App.7.1 Duplicate Detection in EudraVigilance – Collaboration between 2643 the Agency, Member States and MAHs where duplicates originate from the 2644 same sender 2645

2646 2647

2649

Figure VI.7. Figure VI.10. Business process map - Duplicate detection and management of ICSRsDetection in EudraVigilance – Collaboration between the Agency, Member States and MAHs 2648 where duplicates originate from the same sender





2653

Table VI.15. Table VI.17. Process description - Duplicate detection and management of ICSRs Detection in EudraVigilance – Collaboration between the Agency, Member States and MAHs where duplicates originate from the same sender

No	Step	Description	Responsible organisation Organisation
4	Start . Potential duplicate detected.	Potential duplicates have been detected by the PharmacoVigilance DataBase (PhV DB) holder organisation or the PhV DB holder organisation is notified of potential duplicates by a receiver of the cases.EudraVigilance (EV) Duplicate Detection with duplicates originating from the same Sender – Duplicates identified by the Agency	PhV-DB holder
1	Duplicate Detection (DD) in EudraVigilance	A duplicate detection algorithm is operated in EudraVigilance to detect potential duplicates	EMA
2	Assessment-EMA Duplicate Detection Management Process	 All The potential duplicates need assessment identified by the organisation Duplicate Management Team (DMT) to confirm or deny their duplicate status. Following assessment there are 4 possible outcomes: Not a Duplicate (go to step 2.1), More Information Needed (go to step 2.2), Duplicates From Different Sender (go to step 2.3), Duplicates From Same Sender (go to step 2.4). The outcome of all assessments should be recorded to avoid continually reassessing the same cases when further versions arrive. These recorded outcomes can also be used to refine theEudraVigilance duplicate detection methods during future development.algorithm are reviewed in accordance with the applicable SOP/WIN 3323 SOP - Performing duplicate detection in EudraVigilance (in draft) 	DMT EMA

No ,	Step	Description	Responsible organisation Organisation
2.1	Not a Duplicate: Mark as not a duplicate. Are there duplicates?	IfAre the cases are assessed as not beingduplicates of one another, then mark bothcases as such.identified by theEudraVigilance duplicate detectionalgorithm confirmed?Golf Yes, proceed to step-3-(End).If No, proceed to 6.	DMT EMA
2.2	More information needed: Log in tracking tool.	There should be some form of tool for tracking when more information is needed, when correspondence has been sent, whether an answer was received and, if so, when.	ÐMT
2.2.13	Write to Sender. Are the confirmed duplicates from the same sender?	 More information is required in order to be able to make a definite assessment. The sender (who transmitted the case(s) in question to the PhVDB holder's organisation) should be contacted to request specific information necessary to confirm or deny duplication. Personal data protection must remain paramount, so unsecured communications should not include sufficient data to identify an individual. Are the confirmed duplicates from the same sender organisation? If Yes, proceed to 4. If No, proceed according to the business process map related to duplicate detection of ICSRs from different senders outlined in Figure VI.11. 	PhV-DB holderEMA
2.2.2 4	Receive request, draft and send response.EMA to contact ICSR Sender (MAH/NCA)	Once a request for more information has been received, the Sender of the case should respond promptly, either as a follow-up version of the case or by responding to the requester. The DMT should then reassess the case based on the new information (Go back to step 2).Contact the ICSR sender organisation to inform about the ICSRs that have been identified and confirmed as duplicates in EudraVigilance in	Sender EMA


No .	Step	Description	Responsible organisation Organisation
		 accordance with the applicable WIN: 3325 WIN Following-up potential duplicates ICSRs with the original senders (in draft) 	
2.3 4.1	Duplicates Different Senders: Create or nominate master. EMA to record/monitor the outcome of the duplicate management	Once cases have been determined to be duplicates of one another and have been transmitted to the PhV DB holder by different senders or reporters, then they should be merged under a master case, following the process described in chapter 2.3 "Management of duplicate cases" of the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs), EMA/13432/2009: Record the outcome of the duplicate management and monitor that duplicates have been addressed by the sender organisation	DMT EMA
2.3.1	Deal with follow-ups.	If any follow-ups arrive for any of the cases, this information may require a reassessment of the master case. Reassess and, if necessary, amend the master case as with any received follow- up information. Go to step 3 (End).	ÐMŦ
4.2 .4	Duplicates Same Sender: Log in tracking tool. Are the duplicates addressed?	Once cases have been determined to be duplicates of one another, and have been transmitted to the PhV DB holder by the same sender, then this decision and the correspondence referred to in step 2.4.1 should be logged in the tracking tool referred to in step 2.2.Have the duplicates been addressed by the Sender Organisation? If Yes, the process ends. If No, progress with point 4	ÐMŦ
2.4.1 5	Write to Sender: (MAH/NCA) to update/nullify cases	The sender organisation, asSender Organisation has to update/nullify the source of the duplicates, should be contacted duplicate cases in their pharmacovigilance database in accordance with-chapter 2.3.3 of the Guideline on the	PhV DB holder Organis ation (MAH/NCA)

No ,	Step	Description	Responsible organisation
			Organisation
		Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs),) (<u>EMA/13432/2009</u> , The sender should be asked to confirm or deny duplication and take appropriate steps in accordance with chapter 2.3.1 of the aforementioned Guideline.).	
2.4.2	Receive request.	Receive and log the communication containing information on suspected duplicates in the Sender's PhV DB.	Sender
2.4.3	Is it a duplicate?	Assess the potential duplicates. Are the cases duplicates of one another? If Yes, go to step 2.4.3.1. If No, go to step 2.4.3.2.	Sender
2.4.3 5.1	Merge duplicates.Sender (MAH/NCA) to send updated ICSR/nullification report to EV	Merge the duplicates, taking into account Flowchart 1 of chapter 2.3.1.3 of Sender Organisation has to send an updated ICSR/nullification report to EudraVigilance in accordance with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs),) (EMA/13432/2009-).	SenderOrganis ation (MAH/NCA)
5.2	End		
2.4.3.1.1 6	Send follow- up/nullification. There are no confirmed duplicates	For the cases that are merged under the master, sendAs a nullification message to the PhV DB holder. For the case that is master, send the updated case to the PhV DB holder as follow-up information. The merging & transmission should be completed promptly and in any case within 15 days result of the date of receipt of the information from the PhV DB holder duplicate detection management process it is confirmed that the individual cases were considered to be possible are no duplicates. This date should be treated as the date of receipt of most recent information for regulatory reporting purposes.	SenderEMA
2.4.3.1.2	End.	The duplicates have now been	Sender

No	Step	Description	Responsible organisation Organisation
		Femoved from both the Sender's System and that of the PhV DB holder and only the master should be available for signal detection and data quality analyses. Unless follow-up information is received, then no further steps need be taken.	
2.4.3.2	Draft and send a response.	Reply to the PhV DB holder who sent the communication informing that the cases are not duplicates.	Sender
2.4.3.2 6. 1	Mark as "Not a EMA to record outcome of duplicate"- management	 Upon receiptThe outcome of confirmation from the Sender organisation thatduplicate detection management process is recorded in accordance with the cases are notapplicable SOP/WIN: 3323 SOP - Performing duplicate detection in EudraVigilance (in draft) 3324 WIN - Evaluation and management of detected potential duplicates, mark the cases as "Not a duplicate" & go to step 3 (End). in EudraVigilance (in draft) 	DMT EMA
3 6.2	End .	No further action is required for this couple.	ÐMT

VI.App.7.2 Duplicate Detection in EudraVigilance – Collaboration between 2656 the Agency, Member States and MAHs where duplicates originate from different Senders

Figure VI.11. Business process map - Duplicate Detection in EudraVigilance – Collaboration between the Agency, Member States and MAHs where duplicates originate from different senders 2660



2657 2658 2659

2661

2663

 Table VI.18.
 Process description - Duplicate Detection in EudraVigilance – Collaboration between the Agency, Member States and MAHs where duplicates originate from different senders

No			
	Start	EudraVigilance (EV) Duplicate Detection with duplicates originating from different Senders – Duplicates identified by the Agency	
		Example: there is more than one suspect drug and the same case is submitted by two MAHs; the patient reported the same adverse reaction to a NCA and the MAH	
1	Duplicate Detection (DD) in EudraVigilance	A duplicate detection algorithm is operated in EudraVigilance to detect potential duplicates	EMA
2	EMA Duplicate Detection Management Process	The potential duplicates identified by the EudraVigilance duplicate detection algorithm are reviewed in accordance with the applicable SOP/WIN	EMA
		 3323 SOP - Performing duplicate detection in EudraVigilance (in draft) 3324 WIN - Evaluation and management of detected potential duplicates in EudraVigilance (in draft) 	
2.1	Are there duplicates?	Are the duplicates identified by the EudraVigilance duplicate detection algorithm confirmed? If Yes, proceed to point 3. If No, proceed to point 9.	EMA
3	Are the duplicates from the same Sender?	Are the duplicates identified by the EudraVigilance duplicate detection algorithm confirmed? If Yes, proceed as outlined in Figure VI.10. If No, proceed to point 4.	
4	Is further information required?	Is there further information required to confirm if the duplicates identified by the duplicate detection algorithm are duplicates? If Yes, proceed to point 5. If No, proceed to point 8.	EMA
5	EMA to contact ICSR Senders (MAH/NCA)	Contact the ICSR senders to obtain additional information on the individual cases that have been identified as potential duplicates and indicate timeframe by when the information is to be provided • 3325 WIN Following-up potential duplicates ICSRs	EMA

No	Step	Description	Responsible Organisation
		with the original senders (in draft)	
6	Has Sender provided the information?	Check if the Senders have provided the requested information? If Yes, proceed to point 7. If No, proceed to 5.	EMA
7	EMA to review requested info	The duplicate cases are to be reviewed based on the requested info that has been provided by the Senders to confirm if they are duplicates. If Yes, proceed to point 8. If No, progress with point 9.	
8	The cases are confirmed duplicates		
8.1	EMA to merge duplicate reports and record outcome	Merge the potential duplicates in EudraVigilance in line with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (<u>EMA/13432/2009)</u>	Sender Organisations (MAH/NCA)
8.2	EMA to inform Senders about outcome	Inform the Senders about the outcome of the duplicate management to allow Senders to take action where necessary ⁷² , ⁷³ , ⁷⁴	EMA
8.3	Senders to administrate duplicates locally	Senders of the cases identified as duplicates in EudraVigilance should follow the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (EMA/13432/2009) Note: capture duplicate case reference numbers in data element 'Other case identifiers in previous	Sender Organisations (MAH/NCA)

⁷² NOTE: MAHs will be able to download "master cases" from EudraVigilance in line with the EudraVigilance Access Policy. The message type (equivalent to E2B(R2) - M.1.1) will have the code "master" to distinguish it from all other ICSR messages, which will have the message type "ichicsr" (see EU ICSR Implementation Guide, chapter I.C.3.1.1). MAHs will also be able to export from EudraVigilance the original ICSRs that have been merged under the "master case" and also any nullification to these ICSRs, where applicable (see EU ICSR Implementation Guide, chapter I.C.6.1.2). It is up to the MAH to decide if they wish to process "master cases" or not.

⁷⁴ NCAs can use the EudraVigilance Rerouting Rules Engine to update the rerouting rules to determine if they wish to receive EudraVigilance "master cases" or not. See also further guidance as outlined in EU ICSR Implementation Guide, chapter I.C.2.3 and I.C.6.1.2). The "master cases" must not be retransmitted by the NCA to EudraVigilance if there is no receipt of new information that warrants a follow-up report.


If the MAH does process the "master case" and it involves updating one of their own individual cases with information from the EudraVigilance master case, the MAH MUST NOT resubmit an updated version of this individual case to EudraVigilance.

⁷³ A table of master cases and associated duplicates will be made available to aid duplicate management by Sender organisations.

No	Step	Description	Responsible Organisation
		transmissions' (E2B(R2) A.11/E2B(R3) section C.1.9.1	
8.4	End		
9	The cases are NOT duplicates	The potential duplicates have been reviewed and are not duplicate cases	EMA
9.1	EMA to record outcome of duplicate management	 The outcome of the Duplicate Detection Management process is recorded in accordance with the applicable SOP/WIN: 3323 SOP - Performing duplicate detection in EudraVigilance (in draft) 3324 WIN - Evaluation and management of detected potential duplicates in EudraVigilance (in draft) 	EMA
9.2	End		

VI.App.7.3 Duplicates from same Sender Organisation – duplicates detected by the sender organisation prior to detection by the Agency in EudraVigilance

Figure VI.12. Business process map - Duplicates originating from a pharmacovigilance database of
 the same Sender Organisation (NCA/MAH), which were sent to EudraVigilance – Duplicates detected by
 the Sender Organisation prior detection by the Agency in EudraVigilance




2675 2676

Table VI.19. Process description - Duplicates originating from a pharmacovigilance database of the same Sender Organisation (NCA/MAH) which were sent to EudraVigilance – Duplicates detected by the Sender Organisation prior detection by the Agency in EudraVigilance

	Start	Duplicates originating from a pharmacovigilance database of the same Sender Organisation (NCA/MAH) which were sent to EudraVigilance – Duplicates detected by the Sender Organisation	
1	ICSR duplicates are sent to EudraVigilance	Duplicated ICSRs for the same individual case are sent to EudraVigilance by the same sender	Sender Organisation (NCA/MAH)
2	Re-routing of ICSRs to NCA	MAHs ICSRs are rerouted from EudraVigilance to the NCA in accordance with VI.C.4 and the rerouting principles described in the EU ICSR Implementation Guide (EMA/51938/2013)	EMA/EudraVigilance
3	Duplicate Management Process		NCA
3.1	Duplicates detected, which were sent to EudraVigilance	The NCA identifies the duplicates they sent to EudraVigilance as part of their duplicate management process	NCA
3.2	Review/update/ nullify cases and send to EV	Review and update/nullify duplicated individual cases and send updated ICSRs/nullification ICSRs to EudraVigilance in line with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (<u>EMA/13432/2009</u>)	NCA
3.3	End		
4	Duplicate Management Process		МАН
4.1	Duplicates detected, which were sent to EudraVigilance	Duplicates sent to EudraVigilance are identified as part of their duplicate management process	MAH
4.2	Review/update/ nullify cases and send to EV	Review and update/nullify duplicated individual cases and send updated ICSR/nullification ICSR to EudraVigilance in line with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (<u>EMA/13432/2009</u>)	MAH
4.3	End		

VI.App.7.4 Duplicates from different Sender Organisations - Duplicates detected by an Organisation prior detection by Agency in EudraVigilance

Figure VI.13. Business process map - Duplicates from different Sender Organisations - Duplicates
 detected by an Organisation prior detection by Agency in EudraVigilance



2686 2687

 Table VI.20.
 Process description - Duplicates from different Sender Organisations - Duplicates

 detected by an Organisation prior detection by Agency in EudraVigilance

No	Step	Description	Responsible Organisation
	Start	Duplicates from different Sender Organisations - Duplicates detected by an Organisation where duplicates were previously not identified in EudraVigilance	
		Example: case series described in the medical literature submitted by MAHs to EudraVigilance; these were previously reported by healthcare professionals to a NCA, which submitted the cases to EudraVigilance. Primary source identifiers or patient identifiers were masked and the duplicate detection algorithm did not identify the reports as potential duplicates	
1	ICSR duplicates are sent to EudraVigilance	Duplicated ICSRs for the same individual case are sent to EudraVigilance	Sender Organisation (NCA/MAH)
2	Re-routing of ICSRs to NCA	MAHs ICSRs are rerouted from EudraVigilance to the NCA in accordance with VI.C.4 and the rerouting principles described in the EU ICSR Implementation Guide (EMA/51938/2013)	EMA/EudraVigilance
3	Duplicate Management Process		NCA
3.1	Duplicates detected, which were sent to EudraVigilance	The NCA identifies the duplicates it sent to EudraVigilance as part of its duplicate management process	NCA
3.2	Review/update/ nullify cases and send to EV	Review and update/nullify individual cases and send updated ICSR/nullification ICSR to EudraVigilance in line with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (EMA/13432/2009)	NCA
3.3	End		
4	Duplicate Management Process		МАН
4.1	Duplicates detected, which were sent to EudraVigilance	MAH identifies the duplicates it sent to EudraVigilance as part of its duplicate management process	МАН

No			
4.2	Review/update/ nullify cases and send to EV	Review and update/nullify duplicated individual cases and send updated ICSR/nullification ICSR to EudraVigilance in line with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (EMA/13432/2009)	МАН
4.3	End		




 Table VI.21.
 Process description - Collaboration between the Agency, Member States and MAHs

 where duplicates are first detected in a database other than EudraVigilance

	Start	EudraVigilance (EV) Duplicate Detection with duplicates originating from the same Sender – Duplicates identified by the Agency	
1	Duplicate Detection (DD) NOT in EudraVigilance	A duplicate detection process operating on a database other than EV detects potential duplicates. This is day zero for your process & for any updated versions that will be transmitted	MAH/NCA
2	MAH/NCA Duplicate Detection Management Process	The potential duplicates identified are reviewed in accordance with the applicable SOP/WIN	MAH/NCA
3	Are the duplicates confirmed?	Are the potential duplicates identified by the process confirmed? If Yes, proceed to 4. If No, proceed to 3.1.	MAH/NCA
3.1	End		
4	Where did the cases come from?	From where did your organisation receive the confirmed duplicate cases? If both cases came direct from a primary source or via non-EEA NCAs, proceed to 5 If both cases came via EV (either rerouted for an NCA or accessed from EV for an MAH), proceed to 6 If one case came direct from a primary source & one via EV, proceed to 7	MAH/NCA
5	Both cases came direct from primary source: MAH/NCA to administer the duplicates in accordance with internal policies	If the internal policy is to allocate one case as the master, proceed to step 5.1 If the internal policy is to merge duplicates under a master, proceed to 5.2	MAH/NCA
5.1	MAH/NCA allocates one case as the master	Update one ICSR with the case numbers & other relevant information from the other & send that to EV as follow-up. Nullify the other case &, if it was already transmitted to EV, send the nullification message to EV	MAH/NCA

No	Step	Description	Responsible Organisation
5.1. 1	End		
5.2	MAH/NCA merges the duplicates under a master case	Can the underlying duplicates be nullified and a nullification message sent to EV? If No, proceed to 5.2.1 If Yes, proceed to 5.2.2	MAH/NCA
5.2.	The underlying duplicates cannot be nullified	The Sender Organisation has to send updated ICSRs for the duplicate reports to EudraVigilance in accordance with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (EMA/13432/2009). The updated duplicates should include the case numbers of the other duplicates and also of the master case in the report duplicates section. The master case created from the duplicates should <u>NOT</u> be sent to EV ⁷⁵ .	MAH/NCA
5.2. 2	The underlying duplicates can be nullified	The Sender Organisation has to nullify the duplicate cases in their pharmacovigilance database in accordance with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (EMA/13432/2009). The master case created from the duplicates should be sent to EV. This case should be sent as a standard ICSR & cannot be sent as message type MASTER.	MAH/NCA
5.3	End		
6	Both cases were received via EV	Were the duplicates transmitted to EV by the same sender organisation? If yes, proceed with step 6.1 If no, proceed with step 6.2	MAH/NCA
6.1	Either inform sender organisation or EMA via dedicated mailbox	If you wish to inform the EMA via the dedicated mailbox proceed with step 6.2 If you wish to inform the sender directly, proceed with step 6.3	MAH/NCA
6.2	Inform EMA about duplicates via	Email <u>duplicates@ema.europa.eu</u> to inform them that you have detected that cases you received from	MAH/NCA

⁷⁵ Where, in certain instances based on internal duplicate management process, the recommendation provided under section 5.2.1 cannot be applied by Member States, the management of duplicates will be handled by EMA. Requests should be sent to <u>duplicates@ema.europa.eu</u> with the relevant worldwide case safety IDs of the duplicate cases.

No	Step	Description	Responsible Organisation
	dedicated mailbox	Eudravigilance are duplicates of one another, including the worldwide case safety IDs of the duplicate cases	
6.2. 1	EMA proceed as outlined in Figure VI.11.	EMA to administer duplicates in accordance with defined duplicate management process as outlined in Figure VI.11.	EMA
6.2. 2	End		
6.3	Inform sender about duplicates	Contact the sender organisation to inform them about the duplicates that they have transmitted to EV. Proceed with step 6.4	MAH/NCA
6.4	Sender to proceed as outlined in Figure VI.10.	The sender has to assess the cases and, if confirmed, either merge the cases under a master or allocate as applicable, in accordance with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (EMA/13432/2009).	Original sender organisation (MAH/NCA)
6.5	End		
7	One case came direct from a primary source & one via EV	The sender has to update the ICSR received directly from the primary source with the case number of the case received via EV & retransmit to EV. The duplicates in the sender's database should be managed in accordance with the Guideline on the Detection and Management of Duplicate Individual Cases and Individual Case Safety Reports (ICSRs) (EMA/13432/2009). Once the updated case has been received in EV from the sender, procced to step 6.2.1	MAH/NCA

VI.App. 7.6 Duplicates identified as part of signal management as outlined in GVP Module IX - Collaboration between the Agency, Member States and MAHs

Figure VI.15. Business process map - Duplicates identified as part of signal management as outlined
 in GVP Module IX

2708




Table VI.22. Process description - Duplicates identified as part of signal management based on
 EudraVigilance data as outlined in GVP Module IX

	Start	Duplicates identified as part of signal management as outlined in GVP Module IX	
		As part of the signal management process based on EudraVigilance data as outlined in GVP Module IX, there may be instances where a signal validator of the Agency, a Member State or a MAH may identify potential duplicates.	
1	Signal Management in line with GVP Module IX	Signals are assessed in line with GVP Module IX based on electronic Reaction Monitoring Reports (eRMRs), case line listings and individual case report forms generated by EudraVigilance (EVDAS)	Signal validator (EMA/NCA/MAH)
2	Potential duplicates?	As part of the review of the signal there may be individual cases identified that could be potential duplicates from the signal validator's perspective:	
		If potential duplicates are identified, proceed as outlined under point 3 and point 4.	
		If no potential duplicate are identified, proceed as outlined under point 5.	
3	Potential duplicates have been identified		
3.1	Send e-mail to dedicated mailbox	Send detail request for the verification of the duplicates to <u>duplicate-detection@ema.europa.eu</u> with the Worldwide Unique Case Identifier for all individual cases, which are considered as potential duplicates	Signal validator (EMA/NCA/MAH)
3.2	Review notification	 EMA to review notification of potential duplicates and initiate duplicate management process If duplicates are from the same Sender organisation, proceed as outlined in Figure VI.10. If duplicates are from different Sender organisations, proceed as outlined in Figure VI.11. 	EMA
3.3	Notify signal validator about the outcome of the duplicate management	Inform the Signal Validator about the outcome of the duplicate management process	EMA
	Record the outcome of the duplicate	Record the outcome of the duplicate management	EMA

No	Step	Description	Responsible Organisation
3.4	management		
3.5	End		
4	Potential duplicates have been identified		
4.1	Proceed with signal management	Proceed with the review of the signal in line with GVP Module IX	Signal validator (EMA/NCA/MAH)
4.2	Finalise signal management	Finalise signal management based on duplicate detection management feedback from EMA	Signal validator (EMA/NCA/MAH)
4.3	End		
5	No (potential) duplicates have been identified		
5.1	Proceed with signal management	Proceed with the review of the signal in line with GVP Module IX	Signal validator (EMA/NCA/MAH)
5.2	End		

VI. Appendix 8 Examples of assesment of case validity.

1	Dr. Isabella Queen reports that her patient, a 34 year old white male (initials A.V.) experienced hair loss after taking drug X. Dr. Queen's address and phone number are available.	Valid case. Identifiable reporter and qualification. Patient's qualifying descriptors available (initials, age, gender).
2	Dr. Isabella Queen reports her patient, a male, was reported to have experienced hair loss after taking drug X. Dr. Queen's phone number is available.	Valid case. Identifiable reporter and qualification. Patient's qualifying descriptor available (gender).
3	Dr. Feelgood reports that 2 patients were reported to have given birth, to a premature female infant in one case and a premature male infant in another, while on drug X. Dr.'s phone number and address are available.	Valid case. Identifiable reporter and qualification. 2 patients with qualifying descriptors available (gender).
4	Dr. Bones reports via e-mail that her patient (initials X.X.) developed a melanoma after taking drug Z. While the physician's e-mail address is available, attempts to reach her yielded no response. Address and phone number are not available.	Valid case. Identifiable reporter and qualification. Patient's qualifying descriptor available (initials).
5	A report from a Dr describes a patient (initials X.X.) who developed a melanoma after taking drug Z. No contact details are available regarding the reporter and the case cannot be followed-up.	Non-valid case. Reporter qualification provided but no conta parameters available to allow verification of the case.
6	Dr. Bones reports via e-mail that her patient developed a melanoma after taking drug X. Dr. Bone's address and phone number are not available, but she does respond by e-mail.	Non-valid case. Identifiable reporter and qualification. No patient's qualifying descriptor available. Report should be followed-up.
7	An employee of a drug company is at a barbecue at the house of paediatrician, Dr. Wiener, his neighbour. He hears from Dr. Wiener about his patient who developed hepatitis three weeks after one injection of the company's drug X. The employee sends a memo to the drug safety department with the	Non-valid case. Identifiable reporter and qualification. No patient's qualifying descriptor available. Report should be followed-up.

Table VI.23. Examples of assessment of the validity individual reports based on reporter and patient identifiability.

No.	Examples of case reports (source: Report of CIOMS Working Group V, 2001)	Validity assessment
	clinical details he remembered on the patient and also includes Dr.Wiener's address and phone number.	
8	Dr. Lindbergh on a commercial airplane flight from Paris to New York is seated next to an employee from a drug company. Dr. Lindbergh talks about his patient who experienced severe depression after taking the company's drug A (an oral contraceptive). The company employee, a marketing manager, reports the case to his drug safety department and provides the physician's business card.	Valid case. Identifiable reporter and qualification. Patient's qualifying descriptors available (gender). Patient presumably female as suspected product is an oral contraceptive.
9	The safety department of pharmaceutical company A sends to company B a report it received of a 23 year old female who developed Stevens Johnson Syndrome after taking drug A (a company A product) and drug B (a company B product). On follow-up with the reporting physician, Company A is told that their drug is not considered as a suspect causal agent. Company A sends the contact information on the identifiable physician to company B.	Valid case. Identifiable reporter and qualification. Patient's qualifying descriptor available (age and gender).
10	Professor Messer presents a paper at a medical convention (either orally or as a poster presentation) on a patient that developed thyroiditis after long-term therapy with Drug X. The paper is seen (or heard) by a company employee who reports it to the drug safety department.	Non-valid case. Identifiable reporter and qualification. No patient's qualifying descriptor available. Report should be followed-up.
11	The International Herald Tribune publishes an article describing a 5 year old patient who died after Drug Y ingestion. There is no physician mentioned and no author is listed for the article. The editor of the IHT (or, for example, a reader of the paper) forwards the article to the company.	Valid case. Identifiable reporter and qualification (Editor to IHT, non-HCP). Patient's qualifying descriptor available (age).
12	A company employee reads in a newspaper that several patients at Massachusetts General Hospital have given birth prematurely while taking drug X.	Non-valid case. Identifiable reporter and qualification (Author of article or Journal editor, non-HCP). No patient's qualifying descriptor available. Report should be followed-up.

No.	Examples of case reports (source: Report of CIOMS Working Group V, 2001)	Validity assessment
13	Pharmacist Gene Type reports that a neighbour told him that a female taking drug Z had dyspepsia at that neighbour's house last week.	Non-valid case. No identifiable reporter and qualification
	Only the pharmacist's address and phone number are available. Further information is not forthcoming despite rigorous follow-up.	(second hand information). Patient's qualifying descriptor available.
		Report should be followed-up.
14	Dr. NoRed Cell reports that 6 patients developed aplastic anemia while on drug X. Dr.'s address and phone number are not available, but his/ her e-mail address is given.	Non-valid case. Identifiable reporter and qualification. Report describing definite number of patients with no qualifying descriptor available for each patient. Report should be followed-up.
15	Dr. Onko Gene communicates to a company that 50 patients developed ovarian cancer while on drug X. The Dr.'s address, phone number and e-mail address are available, but attempts to reach her by the usual means are unsuccessful.	Non-valid case. Identifiable reporter and qualification. Report describing definite number of patients with no qualifying descriptor available for each patient.
		Report should be followed-up as possible.